Multi-effector CRISPR-based diagnostic system

Through the CRISPR system combining with target molecules, the activation signal amplification is solved, and the problem of difficulty in taking into account sensitivity and specificity in the prior art is achieved, low-cost and efficient nucleic acid detection is achieved, and it is suitable for rapid diagnosis of laboratory and nursing point environments.

CN111448311BActive Publication Date: 2024-11-19THE BROAD INST INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880072772.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-02-14
Filing Date
2018-09-07
Publication Date
2024-11-19
Estimated Expiration
2038-09-07

AI Technical Summary

Technical Problem

The existing nucleic acid detection methods are difficult to balance the sensitivity, specificity, simplicity and speed, especially in laboratory environments, which are complex and costly, and have low sensitivity in nursing point environments, making it difficult to achieve high specificity and low specificity. Quick diagnosis of costs.

Method used

Using a detection system containing a CRISPR system, which includes a CRISPR effector protein, a guide RNA and signal amplification CRISPR effector protein, and an RNA-based masking construct, the activation signal amplification is generated through the CRISPR system binding to the target molecule to generate a detectable positive signal. Achieve rapid diagnosis.

Benefits of technology

It realizes the provision of high sensitivity and high specificity nucleic acid detection at low cost, simplifies experimental operations, is suitable for laboratory and point-of-care environments, and improves the speed and efficiency of diagnosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111448311B_ABST
    Figure CN111448311B_ABST
Patent Text Reader

Abstract

Embodiments disclosed herein utilize RNA targeting effectors to provide robust CRISPR-based diagnostics with attomole sensitivity. Embodiments disclosed herein can detect both DNA and RNA with a considerable level of sensitivity, and can distinguish targets from non-targets based on single base pair differences. In addition, embodiments disclosed herein can be prepared in a freeze-dried form for ease of distribution and point-of-care (POC) applications. Such embodiments can be used in a variety of situations in human health, including, for example, virus detection, bacterial strain typing, sensitive genotyping, and detection of disease-related cell-free DNA.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 556,408, filed September 9, 2017; U.S. Provisional Application No. 62 / 610,121, filed December 22, 2017; and U.S. Provisional Application No. 62 / 630,808, filed February 14, 2018. The entire contents of the above applications are incorporated herein by reference in their entirety.

[0003] Statement Regarding U.S. Federally Funded Research

[0004] This invention was made with U.S. Government support under Grant No. MH110049 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention. Technical Field

[0005] The subject matter disclosed herein generally relates to rapid diagnostics associated with the use of CRISPR effector systems. Background Art

[0006] Nucleic acids are universal hallmarks of biological information. The ability to rapidly detect nucleic acids with high sensitivity and single-base specificity on a portable platform has the potential to revolutionize the diagnosis and monitoring of many diseases, provide valuable epidemiological information, and serve as a universal scientific tool. Although many methods have been developed for the detection of nucleic acids (Du et al., 2017; Green et al., 2014; Kumar et al., 2014; Pardee et al., 2014; Pardee et al., 2016; Urdea et al., 2006), they inevitably suffer from trade-offs between sensitivity, specificity, simplicity, and speed. For example, qPCR methods are sensitive but expensive and rely on complex instrumentation, limiting their availability to trained operators in a laboratory setting. Other methods, such as novel methods that combine isothermal nucleic acid amplification with portable platforms (Du et al., 2017; Pardee et al., 2016), provide high detection specificity in point-of-care (POC) settings but have limited applications due to low sensitivity. As nucleic acid diagnostics become increasingly relevant to a variety of healthcare applications, detection technologies that provide high specificity and sensitivity at low cost will have great utility in both clinical and basic research settings. Summary of the invention

[0007] In one aspect, the present invention provides a nucleic acid detection system, comprising: a detection CRISPR system, comprising: an effector protein, one or more guide RNAs designed to bind to corresponding target molecules, and one or more signal amplification CRISPR effector proteins; and one or more RNA-based masking constructs.

[0008] In another aspect, the present invention provides a polypeptide detection system, comprising: a detection CRISPR system, comprising: an effector protein, one or more guide RNAs designed to bind to a trigger RNA, and one or more signal amplification CRISPR effector proteins; one or more RNA-based masking constructs; and one or more detection aptamers, wherein the detection aptamers comprise a masked RNA polymerase promoter binding site or a masked primer binding site.

[0009] In certain embodiments, the one or more signal amplification CRISPR effector proteins include a type IIIa CRISPR protein. The type III CRISPR protein may be a Csm6 protein. The Csm6 protein may be selected from EiCsm6 and LsCsm6.

[0010] In certain embodiments, the one or more signal amplification CRISPR effector proteins include Csx28 or Csx27.

[0011] In certain embodiments, the one or more signal amplification CRISPR effector proteins include one or more of Csm6, Csx28, Csx27, or any combination thereof.

[0012] In certain embodiments, the system further comprises nucleic acid amplification reagents.

[0013] In certain embodiments, the target molecule is a target DNA, and the system further comprises a primer that binds to the target DNA and comprises an RNA polymerase promoter.

[0014] In certain embodiments, the CRISPR system effector protein is an RNA targeting effector protein. The RNA targeting effector protein may comprise one or more HEPN domains. The one or more HEPN domains may comprise an RxxxxH motif sequence. The RxxxH motif may comprise R{N / H / K]X 1 X 2 X 3 H sequence. X 1 Can be R, S, D, E, Q, N, G, or Y, and X 2 can independently be I, S, T, V or L, and X 3Can independently be L, F, N, Y, V, I, S, D, E or A.

[0015] In certain embodiments, the CRISPR RNA targeting effector protein is C2c2. The C2c2 may be within 20 kb of the Cas1 gene. The C2c2 effector protein may be from an organism selected from the following genera: Leptotrichia, Listeria, Corynebacterium, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides. des), Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, Campylobacter, and Lachnospira.The C2c2 or Cas13b effector protein can be from an organism selected from the group consisting of: Leptotrichia shahii; Leptotrichia wadei (Lw2); Listeria seeligeri; Lachnospiraceae bacterium MA2020; Lachnospiraceae bacterium NK4A179; [Clostridium] aminophilum DSM10710; Carnobacterium gallinarum DSM 4847; Carnobacterium gallinarum DSM 4847 (second CRISPR locus); Paludibacter propionicigenes WB4; Listeria weihenstephanensis FSL R9-0317; Listeriaceae bacterium FSL M6-0635; Leptotrichia wadei F0279; Rhodobacter capsulatus SB 1003; Rhodobacter capsulatus R121; Rhodobacter capsulatus DE442; Leptotrichia buccalis C-1013-b; Herbinix hemicellulosilytica; [Eubacteriaceae bacteriumCHKCI004]; Blautia sp.Marseille-P2398; Leptotrichia sp.oral taxon 879str.F0557; Lachnospiraceae bacterium NK4A144; Chloroflexus aggregans; Demequinaaurantiaca; Thalassospira sp.TSL5-1; sp.Marseille-P3007; Bacteroides ihuae; Porphyromonadaceae bacterium KH3CP3RA; Listeria riparia; and Insolitisspirillum peregrinum.The C2c2 effector protein can be L. wadei F0279 or L. wadei F0279 (Lw2) C2c2 effector protein.

[0016] In certain embodiments, the one or more RNA-based masking constructs inhibit the generation of a detectable positive signal.

[0017] In certain embodiments, the one or more RNA-based masking constructs can inhibit the generation of a detectable positive signal by masking the detectable positive signal or otherwise generating a detectable negative signal.

[0018] In certain embodiments, the one or more RNA-based masking constructs may comprise a silencing RNA that inhibits the production of a gene product encoded by the reporter construct, wherein the gene product produces the detectable positive signal when expressed.

[0019] In certain embodiments, the one or more RNA-based masking constructs can be ribozymes that produce the detectable negative signal, and wherein the detectable positive signal is produced when the ribozyme is inactivated. The ribozyme can convert a substrate into a first color, and wherein the substrate is converted into a second color when the ribozyme is inactivated.

[0020] In certain embodiments, the RNA-based masking agent is an RNA aptamer and / or comprises an RNA-tethered inhibitor.

[0021] The inhibitor of the aptamer or RNA connection can chelate an enzyme, wherein the enzyme produces a detectable signal after being released from the inhibitor of the aptamer or RNA connection by acting on a substrate. The aptamer can be an inhibitory aptamer that inhibits an enzyme and prevents the enzyme from catalyzing a detectable signal from a substrate, or the inhibitor of the RNA connection inhibits an enzyme and prevents the enzyme from catalyzing a detectable signal from a substrate. The enzyme can be thrombin, protein C, neutrophil elastase, subtilisin, horseradish peroxidase, beta-galactosidase or calf alkaline phosphatase. The enzyme can be thrombin, and the substrate can be p-nitroaniline covalently linked to a peptide substrate for thrombin, or 7-amino-4-methylcoumarin covalently linked to a peptide substrate for thrombin.

[0022] In certain embodiments, the aptamer sequesters a pair of agents that combine to produce a detectable signal when released from the aptamer.

[0023] In certain embodiments, the one or more RNA-based masking constructs comprise an RNA oligonucleotide to which both a detectable ligand and a masking component are attached.

[0024] In certain embodiments, the one or more RNA-based masking constructs comprise nanoparticles aggregated by bridge molecules, wherein at least a portion of the bridge molecules comprise RNA, and wherein the solution undergoes a color shift when the nanoparticles are distributed in a solution. The nanoparticles may be colloidal metals. The colloidal metal may be colloidal gold.

[0025] In certain embodiments, the one or more RNA-based masking constructs comprise quantum dots linked to one or more quencher molecules via a linker molecule, wherein at least a portion of the linker molecule comprises RNA.

[0026] In certain embodiments, the one or more RNA-based masking constructs comprise RNA complexed with an intercalating agent, wherein the intercalating agent changes absorbance upon cleavage of the RNA. The intercalating agent may be pyronine-Y or methylene blue.

[0027] In certain embodiments, the detectable ligand is a fluorophore and the masking component is a quenching molecule.

[0028] In certain embodiments, the one or more RNA-based masking constructs can be cut by the CRISPR RNA targeting effector protein and the type IIIa CRISPR protein. In other words, the RNA-based masking construct can be a single construct that can be cut by the CRISPR RNA targeting effector protein and the type IIIa CRISPR protein, or more than one construct that can be cut by both, or more than one construct that can be cut by either. The one or more RNA-based masking constructs can include an RNA-based masking construct that can be cut by the CRISPR RNA targeting effector protein. The one or more RNA-based masking constructs can include an RNA-based masking construct that can be cut by the type IIIa CRISPR protein. The one or more RNA-based masking constructs can include an RNA-based masking construct that can be cut by the CRISPR RNA targeting effector protein and an RNA-based masking construct that can be cut by the type IIIa CRISPR protein. The RNA-based masking construct that can be cut by the type IIIa CRISPR protein can contain homopolymeric A or C-RNA.

[0029] In certain embodiments, the one or more guide RNAs designed to bind to the corresponding target molecule contain (synthesized) mismatches. The mismatches can be upstream or downstream of a SNP or other single nucleotide variation in the target molecule.

[0030] In certain embodiments, the one or more guide RNAs are designed to detect single nucleotide polymorphisms in target RNA or DNA, or splice variants of RNA transcripts.

[0031] In certain embodiments, the one or more guide RNAs are designed to detect a target molecule or trigger RNA that produces hexadenylates containing a 2'3' cyclic phosphate end when cleaved by the CRISPR RNA targeting effector protein. The one or more guide RNAs can be designed to detect a target molecule or trigger RNA containing a poly A stretch.

[0032] In certain embodiments, the one or more guide RNAs are designed to bind to one or more disease state diagnostic target molecules. The disease state can be cancer. The disease state can be an autoimmune disease. The disease state can be an infection.

[0033] In certain embodiments, the infection is caused by a virus, bacteria, fungus, protozoa, or parasite.

[0034] In certain embodiments, the infection may be a viral infection. The viral infection may be caused by a DNA virus. The DNA virus may be a Myoviridae, Podoviridae, Siphoviridae, Alloherpesviridae, Herpesviridae (including human herpes virus and Varicella zoster) Zoster virus), Malocoherpesviridae, Lipothrixviridae, Rudiviridae, Adenoviridae, Ampullaviridae, Ascoviridae, Asfarviridae (including African swine fever virus), Baculoviridae, Cicaudaviridae, Clavaviridae, Corticoviridae, Fuselloviridae, Globuloviridae, Guttaviridae, Hytrosaviridae, Iridoviridae The viral infection may be caused by a double-stranded RNA virus, a positive-sense RNA virus, a negative-sense RNA virus, a retrovirus, or a combination thereof. The viral infection may be caused by a Coronaviridae virus, a Picornaviridae virus, a Caliciviridae virus, a Flaviviridae virus, a Togaviridae virus, a Bornaviridae virus, a Filoviridae virus, a Paramyxoviridae virus, a Pneumoviridae virus, a Rhabdoviridae virus, an Arenaviridae virus, a Bunyaviridae virus, an Orthomyxoviridae virus, or a Deltavirus virus.The viral infection may be caused by coronavirus, SARS, poliovirus, rhinovirus, hepatitis A, Norwalk virus, yellow fever virus, West Nile virus, hepatitis C virus, dengue virus, Zika virus, rubella virus, Ross River virus, Sindbis virus, Chikungunya virus, Borna disease virus, Ebola virus, Marburg virus, measles virus, mumps virus, Nipah virus, Hendra virus, Newcastle disease virus, human respiratory syncytial virus, rabies virus, Lassa virus, Hanta virus, Crimean-Congo hemorrhagic fever virus, influenza or hepatitis D virus.

[0035] In certain embodiments, the infection is a bacterial infection. The bacteria causing the bacterial infection can be Acinetobacter species, Actinobacillus species, Actinomycetes species, Actinomyces species, Aerococcus species, Aeromonas species, Anaplasma species, Alcaligenes species, Bacillus species, Bacteriodes species, Bartonella species, Bifidobacterium species, Bordetella species, Borrelia species, Brucella species, Burkholderia species, Campylobacter species, Capnocytophaga species. species, Chlamydia species, Citrobacter species, Coxiella species, Corynbacterium species, Clostridium species, Eikenellaspecies, Enterobacter species, Escherichia species, Enterococcus species, Ehlichia species, Epidermophyton species, Erysipelothrix species, Eubacterium species, Francisella species, Fusobacterium species, Gardnerella speciesspecies), Gemella species, Haemophilus species, Helicobacter species, Kingella species, Klebsiella species, Lactobacillus species, Lactococcus species, Listeria species, Leptospira species, Legionella species, Leptospira species, Leuconostoc species, Mannheimia species, Microsporum species, Micrococcus species, Moraxella species, Morganell species, Mobiluncus species, Micrococcus species species, Mycobacterium species, Mycoplasm species, Nocardia species, Neisseria species, Pasteurelaa species, Pediococcus species, Peptostreptococcus species, Pityrosporum species, Plesiomonas species, Prevotella species, Porphyromonas species, Proteus species, Providencia species, Pseudomonas species, Propionibacteriums species, Rhodococcus species, Rickettsia species

[0013] The invention further comprises the following: a) bacteria, bacteria, fungi, and fungi, and b) bacteria, and b) fungi, bacteria, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi, fungi,

[0036] In certain embodiments, the infection is caused by a fungus. The fungus can be Aspergillus, Blastomyces, Candidiasis, Coccidiodomycosis, Cryptococcus neoformans, Cryptococcus gatti, sp., Histoplasma sp. (e.g., Histoplasma capsulatum), Pneumocystis sp. (e.g., Pneumocystis jirovecii), Stachybotrys (e.g., Stachybotrys jirovecii), chartarum), Mucroymcosis, Sporothrix, fungal eye infection, tinea, Exserohilum, Cladosporium, Geotrichum, Saccharomyces, Hansenula species, Candida species, Kluyveromyces species, Debaryomyces species, Pichia species, Penicillium species, Cladosporium species, Byssochlamys species, or a combination thereof.

[0037] In certain embodiments, the infection is caused by a protozoa. The protozoa can be from the Euglenozoa, Heterolobosea, Diplomonadida, Amoebozoa, Blastocystic, Apicomplexa, or a combination thereof.

[0038] In certain embodiments, the infection is caused by a parasite. The parasite can be Trypanosoma cruzi (Chagas disease), T. brucei gambiense, T. brucei rhodesiense, Leishmania braziliensis, L. infantum, L. mexicana, L. major, L. tropica, L. donovani, Naegleria fowleri, Giardia intestinalis (G. lamblia, G. duodenalis), canthamoeba castellanii, Balamuthiamadrillaris, Entamoeba histolytica, Blastocystic hominis, Babesia microti, Cryptosporidium parvum, Cyclospora cayetanensis, Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and Toxoplasma gondii, or a combination thereof.

[0039] In certain embodiments, reagents for amplifying target RNA molecules include nucleic acid sequence-based amplification (NASBA), recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), helicase-dependent amplification (HDA), nickase amplification reaction (NEAR), PCR, multiple displacement amplification (MDA), rolling circle amplification (RCA), ligase chain reaction (LCR) or branched amplification method (RAM).

[0040] In certain embodiments, the system further comprises an enrichment CRISPR system, wherein the enrichment CRISPR system is designed to bind to the corresponding target molecule prior to detection with the detection CRISPR system. The enrichment CRISPR system may comprise a catalytically inactive CRISPR effector protein. The catalytically inactive CRISPR effector protein may be a catalytically inactive C2c2. The enrichment CRISPR effector protein may further comprise a tag, wherein the tag is used to pull down the enrichment CRISPR effector system, or to bind the enrichment CRISPR system to a solid substrate. The solid substrate may be a flow cell.

[0041] In certain embodiments, the synthetic mismatch in the guide RNA is located at position 3, 4, 5 or 6 of the spacer, preferably position 3. The mismatch in the guide RNA may be located at position 1, 2, 3, 4, 5, 6, 7, 8 or 9 of the spacer, preferably position 5. The mismatch may be 1, 2, 3, 4 or 5 nucleotides upstream or downstream of the SNP or other single nucleotide variation in the guide RNA, preferably 2 nucleotides, preferably downstream.

[0042] In some embodiments, the guide RNA may include a spacer truncated relative to a wild-type spacer. In some embodiments, the guide RNA includes a spacer comprising less than 28 nucleotides, preferably between 20 and 27 nucleotides and including 20 and 27 nucleotides. The guide RNA may include a spacer consisting of 20-25 nucleotides or 20-23 nucleotides, for example preferably 20 or 23 nucleotides.

[0043] In certain embodiments, the masking construct comprises an RNA oligonucleotide designed to bind to a G-quadruplex forming sequence, wherein a G-quadruplex structure is formed by the G-quadruplex forming sequence upon cleavage of the masking construct, and wherein the G-quadruplex structure produces a detectable positive signal.

[0044] In another aspect, the present method provides a diagnostic device comprising one or more individual discrete volumes, each individual discrete volume comprising a CRISPR system of any embodiment herein.

[0045] In certain embodiments, each individual discrete volume may further comprise one or more detection aptamers comprising a masked RNA polymerase promoter binding site or a masked primer binding site.

[0046] In certain embodiments, each individual discrete volume further comprises a nucleic acid amplification reagent.

[0047] In certain embodiments, the target molecule is a target DNA, and the individual discrete volumes further comprise a primer that binds to the target DNA and comprises an RNA polymerase promoter.

[0048] In certain embodiments, the individual discrete volumes are droplets.

[0049] In certain embodiments, the individual discrete volumes are defined on a solid substrate. The individual discrete volumes may be micropores. The individual discrete volumes may be spots defined on a substrate. The substrate may be a flexible material substrate. The flexible material substrate may be a paper substrate or a flexible polymer-based substrate.

[0050] In another aspect, the present invention provides a method for detecting a target nucleic acid in a sample, comprising: distributing a sample or set of samples into one or more individual discrete volumes, the individual discrete volumes comprising a CRISPR system as described herein; incubating the sample or set of samples under conditions sufficient to allow the one or more guide RNAs to bind to one or more target molecules; activating the CRISPR effector protein by binding of the one or more guide RNAs to the one or more target molecules, wherein activation of the CRISPR effector protein results in modification of the RNA-based masking construct such that a detectable positive signal is generated; and detecting the detectable positive signal, wherein detection of the detectable positive signal indicates the presence of one or more target molecules in the sample.

[0051] In another aspect, the present invention provides a method for detecting a polypeptide in a sample, comprising: allocating a sample or a sample group into a group of individual discrete volumes, wherein the individual discrete volumes contain a peptide detection aptamer, a CRISPR system as described herein; incubating the sample or sample group under conditions sufficient to allow the peptide detection aptamer to bind to the one or more target molecules, wherein the binding of the aptamer to the corresponding target molecule exposes the RNA polymerase binding site or the primer binding site, resulting in the production of a trigger RNA; activating the RNA effector protein by binding of the one or more guide RNAs to the trigger RNA, wherein activation of the RNA effector protein results in modification of the RNA-based masking construct, such that a detectable positive signal is produced; and detecting the detectable positive signal, wherein detection of the detectable positive signal indicates the presence of one or more target molecules in the sample.

[0052] In certain embodiments, the target molecule is a target DNA, and the method further comprises binding the target DNA to a primer comprising an RNA polymerase site.

[0053] In certain embodiments, the method further comprises amplifying the sample RNA or the trigger RNA. Amplifying RNA may comprise amplifying by NASBA. Amplifying RNA may comprise amplifying by RPA.

[0054] In some embodiments, the sample is a biological sample or an environmental sample. The biological sample can be blood, plasma, serum, urine, feces, sputum, mucus, lymph, synovial fluid, bile, ascites, pleural effusion, seroma, saliva, cerebrospinal fluid, aqueous humor or vitreous humor or any body secretions, exudate, discharge (for example, from abscess or any other infection or the liquid obtained at inflammation site) or from the liquid obtained from joint (for example, normal joint or the joint affected by disease, such as rheumatoid arthritis, osteoarthritis, gout or suppurative arthritis) or the swab of skin or mucosal surface. The environmental sample can be obtained from food sample, paper surface, fabric, metal surface, wood surface, plastic surface, soil sample, fresh water sample, wastewater sample, salt water sample or its combination.

[0055] In certain embodiments, the one or more guide RNAs are designed to detect single nucleotide polymorphisms in target RNA or DNA, or splice variants of RNA transcripts.

[0056] In certain embodiments, the one or more guide RNAs are designed to bind to one or more disease state diagnostic target molecules.

[0057] In certain embodiments, the one or more guide RNAs are designed to bind to cell-free nucleic acid.

[0058] In certain embodiments, the disease state is an infection, an organ disease, a blood disease, an immune system disease, a cancer, a brain and nervous system disease, an endocrine disease, a pregnancy or childbirth related disease, a genetic disease, or an environmentally acquired disease. The disease state may be characterized by the presence or absence of an antibiotic or drug resistance or susceptibility gene or transcript or polypeptide, preferably in a pathogen or cell. The target molecule may be an antibiotic or drug resistance or susceptibility gene or transcript or polypeptide.

[0059] In certain embodiments, the method may further comprise comparing the detectable positive signal to a (synthetic) standard signal.

[0060] On the other hand, the present invention provides a method for detecting a target nucleic acid in a sample, comprising: contacting the sample with a nucleic acid detection system as described herein; and applying the contacted sample to a lateral flow immunochromatographic assay. The nucleic acid detection system may include an RNA-based masking construct comprising a first and a second molecule, and wherein the lateral flow immunochromatographic assay includes detecting the first and second molecules, preferably at discrete detection sites of a lateral flow strip. The first molecule and the second molecule can be detected by binding an antibody that recognizes the first or second molecule and detecting the bound molecule, preferably using a sandwich antibody. The lateral flow strip may include an upstream first antibody for the first molecule and a downstream second antibody for the second molecule, and wherein if the target nucleic acid is not present in the sample, the uncut RNA-based masking construct is bound by the first antibody, and wherein if the target nucleic acid is present in the sample, the cut RNA-based masking construct is bound by both the first antibody and the second antibody. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 – Demonstrated Csm6 activation by poly A oligomers.

[0062] Figure 2 – Cleavage preferences of three Csm6 orthologs are provided. EiCsm6 showed the strongest activity with a preference for C or A nucleotides. LsCsm6 showed activity with a preference for A nucleotides.

[0063] Figure 3 – Gels showing the cleaved ends of RNA cleaved by Prevotella sp. MA2016 Cas13 (“Cas13b5”) and L. wadei Cas13a are provided. In the absence of alkaline phosphatase, only fragments with 5′ hydroxyl groups can be labeled with dye and displayed on the gel, as shown in lanes 3 and 7.

[0064] Figure 4 – A graph showing that Cas13b5 detection of dengue targets is significantly enhanced by Csm6 positive feedback is provided. Cas13b5 detection of dengue ssRNA was supplemented with LsCsm6 or ttCsm6 and poly A oligomers of 6 or 7 nucleotides in length. These oligomers are cleaved by Cas13b5 and terminate with a 2,3-cyclic phosphate on the 3' end, which can activate Csm6 for cleavage of the FAM-poly-A-quencher reporter construct.

[0065] Figure 5- Protein purification of Csx28 orthologs. Chromatograms of ion exchange chromatography (IEC) of PinCsx28, PauCsx28 and PguCsx28 used in this study. The measured UV absorbance (mAU) relative to the elution volume (ml) is shown. The red line shows the increasing NaCl concentration used for protein elution. SDS PAGE of concentrated Csx28 orthologs of PinCsx28, PauCsx28 and PguCsx28 is shown.

[0066] Figure 6 Effect of co-incubation with -Csx28 on Cas13 cleavage activity. (A) Cleavage activity of PinCas13b co-incubated with PinCsx28, PauCsx28, PguCsx28 or without Csx28. (B) Cleavage activity of PsmCas13b co-incubated with PinCsx28, PauCsx28, PguCsx28 or without Csx28. (C) Cleavage activity of PauCas13b co-incubated with PinCsx28, PauCsx28, PguCsx28 or without Csx28. (D) Cleavage activity of CcaCas13b co-incubated with PinCsx28, PauCsx28, PguCsx28 or without Csx28. (E) Cleavage activity of PguCas13b co-incubated with PinCsx28, PauCsx28, PguCsx28 or without Csx28. (F) Cleavage activity of LwaCas13a co-incubated with PinCsx28, PauCsx28, PguCsx28 or without Csx28.

[0067] Figure 7– SHERLOCK signal enhanced by positive feedback from Csm6. (A) Schematic representation of detection of 2,3-cyclic phosphate ends by PNK labeling and gel electrophoresis (B) Electrophoretic gel showing 2,3-cyclic phosphate ends generated by LwaCas13a or PsmCas13b cleavage of ssRNA target 2 (homopolymer ring). Cas13 enzymes were incubated with appropriate crRNAs targeting ssRNA targets, and cleavage products were 5' labeled with the dye IR800 (with or without alkaline phosphatase treatment). (C) Schematic representation of Csm6-mediated positive feedback in the SHERLOCK reaction. (D) Activation of two Csm6 orthologs by adenine oligomers of different lengths ending in 2,3-cyclic phosphates. Csm6 cleavage was measured using an RNA sensor composed of six homopolymers of A, C, G, or U, end-labeled with a fluorophore and a quencher. (E) Activation of two Csm6 orthologs by LwaCas13a cleavage with adenine-uridine activators of different lengths of adenine stretches. LwaCas13a targets synthetic dengue sRNA. (F) Mass spectrometry analysis of digestion products from LwaCas13a collateral cleavage (left) or 2,3-cyclic phosphate activator alone (right). Major peaks are labeled with mass and corresponding structures. (G) Schematic diagram of the cleavage motif preference discovery screen for Csm6 orthologs. (H) Heat map of preferred 3-base motifs for EiCsm6 cleavage activity. The values ​​represented in the heat map are the counts of each 3-base in all depleted motifs. If -log 2 A motif is considered depleted if the (target / non-target) value is greater than 0.5. 2 In the (target / non-target) values, target and non-target represent the frequencies of the motifs under target and non-target conditions, respectively. (I) Sequence logo of the preferred sequence motif for EiCsm6 cleavage activity. (J) Detection of increasing concentrations of dengue ssRNA at 20 nM in (A) 6 -(U) 5Combined LwaCas13a and EiCsm6 signals of activators. (K) EiCsm6-enhanced LwaCas13a SHERLOCK detection of P. aeruoginosa acyltransferase synthetic target in combination with LwaCas13a. (L) Kinetics of EiCsm6-enhanced LwaCas13a SHERLOCK detection of P. aeruoginosa acyltransferase synthetic target. (M) EiCsm6-enhanced lateral flow detection of synthetic dengue RNA in combination with LwaCas13a without pre-amplification by RPA. Band intensity quantification is shown on the right. (N) EiCsm6-enhanced lateral flow SHERLOCK of P. aeruoginosa acyltransferase gene in combination with LwaCas13a. Band intensity quantification is shown on the right.

[0068] Figure 8 – Protein purification of Csm6 orthologs. (A) Chromatograms of size exclusion chromatography of EiCsm6, TtCsm6, LsCsm6, and SaCsm6 used in this study. The measured UV absorbance (mAU) relative to the elution volume (ml) is shown. (B) SDS-PAGE gel of EiCsm6, TtCsm6, and LsCsm6 fractions before size exclusion chromatography. The fractions show bacterial lysate supernatant after streptactin incubation (1), streptactin resin after cleavage with SUMO protease (2), and released, untagged Csm6 protein (3). (C) Final SDS-PAGE of concentrated Csm6 protein after size exclusion chromatography. A BSA standard curve (left) was used to quantify Csm6 protein (right). Five dilutions of BSA and two dilutions of EiCsm6, TtCsm6, and LsCsm6 are shown.

[0069] Fig. 9 -Base preference of TtCsm6 cleavage using activators of different lengths with 3' 2,3-cyclic phosphate termini.

[0070] Fig.10 – Evaluation of EiCsm6, TtCsm6, and LsCsm6 activities using activators with different lengths and different 3' end groups. (A) Evaluation of EiCsm6, TtCsm6, and LsCsm6 cleavage activities using adenine oligomers with a length of 5-7 nucleotides and either a 3'OH or 3'phosphate terminus. Cleavage activities were measured using a fluorescent RNase alarm sensor. (B) Base preferences of EiCsm6 and LsCsm6 stimulated with 3'OH adenine oligomers with a length of 5nt and 6nt, respectively. The fluorescent homopolymer sensor used to detect RNase activity was 5nt in length.

[0071] Fig.11 – Size analysis and representation of various motifs after Csm6 cleavage. (A) Bioanalyzer trace of EiCsm6 sample showing the change in library size following activator-dependent RNase activity. (B) Box plots showing the motif distribution of the ratio of target to non-target motifs for Csm6, Csm6 with activator, Csm6 with activator and rNTPs, or background libraries at the 5 and 60 minute time points. (C) Number of depleted motifs for Csm6, Csm6 with activator, Csm6 with activator and rNTPs, or background libraries at the 60 minute time point.

[0072] Fig.12 – Single-base and two-base preferences of Csm6 conditions determined by random motif library screening. (A) Heatmaps showing single-base preferences of Csm6, Csm6 with activator, and Csm6 with activator and rNTP at the 60-min time point, as determined by random motif library cleavage screening. Values ​​represented in the heatmap are counts for each single base across all depleted motifs. If -log 2 A motif is considered depleted if the (target / non-target) value is greater than 0.5. 2 In the (target / non-target) values, target and non-target represent the frequencies of the motifs under target and non-target conditions, respectively. (B) Heat map showing the two-base preferences of Csm6, Csm6 with activator, and Csm6 with activator and rNTP at the 60-min time point, as determined by random motif library cleavage screening. The values ​​represented in the heat map are the counts of each two-base in all depleted motifs. If -log 2 A motif is considered depleted if the (target / non-target) value is greater than 0.5. 2 In the (target / non-target) values, target and non-target represent the frequencies of the motif under target and non-target conditions, respectively.

[0073] Fig.13 – Conditional tri-base preferences of Csm6 as determined by random motif library screening. (A) Heat map showing the tri-base preferences of Csm6 at the 60 min time point, as determined by random motif library cleavage screening. The values ​​represented in the heat map are the counts for each tri-base across all depleted motifs. If -log 2 A motif is considered depleted if the (target / non-target) value is greater than 0.5. 2 In the (target / non-target) values, target and non-target represent the frequencies of the motifs under target and non-target conditions, respectively. (B) Heat map showing the tri-base preferences of Csm6 with activators at the 60-min time point, as determined by random motif library cleavage screening. The values ​​represented in the heat map are the counts of each tri-base across all depleted motifs. If -log 2A motif is considered depleted if the (target / non-target) value is greater than 0.5. 2 In the (target / non-target) values, target and non-target represent the frequencies of the motifs under target and non-target conditions, respectively. (C) Heat map showing the tri-base preferences of Csm6 with activators and rNTPs at the 60-min time point, as determined by random motif library cleavage screening. The values ​​represented in the heat map are the counts of each tri-base across all depleted motifs. If -log 2 A motif is considered depleted if the (target / non-target) value is greater than 0.5. 2 In the (target / non-target) values, target and non-target represent the frequencies of the motif under target and non-target conditions, respectively.

[0074] Fig.14 – Single-base and two-base preferences of Csm6 conditions as determined by random motif library screening. (A) Heat map showing the four-base preferences of Csm6 at the 60-min time point, as determined by random motif library cleavage screening. The values ​​represented in the heat map are counts for each four-base across all depleted motifs. If -log 2 A motif is considered depleted if the (target / non-target) value is greater than 0.5. 2 In the (target / non-target) values, target and non-target represent the frequencies of the motifs under target and non-target conditions, respectively. (B) Heat map showing the tetrabase preferences of Csm6 with activators at the 60-min time point, as determined by random motif library cleavage screening. The values ​​represented in the heat map are the counts of each tetrabase across all depleted motifs. If -log 2 A motif is considered depleted if the (target / non-target) value is greater than 0.5. 2 In the (target / non-target) values, target and non-target represent the frequencies of the motifs under target and non-target conditions, respectively. (C) Heat map showing the tetrabase preferences of Csm6 with activators and rNTPs at the 60-min time point, as determined by random motif library cleavage screening. The values ​​represented in the heat map are the counts of each tetrabase across all depleted motifs. If -log 2 A motif is considered depleted if the (target / non-target) value is greater than 0.5. 2 In the (target / non-target) values, target and non-target represent the frequencies of the motif under target and non-target conditions, respectively.

[0075] Fig.15 – Csm6-enhanced detection of PsmCas13b and LwaCas13a for agricultural applications. EiCsm6-enhanced detection of PsmCas13b at various lengths of poly A activators.

[0076] Fig.16– Mass spectrometry analysis of cleaved ends from LwaCas13a. (A) Chromatogram traces show the elution profiles of LwaCas13a-digested activators (top) or 2,3-cyclic phosphate activators (bottom). Figure 5 (B) Abundance table of different compounds detected by mass spectrometry in LwaCas13a digested activator (left) or 2,3 cyclic phosphate activator (right) (SEQ ID NO: 137) samples.

[0077] Fig.17 - Effect of reporter and activator optimization on Csm6 enhancement of LwaCas13a activity. (A) Schematic diagram of different activator designs for Csm6 enhancement of Cas13a activity (SEQ ID NOs: 137, 138, and 139). (B) Performance of EiCsm6 enhancement detected by LwaCas13a for different activator designs.

[0078] Fig.18 – Effects of reporter and activator concentrations on Csm6 enhancement of LwaCas13a activity. (A) Enhancement of EiCsm6 detected by LwaCas13a at different ratios of poly-A and poly-U reporters. (B) 6 -(U) 5 In the presence of activators, EiCsm6 detected by LwaCas13a was enhanced.

[0079] Fig.19 – Csm6-enhanced detection of PsmCas13b and LwaCas13a for agricultural applications. (A) Csm6-enhanced detection of CP4-EPSPS herbicide resistance gene or lectin in Roundup-Ready or WT soybean crude extracts using LwaCas13a. (B) Kinetics of Csm6-enhanced detection of CP4-EPSPS herbicide resistance gene or lectin in Roundup-Ready or WT soybean crude extracts using LwaCas13a.

[0080] Fig. 20 -(A)-(D) Csm6 enhances the signal from the U-cleaving CcaCas13b enzyme.

[0081] Fig.21 – Effect of in vitro transcription components on Csm6 activity. (A) EiCsm6 activity in the presence and absence of 2,3 cyclic phosphate activators in the IVT components. The components included 3 mM additional MgCl 2 , 1mM rNTP mixture, 30U T7 polymerase. (B) In the presence of various concentrations of ribonucleotides, the 6-(U) 5 Activator and poly A reporter EiCsm6 and LwaCas13a activities. (C) In the presence of various ribonucleotide concentrations, the 6 -(U) 5 Activator and poly A / RNaseAlert reporter combination, combined EiCsm6 and LwaCas13a activity. (D) In ​​the presence of various ribonucleotide concentrations, the EiCsm6 and LwaCas13a proteins were expressed in the presence of various ribonucleotide concentrations. 6 -(U) 5 Activator and poly A / 5x RNaseAlert reporter combination, combined EiCsm6 and LwaCas13a activity. (E) 5x (A) 6 -(U) 5 (F) Combined EiCsm6 and LwaCas13a activities using a cyclic phosphate activator and a poly A / RNaseAlert reporter combination in the presence of various ribonucleotide concentrations.

[0082] Fig. 22 – Inhibition of Csm6 activity by various rNTPs. RNase activity of EiCsm6 with 2,3-cyclic phosphates in the presence of 1 mM of various ribonucleotides or in the absence of a mixture of rNTPs at 1 mM each.

[0083] Fig.23 – Three-step SHERLOCK assay for herbicide resistance genes. RNase activity of EiCsm6 with 2,3 cyclic phosphates in the presence of 1 mM of various ribonucleotides or in the absence of a mixture of rNTPs at 1 mM each.

[0084] Fig.24 – Lateral flow Csm6-enhanced SHERLOCK with different reporter combinations. (A) Lateral flow assay of Csm6-enhanced SHERLOCK using various reporter designs. sA: short poly-A sensor; lA: long poly-A sensor; sC: short poly-C sensor; lC: long poly-C sensor; sA / C: short poly-A / C sensor; lA / C: long poly-A / C sensor; M: hybrid RNase alarm-like sensor. (B) Quantification of band intensity from the assay in (A).

[0085] Fig.25– Single molecule quantification and enhanced signal using SHERLOCK and Csm6. (A) Schematic diagram of the DNA reaction scheme for quantification of P. aeruginosa synthetic DNA. (B) Quantification of P. aeruginosa synthetic DNA at various RPA primer concentrations. Values ​​represent mean ± SEM. (C) Correlation of P. aeruginosa synthetic DNA concentration with detected fluorescence. Values ​​represent mean + / - SEM. (D) Schematic diagram of independent readouts of LwaCas13a and Csm6 cleavage activities using orthogonal reporters. (E) Activation of EiCsm6 by LwaCas13a cleavage of adenine-uridine 332 activators with different lengths of adenine stretches. LwaCas13a targets synthetic DENV ssRNA. Values ​​represent mean + / - SEM. (F) Detection of increasing concentrations of 20 nM DENV ssRNA in (A) 6 -(U) 5 Combined LwaCas13a and EiCsm6 signals for activators. Values ​​represent mean + / - SEM. (G) Kinetics of EiCsm6-enhanced LwaCas13a SHERLOCK detection of P. aeruginosa acyltransferase synthetic targets.

[0086] Fig.26– Adaptation of SHERLOCK to lateral flow assays. (A) Schematic of lateral flow assays using SHERLOCK. (B) Detection of synthetic ZIKV ssRNA using lateral flow SHERLOCK and a 1-hour LwaCas13a reaction. (C) Quantification of band intensities from assays in (B). (D) Schematic of lateral flow assays for therapeutically relevant EGFR mutations from patient liquid biopsy samples. (E) Detection of EGFR L858R mutations in patient-derived cell-free DNA samples with L858R or WT cancer mutations. Values ​​represent mean + / –SEM. (F) Lateral flow assay of EGFR L858R mutations in patient-derived cell-free DNA samples with L858R or WT alleles. (G) Quantification of band intensities from assays in (E). (H) Detection of EGFR exon 19 deletion mutations in patient-derived cell-free DNA samples with exon 19 deletion or WT alleles. Values ​​represent mean + / –SEM. (I) Lateral flow detection of EGFR exon 19 deletion mutations in patient-derived cell-free DNA samples with exon 19 deletion or WT allele. (J) Quantification of band intensities from the assay in (H). (K) Schematic diagram of lateral flow readout of EiCsm6-enhanced LwaCas13a detection of DENV ssRNA. (L) EiCsm6-enhanced lateral flow detection of synthetic DENV RNA in combination with LwaCas13a without pre-amplification by RPA. Band intensity quantification is shown on the right.

[0087] Fig. 27 – Dinucleotide preferences of Cas13a / b enzymes. (A) Heatmap of dinucleotide base preferences of 10 Cas13a / b orthologs targeting ssRNA 1, unless otherwise indicated, the reporter consisted of dinucleotides of A, C, G or U RNA bases, (*) indicates non-background subtracted orthologs with high background activity. (B) Heatmap of dinucleotide base preferences of high background activity orthologs LbuCas13a and PinCas13b tested against the indicated targets. (C) Cleavage activity of LbuCas13a tested with different spacer lengths against AU dinucleotide motifs in the presence and absence of 20 nM DENV ssRNA target. (D) Cleavage activity of LbuCas13a tested with different spacer lengths against UG dinucleotide motifs in the presence and absence of 20 nM DENV ssRNA target.

[0088] Fig.28– Analysis of cleavage ends produced by LwaCas13a and PsmCas13b. (A) Schematic diagram of detection of 2,3-cyclic phosphate ends by PNK labeling and gel electrophoresis. (B) Electrophoresis gel showing 2,3-cyclic phosphate ends produced by LwaCas13a or PsmCas13b cleavage of ssRNA targets 2 or 3 (homopolymer rings). Cas13 enzymes were incubated with appropriate crRNAs targeting the ssRNA targets, and the cleavage products were 5' labeled with the dye IR800, with or without alkaline phosphatase treatment.

[0089] Fig.29 – Protein purification of Csm6 orthologs. (A) Chromatograms of size exclusion chromatography of EiCsm6, TtCsm6, LsCsm6, and SaCsm6 used in this study. The measured UV absorbance (mAU) relative to the elution volume (ml) is shown. (B) SDS-PAGE gel of EiCsm6, TtCsm6, and LsCsm6 fractions before size exclusion chromatography. The fractions show the bacterial lysate supernatant after incubation with streptactin (1), the streptactin resin after cleavage with SUMO protease (2), and the released, untagged Csm6 protein (3). (C) Final SDS-PAGE of concentrated Csm6 proteins after size exclusion chromatography. A BSA standard curve (left) was used to quantify Csm6 proteins (right). Five dilutions of BSA and two dilutions of EiCsm6, TtCsm6, and LsCsm6 are shown.

[0090] Fig.30 – Base preference and activation of Csm6 orthologs. (A) Schematic representation of the positive feedback mediated by Csm6 in the SHERLOCK reaction. (B) Activation of EiCsm6 by adenine oligomers of different lengths ending in 2',3'-cyclic phosphates. Csm6 cleavage was measured using RNA reporters consisting of A, C, G, or U homopolymers end-labeled with a fluorophore and a quencher. (C) Base preference of LsCsm6 cleavage activated by adenine oligomers ending in 2',3'-cyclic phosphates. (D) Base preference of TtCsm6 cleavage activated by adenine oligomers ending in 2',3'-cyclic phosphates.

[0091] Fig.31– Size analysis and representation of various motifs after Csm6 cleavage. (A) Schematic diagram of the cleavage motif preference discovery screen for Csm6 orthologs. (B) Bioanalyzer trace of the EiCsm6 sample showing the change in library size following activator-dependent RNase activity. (C) Box plots showing the motif distribution of the target to non-target motif ratio for Csm6, Csm6 with activator, Csm6 with activator and rNTPs, or background libraries at the 5 and 60 minute time points. (D) Number of depleted motifs for Csm6, Csm6 with activator, Csm6 with activator and rNTPs, or background libraries at the 60 minute time point.

[0092] Fig.32 – Single-base and two-base preferences of Csm6 conditions determined by random motif library screening. (A) Sequence logos of preferred sequence motifs for EiCsm6 cleavage activity. (B) Heatmaps showing single-base preferences of Csm6, Csm6 with activator, and Csm6 with activator and rNTP at the 60-minute time point, as determined by random motif library cleavage screening. The values ​​represented in the heatmaps are counts of each single base among all depleted motifs. A motif was considered depleted if the -log2(target / non-target) value was greater than 0.5. In the -log2(target / non-target) values, target and non-target represent the frequency of the motif under target and non-target conditions, respectively. (C) Heatmaps showing two-base preferences of Csm6, Csm6 with activator, and Csm6 with activator and rNTP at the 60-minute time point, as determined by random motif library cleavage screening. The values ​​represented in the heat map are the counts of each two bases in all depletion motifs. If the -log2 (target / non-target) value is greater than 0.5, the motif is considered to be depleted. In the -log2 (target / non-target) value, target and non-target represent the frequency of the motif under target conditions and non-target conditions, respectively. (D) Heat map of preferred 3-base motifs for EiCsm6 cleavage activity. The values ​​represented in the heat map are the counts of each 3 bases in all depletion motifs. If the -log2 (target / non-target) value is greater than 0.5, the motif is considered to be depleted. In the -log2 (target / non-target) value, target and non-target represent the frequency of the motif under target conditions and non-target conditions, respectively. (E) EiCsm6 cleavage activity for the top reporter sequences derived from random motif library screening. (F) Activation of LsCsm6 by LwaCas13a cleavage of adenine-uridine activators with different lengths of adenine segments. LwaCas13a targeted synthesis of DENV ssRNA.

[0093] Fig.33– Mass spectrometry analysis of cleavage ends from LwaCas13a. (A) Schematic diagram of LwaCas13a digestion and mass spectrometry analysis of validation cleavage products. (B) Mass spectrometry analysis of digestion products from LwaCas13a incidental cleavage (left) or 2,3-cyclic phosphate activator alone (right). Major peaks are labeled with mass and corresponding structures. (C) Chromatogram traces showing the elution profiles of LwaCas13a digested activator (top) or 2,3-cyclic phosphate activator (bottom). (D) Abundance table of different compounds detected by mass spectrometry in LwaCas13a digested activator (left) or 2,3-cyclic phosphate activator (right) samples.

[0094] Fig.34 – Effects of reporter and activator optimization on Csm6 enhancement of LwaCas13a activity. (A) Schematic representation of different activator designs for Csm6 enhancement of Cas13a activity. (B) Performance of EiCsm6 enhancement of LwaCas13a assays in response to different activator designs.

[0095] Fig.35 – Effect of reporter and activator concentration on Csm6 enhancement of LwaCas13a activity. (A) Enhancement of EiCsm6 detected by LwaCas13a at various ratios of poly A and poly U reporters. (B) 6 -(U) 5 In the presence of activators, EiCsm6 detected by LwaCas13a was enhanced.

[0096] Fig.36 – Effect of in vitro transcription components on Csm6 activity. (A) EiCsm6 activity in the presence and absence of 2,3 cyclic phosphate activators in the IVT components. The components included 3 mM additional MgCl 2 , 1mM rNTP mixture, 30U T7 polymerase. (B) In the presence of various concentrations of ribonucleotides, using (A) 6 -(U) 5 Activator and poly A reporter, EiCsm6 and LwaCas13a activity. (C) In the presence of various ribonucleotide concentrations, the activity of (A) 6 -(U) 5 Activator and poly A / RNaseAlert reporter combination, combined EiCsm6 and LwaCas13a activity. (D) In ​​the presence of various ribonucleotide concentrations, the EiCsm6 and LwaCas13a proteins were expressed in the presence of various ribonucleotide concentrations. 6 -(U) 5Activator and poly A / 5x RNaseAlert reporter combination, combined EiCsm6 and LwaCas13a activity. (E) 5x (A) 6 -(U) 5 (F) Combined EiCsm6 and LwaCas13a activities using a cyclic phosphate activator and a poly A / RNaseAlert reporter combination in the presence of various ribonucleotide concentrations.

[0097] Fig.37 – Lateral flow Csm6-enhanced SHERLOCK with different reporter combinations. (A) Lateral flow assays of Csm6-enhanced SHERLOCK using various reporter designs. sA: short poly A sensor; lA: long poly A sensor; sC: short poly C sensor; lC: long poly C sensor; sA / C: short poly A / C sensor; lA / C: long poly A / C sensor; M: hybrid RNase alarm-like sensor. (B) Quantification of band intensities from assays in (A). (C) Schematic representation of lateral flow readout of EiCsm6-enhanced LwaCas13a SHERLOCK assay of acyltransferase ssDNA with separate RPA and IVT steps. (D) EiCsm6-enhanced lateral flow SHERLOCK of P. aeruginosa acyltransferase gene in combination with LwaCas13a. Band intensity quantification is shown on the right.

[0098] Fig.38 - Table of Csm6 activators used in this study. Shown are SEQ ID NO: 140 (Csm6 poly A poly U probe for U cutter 5A), SEQ ID NO: 141 (Csm6 poly A poly U probe for U cutter 6A), SEQ ID NO: 142 (Csm6 poly A poly U probe for U cutter 7A), SEQ ID NO: 143 (5' poly U / poly A 6A probe 2,3 cyclic phosphate), and SEQ ID NO: 144 (5' poly A / poly U / poly A 6A probe 2,3 cyclic phosphate). The remaining sequences in this table are shorter than 10 nucleotides and have not been assigned a sequence identifier.

[0099] Fig.39 - Table of Cas13 and Csm6 proteins purified in this study.

[0100] Fig.40- Table of crRNA used in this study. Shown are SEQ ID NOs: 145-519, where SEQ ID NOs: 145-147 represent complete crRNA sequences, spacers, and direct repeats for ssRNA / ssDNA 1crRNA2, respectively. The remaining sequence identifiers follow the same pattern.

[0101] Fig.41 - Table of RNA and DNA targets used in this study. Shown are SEQ ID NOs: 520-533.

[0102] Fig.42 - Table of RPA primers used in this study. Shown are SEQ ID NOs: 534-563, where SEQ ID NOs: 534-536 represent the forward primer sequence for DENV ssRNA, forward primer sequence (with T7 RNAP promoter), and reverse primer sequence, respectively. The rest of the sequence identifiers follow the same pattern.

[0103] Fig.43 - Table of cleavage reporters used in this study. Shown are SEQ ID NO: 564 (lateral flow reporter with FAM / biotin), SEQ ID NO: 565 (RNA motif library for base preference screening), SEQ ID NO: 566 (gold nanoparticle linker), SEQ ID NO: 567 (magnetic bead conjugate oligomer), SEQ ID NO: 568 (long poly A for lateral flow), SEQ ID NO: 569 (long poly C for lateral flow), and SEQ ID NO: 570 (long poly A / C for lateral flow). The remaining sequences listed in this table are shorter than 10 nucleotides and have not been assigned a sequence identifier. DETAILED DESCRIPTION

[0104] General Definition

[0105] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. Definitions of common terms and techniques of molecular biology can be found in: Molecular Cloning: A Laboratory Manual, 2 nd edition (1989) (Sambrook, Fritsch, and Maniatis); Molecular Cloning: A Laboratory Manual, 4 thedition(2012)(Green and Sambrook); Current Protocols in Molecular Biology(1987)(F.M. Ausubel et al. eds.); the series Methods in Enzymology(Academic Press, Inc.): PCR 2: A Practical Approach(1995)(M.J. MacPherson, B.D. Hames, and G.R. Taylor eds.): Antibodies, A Laboratory Manual(1988)(Harlow and Lane, eds.): Antibodies A Laboratory Manual, 2 ndedition2013 (EAGreenfield ed.); Animal Cell Culture (1987) (RIFreshney, ed.); BenjaminLewin, Genes IX, published by Jones and Bartlet, 2008 (ISBN 0763752223); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0632021829); Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 9780471185710); Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley&Sons (New York, NY1994), March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed., John Wiley & Sons (New York, NY1992); and Marten H. Hofker and Jan van Deursen, Transgenic MouseMethods and Protocols, 2 nd edition (2011).

[0106] As used herein, the singular forms "a", "an", and "the" include singular and plural referents unless the context clearly dictates otherwise.

[0107] The terms "optional" or "optionally" means that the subsequently described event, circumstance or substitution may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0108] The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within the respective ranges, as well as the recited endpoints.

[0109] As used herein, the terms "about" or "approximately" when referring to a measurable value, such as a parameter, amount, duration, etc., are meant to include variations or changes from the specified value, such as + / -10% or less, + / -5% or less, + / -1% or less, and + / -0.1% or less of the specified value, as long as such variations are suitable for making in the disclosed invention. It should be understood that the value referred to by the modifier "about" or "approximately" itself is also specifically and preferably disclosed.

[0110] References throughout this specification to "one embodiment," "an embodiment," or "an exemplary embodiment" mean that a particular feature, structure, or characteristic described in conjunction with that embodiment is included in at least one embodiment of the present invention. Thus, the phrases "in one embodiment," "in an embodiment," or "an exemplary embodiment" appearing in various places throughout this specification do not necessarily all refer to the same embodiment, but may refer to the same embodiment. Furthermore, in one or more embodiments, the particular features, structures, or characteristics may be combined in any suitable manner, as would be apparent to one skilled in the art from this disclosure. Furthermore, while some embodiments described herein include some features included in other embodiments but not other features, combinations of features of different embodiments are intended to be within the scope of the present invention. For example, in the appended claims, any claimed embodiment may be used in any combination.

[0111] All publications, published patent documents, and patent applications cited herein are incorporated by reference to the same extent as if each individual publication, published patent document, or patent application was specifically and individually indicated to be incorporated by reference.

[0112] Overview

[0113] The disclosed embodiments provide nucleic acid detection compositions, systems and methods. In certain embodiments, the nucleic acid detection composition comprises at least two CRISPR proteins. In certain exemplary embodiments, the composition and system comprise one or more detection proteins and one or more signal amplification proteins. The detection protein is activated by binding to the target sequence with the corresponding guide sequence, and the activation ultimately results in the generation of a detectable signal. The signal amplification protein is activated by the activity of the detection protein and further amplifies the detectable signal. In certain exemplary embodiments, the nucleic acid detection composition comprises at least one.

[0114] In one aspect, embodiments disclosed herein relate to nucleic acid detection compositions. The composition comprises at least one CRISPR detection effector protein and at least one CRISPR signal amplification effector protein. In an exemplary embodiment, the CRISPR detection effector protein is a type VI CRISPR effector protein. In an exemplary embodiment, the type VI CRISPR effector protein is a Cas13a effector protein. In another exemplary embodiment, the type VI CRISPR effector protein is a Cas13b effector protein. In certain exemplary embodiments, the CRISPR signal amplification protein is a type III CRISPR protein. In certain exemplary embodiments, the type III CRISPR protein is a Csm6 protein. In certain exemplary embodiments, the composition further comprises one or more guide sequences for detecting CRISPR effector proteins, wherein the guide sequence is designed to bind to one or more target sequences. In certain exemplary embodiments, the composition may further comprise an activation sequence for activating a signal amplification CRISPR protein. The activation sequence is different from the guide sequence and the target sequence. In certain exemplary embodiments, the activation sequence is a poly A nucleotide sequence. The poly A nucleotide sequence may have a variable length, depending on the type of CRISPR signal amplification effector protein used. In certain exemplary embodiments, the poly A activation sequence can be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. In certain exemplary embodiments, the composition comprises both a guide sequence and an activation sequence. In certain exemplary embodiments, the composition may further comprise a reporter construct as described in more detail below.

[0115] In certain other aspects, embodiments disclosed herein relate to systems comprising at least one detection CRISPR effector protein and at least one signal amplification CRISPR detection protein, one or more guide sequences, one or more guide activation sequences, and one or more reporter constructs. Each of the above elements is described in further detail below.

[0116] In certain other aspects, the compositions and systems described herein can be incorporated into devices. Suitable device platforms are described in further detail below.

[0117] In certain other aspects, embodiments disclosed herein relate to methods of detecting target nucleic acid sequences, and / or in certain exemplary embodiments, detecting proteins, using the compositions, systems, and devices disclosed herein.

[0118] For ease of reference, the embodiments disclosed herein may also be referred to as SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing).

[0119] CRISPR detection of effector proteins

[0120] Generally, CRISPR-Cas or CRISPR systems as used herein and in the literature, such as WO2014 / 093622 (PCT / US2013 / 074667), collectively refer to transcripts and other elements involved in expressing CRISPR-associated ("Cas") genes or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding: Cas genes, tracr (trans-activating CRISPR) sequences (e.g., tracrRNA or a partial tracrRNA with activity), tracr-pairing sequences (including "direct repeats" in the context of endogenous CRISPR systems and partial direct repeats processed by tracrRNA), guide sequences (also referred to as "spacers" in the context of endogenous CRISPR systems), or as the term "RNA" is used herein (e.g., RNA guiding Cas, such as Cas9, such as CRISPR RNA and trans-activating (tracr) RNA or single guide RNA (sgRNA) (chimeric RNA)) or other sequences and transcripts from a CRISPR locus. Typically, the CRISPR system is characterized by an element that promotes the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system). When the CRISPR protein is a C2c2 protein, tracrRNA is not required. C2c2 has been described in Abudayyeh et al. (2016) "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector"; Science; DOI: 10.1126 / science.aaf5573; and Shmakov et al. (2015) "Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems", Molecular Cell, DOI: dx.doi.org / 10.1016 / j.molcel.2015.10.008, the entire contents of which are incorporated herein by reference.Cas13b has been described in Smargon et al. (2017) “Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNases Differentially Regulated by Accessory Proteins Csx27 and Csx28,” Molecular Cell. 65, 1-13; dx.doi.org / 10.1016 / j.molcel.2016.12.023, the entire contents of which are incorporated herein by reference.

[0121] In certain embodiments, a protospacer adjacent motif (PAM) or PAM-like motif directs binding of an effector protein complex disclosed herein to a target locus of interest. In some embodiments, the PAM may be a 5' PAM (i.e., located upstream of the 5' end of the protospacer). In other embodiments, the PAM may be a 3' PAM (i.e., located downstream of the 5' end of the protospacer). The term "PAM" may be used interchangeably with the term "PFS" or "protospacer flanking site" or "protospacer flanking sequence".

[0122] In preferred embodiments, the CRISPR effector protein can recognize a 3'PAM. In certain embodiments, the CRISPR effector protein can recognize a 3'PAM that is 5'H, wherein H is A, C or U. In certain embodiments, the effector protein can be Leptotrichia shahii C2c2p, more preferably Leptotrichia shahii DSM 19757C2c2, and the 3'PAM is 5'H.

[0123] In the context of the formation of a CRISPR complex, a "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, wherein hybridization between the target sequence and the guide sequence promotes the formation of a CRISPR complex. The target sequence may include an RNA polynucleotide. The term "target RNA" refers to an RNA polynucleotide that is a target sequence or comprises a target sequence. In other words, the target RNA may be an RNA polynucleotide, or a portion of a gRNA (i.e., a guide sequence) is designed to have complementarity therewith and a portion of an RNA polynucleotide to which an effector function mediated by a complex comprising a CRISPR effector protein and a gRNA is directed. In some embodiments, the target sequence is located in the nucleus or cytoplasm of a cell.

[0124] The nucleic acid molecule encoding the CRISPR effector protein, in particular C2c2, is advantageously a codon-optimized CRISPR effector protein. Examples of codon-optimized sequences in this case are sequences optimized for expression in eukaryotes, such as humans (i.e., optimized for expression in humans), or for another eukaryote, animal, or mammal discussed herein; see, for example, the SaCas9 human codon-optimized sequence in WO2014 / 093622 (PCT / US2013 / 074667). Although this is preferred, it should be understood that other examples are possible, and codon optimization for host species other than humans, or codon optimization for specific organs is known. In some embodiments, the enzyme coding sequence encoding the CRISPR effector protein is a codon optimized for expression in a specific cell (e.g., a eukaryotic cell). Eukaryotic cells can be those derived from specific organisms, such as plants or mammals, including but not limited to humans, or non-human eukaryotic organisms, or animals or mammals discussed herein, such as mice, rats, rabbits, dogs, livestock or non-human mammals or primates. In some embodiments, the method for modifying the germline genetic characteristics of people and / or the method for modifying the genetic characteristics of animals, which may cause them to suffer without any substantial medical benefit to people or animals, and the animals produced by such methods, can be excluded. Generally, codon optimization refers to by replacing at least one codon of a native sequence (for example, about or more than about 1,2,3,4,5,10,15,20,25,50 or more codons) with a codon more frequently or most frequently used in the gene of a host cell while keeping the native amino acid sequence to modify the nucleic acid sequence to enhance the process of expression in the host cell of interest. Various species show specific preferences to certain codons of specific amino acids. Codon bias (differences in codon usage between organisms) is often associated with the efficiency of translation of messenger RNA (mRNA), which in turn is thought to depend on the properties of the codons being translated and the availability of specific transfer RNA (tRNA) molecules. The dominance of the selected tRNA in the cell is often a reflection of the most frequently used codons in peptide synthesis. Therefore, genes can be customized based on codon optimization for optimal gene expression in a given organism. Codon usage tables are readily available, for example, in the "Codon Usage Database" available at kazusa.orjp / codon / , and these tables can be adjusted in a variety of ways. See Nakamura, Y et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28: 292 (2000).Computer algorithms for codon optimization of specific sequences for expression in specific host cells are also available, such as Gene Forge (Aptagen; Jacobus, PA). In some embodiments, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more or all codons) in the sequence encoding Cas correspond to the most frequently used codons for a specific amino acid. The present invention will be further described in the examples below, which do not limit the scope of the invention described in the claims.

[0125] In an exemplary embodiment, the detection effector protein comprises one or more HEPN domains comprising a RxxxxH motif sequence. The RxxxxH motif sequence can be, but is not limited to, from a HEPN domain described herein or a HEPN domain known in the art. The RxxxxH motif sequence also comprises a motif sequence generated by combining portions of two or more HEPN domains. As described above, the consensus sequence can be obtained from the sequences of the orthologs disclosed in the following: U.S. Provisional Patent Application 62 / 432,240 entitled “Novel CRISPR Enzymes and Systems”, U.S. Provisional Patent Application 62 / 471,710 entitled “Novel Type VI CRISPR Orthologs and Systems” filed on March 15, 2017, and U.S. Provisional Patent Application marked with Attorney Docket No. 47627-05-2133 and filed on April 12, 2017, entitled “Novel Type VICRISPR Orthologs and Systems”.

[0126] In an embodiment of the invention, the HEPN domain comprises at least one RxxxxH motif comprising a sequence of R{N / H / K}X1X2X3H (SEQ ID NO: 571). In an embodiment of the invention, the HEPN domain comprises a RxxxxH motif comprising a sequence of R{N / H}X1X2X3H (SEQ ID NO: 572). In an embodiment of the invention, the HEPN domain comprises a sequence of R{N / K}X1X2X3H (SEQ ID NO: 573). In certain embodiments, X1 is R, S, D, E, Q, N, G, Y or H. In certain embodiments, X2 is I, S, T, V or L. In certain embodiments, X3 is L, F, N, Y, V, I, S, D, E or A.

[0127] Other effectors used according to the present invention can be identified by their proximity to the cas1 gene, for example, but not limited to, within a region of 20 kb from the start of the cas1 gene and 20 kb from the end of the cas1 gene. In certain embodiments, the effector protein comprises at least one HEPN domain and at least 500 amino acids, and wherein the C2c2 effector protein is naturally present in a prokaryotic genome within 20 kb upstream or downstream of a Cas gene or CRISPR array. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof. In certain exemplary embodiments, the C2c2 effector protein is naturally present in the genome of a prokaryotic organism within 20 kb upstream or downstream of the Cas1 gene. The terms "orthologs" (also referred to herein as "orthologs") and "homologs" (also referred to herein as "homologs") are well known in the art. By further guidance, a "homolog" of a protein used herein is a protein of the same species that performs the same or similar function as the protein to which it is a homolog. Homologous proteins may, but need not, be structurally related, or only partially related in structure. An "ortholog" of a protein used herein is a protein of a different species that performs the same or similar function as the protein to which it is an ortholog. Orthologous proteins may, but need not, be structurally related, or only partially related in structure.

[0128] In a particular embodiment, the CRISPR detection effector protein is a type VI RNA-targeted Cas enzyme. In certain exemplary embodiments, the type VI RNA-targeted Cas enzyme is Cas 13a, also referred to herein as C2c2. In other exemplary embodiments, the type VI RNA-targeted Cas enzyme is Cas 13b. In a specific embodiment, a homolog or ortholog of a Type VI protein, such as C2c2, has at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, more preferably at least 85%, even more preferably at least 90%, for example at least 95% sequence homology or identity with a Type VI protein, such as C2c2 (e.g., based on Leptotricia shahii C2c2, Lachnospiraceae bacterium MA2020 C2c2, Lachnospiraceae bacterium NK4A179 C2c2, Clostridium aminophilum (DSM10710) C2c2, Carnobacterium gallinarum (DSM 4847) C2c2, Paludibacter propionicigenes (WB4) C2c2, Listeria weihenstephanensis (FSL R9-0317) C2c2, Listeria monocytogenes (FSL M6-0635) C2c2, Listeria newyorkensis (FSL M6-0635) C2c2, Leptotrichiawadei (F0279) C2c2, Rhodobacter capsulatus (SB 1003) C2c2, Rhodobacter capsulatus (R121) C2c2, Rhodobacter capsulatus (DE442) C2c2, Leptotrichia wadei (Lw2) C2c2 or Listeria seeligeri C2c2).In another embodiment, the homolog or ortholog of the type VI protein, such as C2c2, mentioned herein has at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, more preferably at least 85%, even more preferably at least 90%, for example at least 95% sequence identity with wild-type C2c2 (e.g., based on Leptotricia shahii C2c2, Lachnospiraceae bacterium MA2020 C2c2, Lachnospiraceae bacterium NK4A179 C2c2, Clostridium aminophilum (DSM 10710) C2c2, Carnobacterium gallinarum (DSM 4847) C2c2, Paludibacter propionicigenes (WB4) C2c2, Listeria weihenstephanensis (FSL R9-0317) C2c2, Listeria monocytogenes (FSL M6-0635) C2c2, Listeria newyorkensis (FSL M6-0635) C2c2, Leptotrichia wadei (F0279) C2c2, Rhodobacter capsulatus (SB 1003) C2c2, Rhodobacter capsulatus (R121) C2c2, Rhodobacter capsulatus (DE442) C2c2, Leptotrichia wadei (Lw2) C2c2 or Listeria seeligeri C2c2).

[0129] In certain other exemplary embodiments, the CRISPR effector protein is a C2c2 nuclease. The activity of C2c2 may depend on the presence of two HEPN domains. These have been shown to be RNase domains, i.e., nucleases (particularly endonucleases) that cut RNA. C2c2 HEPN can also target DNA, or potential DNA and / or RNA. Based on the HEPN domain of C2c2 being at least able to bind and cut RNA in its wild-type form, it is preferred that the C2c2 effector protein has RNase function. With respect to the C2c2 CRISPR system, reference is made to U.S. Provisional Application No. 62 / 351,662 filed on June 17, 2016 and U.S. Provisional Application No. 62 / 376,377 filed on August 17, 2016. Reference is also made to U.S. Provisional Application No. 62 / 351,803 filed on June 17, 2016. Reference is also made to U.S. Provisional Application entitled “Novel Crispr Enzymes and Systems” filed on December 8, 2016 bearing Broad Institute No. 10035.PA4 and Attorney Docket No. 47627.03.2133. Reference is further made to East-Seletsky et al. “Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection” Nature doi:10 / 1038 / nature19802 and Abudayyeh et al. “C2c2 is a single-component programmable RNA-guided RNA targeting CRISPR effector” bioRxiv doi:10.1101 / 054742.

[0130] RNase function in CRISPR systems is known, for example, mRNA targeting has been reported for certain type III CRISPR-Cas systems (Hale et al., 2014, Genes Dev, vol. 28, 2432-2443; Hale et al., 2009, Cell, vol. 139, 945-956; Peng et al., 2015, Nucleic acids research, vol. 43, 406-417) and provides significant advantages. In the type III-A system of Staphylococcus epidermidis, transcription throughout the target leads to the cleavage of the target DNA and its transcripts mediated by independent active sites within the Cas10-Csm ribonucleoprotein effector protein complex (see Samai et al., 2015, Cell, vol. 151, 1164-1174). Therefore, a CRISPR-Cas system, composition or method for targeting RNA by the present effector protein is provided.

[0131] In one embodiment, the Cas protein may include, but is not limited to, C2c2 orthologs of organisms of the following genera: Leptotrichia, Listeria, Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, The biological species of such genus can be as discussed in addition herein.

[0132] Some methods of identifying orthologs of CRISPR-Cas system enzymes can include identifying tracr sequences in the genome of interest. Identification of tracr sequences can involve the following steps: Searching for direct repeat sequences or tracr mate sequences in a database to identify CRISPR regions containing CRISPR enzymes. Searching for homologous sequences in the CRISPR regions flanking the CRISPR enzyme in both sense and antisense directions. Looking for transcription terminators and secondary structures. Identify any sequence that is not a direct repeat sequence or tracr mate sequence but has more than 50% identity with a direct repeat sequence or tracr mate sequence as a potential tracr sequence. Take a potential tracr sequence and analyze the transcription terminator sequence associated with it.

[0133] It should be understood that any functionality described herein can be engineered into CRISPR enzymes from other orthologs, including chimeric enzymes comprising fragments from multiple orthologs. Examples of such orthologs are described elsewhere herein. Thus, a chimeric enzyme may comprise a fragment of an ortholog of a CRISPR enzyme from an organism including, but not limited to, Leptotrichia, Listeria, Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, The chimeric enzyme may comprise a first fragment and a second fragment, and the fragments may be orthologs of CRISPR enzymes of organisms of the genus mentioned herein or of the species mentioned herein; advantageously, the fragments are orthologs of CRISPR enzymes from different species.

[0134] In an embodiment, the C2c2 protein referred to herein also encompasses functional variants of C2c2 or homologs or orthologs thereof. As used herein, a "functional variant" of a protein refers to a variant of such a protein that at least partially retains the activity of the protein. Functional variants may include mutants (which may be insertion, deletion or substitution mutants), including polymorphs, etc. Functional variants also include fusion products of such a protein with another generally unrelated nucleic acid, protein, polypeptide or peptide. Functional variants may be naturally occurring or may be artificial. Advantageous embodiments may relate to engineered or non-naturally occurring Type VI RNA targeting effector proteins.

[0135] In one embodiment, one or more nucleic acid molecules encoding C2c2 or its orthologs or homologs can be codon optimized for expression in eukaryotic cells. The eukaryotic organism can be as described herein. The one or more nucleic acid molecules can be engineered or non-naturally occurring.

[0136] In one embodiment, C2c2 or its ortholog or homolog may comprise one or more mutations (and thus the nucleic acid molecule encoding it may have one or more mutations. The mutation may be an artificially introduced mutation and may include, but is not limited to, one or more mutations in the catalytic domain. Examples of catalytic domains of reference Cas9 enzymes may include, but are not limited to, RuvC I, RuvC II, RuvC III, and HNH domains.

[0137] In one embodiment, C2c2 or its ortholog or homolog may comprise one or more mutations. The mutation may be an artificially introduced mutation and may include, but is not limited to, one or more mutations in the catalytic domain. Examples of reference Cas enzyme catalytic domains may include, but are not limited to, HEPN domains.

[0138] In one embodiment, C2c2 or its orthologs or homologs can be used as universal nucleic acid binding proteins fused or operably linked to functional domains. Exemplary functional domains can include, but are not limited to, translation initiators, translation activators, translation repressors, nucleases, particularly ribonucleases, spliceosomes, beads, light-inducible / controllable domains, or chemically-inducible / controllable domains.

[0139] In certain exemplary embodiments, the C2c2 effector protein can be from an organism selected from the group consisting of Leptotrichia, Listeria, Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, Campylobacter.

[0140] In certain embodiments, the effector protein can be Listeria C2c2p, preferably Listeria seeligeria C2c2p, more preferably Listeria seeligeria serovar 1 / 2b str. SLCC3954 C2c2p, and the crRNA sequence length can be 44 to 47 nucleotides with a 5' 29-nt direct repeat (DR) and a 15-nt to 18-nt spacer.

[0141] In certain embodiments, the effector protein can be Leptotrichia C2c2p, preferably Leptotrichia shahii C2c2p, more preferably Leptotrichia shahii DSM 19757 C2c2p, and the crRNA sequence length can be 42 to 58 nucleotides, with a 5' direct repeat of at least 24 nt, such as a 5' 24-28-nt direct repeat (DR), and a spacer of at least 14 nt, such as a 14-nt to 28-nt spacer, or a spacer of at least 18 nt, such as 19, 20, 21, 22 or more nt, such as 18-28, 29-28, 20-28, 21-28 or 22-28 nt.

[0142] In certain exemplary embodiments, the effector protein may be Leptotrichia, Leptotrichia wadeiF0279, or Listeria, preferably Listeria newyorkensis FSL M6-0635.

[0143] In certain exemplary embodiments, the C2c2 effector proteins of the invention include, but are not limited to, the following 21 orthologous species (including multiple CRISPR loci: Leptotrichia shahii; Leptotrichia wadei (Lw2); Listeria seeligeri; Lachnospiraceae bacterium MA2020; Lachnospiraceae bacterium NK4A179; [Clostridium] aminophilum DSM 10710; Carnobacterium gallinarum DSM 4847; Carnobacterium gallinarum DSM 4847 (second CRISPR locus); Paludibacterpropionicigenes WB4; Listeria weihenstephanensis FSL R9-0317; Listeriaceaebacterium FSL M6-0635; Leptotrichia wadei F0279; Rhodobacter capsulatus SB1003; Rhodobacter capsulatus R121; Rhodobacter capsulatus DE442; Leptotrichiabuccalis C-1013-b; Herbinix hemicellulosilytica; [Eubacteriaceae] recale; Eubacteriaceae bacterium CHKCI004; Blautia sp.Marseille-P2398;Twelve (12) additional non-limiting examples are: Lachnospiraceae bacterium NK4A144; Chloroflexus aggregans; Demequina aurantiaca; Thalassospirasp.TSL5-1; Pseudobutyrivibrio sp.OR37; Butyrivibrio sp.YAB3001; Blautiap.Marseille-P2398; Leptotrichia sp.Marseille-P3007; Bacteroides ihuae; Porphyromonadaceae bacterium KH3CP3RA; Listeria riparia; and Insolitispirillumperegrinum.

[0144] In certain embodiments, a C2c2 protein according to the present invention is or is derived from one of the orthologs described in the table below, or is a chimeric protein of two or more orthologs described in the table below, or is a mutant or variant (or chimeric mutant or variant) of one of the orthologs described in the table below, including dead C2c2, split C2c2, destabilized C2c2, etc., as defined elsewhere herein, with or without fusion to a heterologous / functional domain.

[0145] In certain exemplary embodiments, the C2c2 effector protein is selected from Table 1 below.

[0146] Table 1

[0147]

[0148]

[0149] Table 2

[0150] The wild-type protein sequences of the above species are listed in Table 2 below. In certain embodiments, a nucleic acid sequence encoding a C2c2 protein is provided.

[0151]

[0152]

[0153] In one embodiment of the present invention, an effector protein is provided, which comprises a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a polypeptide having a The wild-type sequence of any one of Rhodobacter capsulatus (R121) C2c2, Rhodobacter capsulatus (DE442) C2c2, Leptotrichia wadei (Lw2) C2c2 or Listeria seeligeri C2c2 has an amino acid sequence with at least 80% sequence homology.

[0154] In an embodiment of the invention, the effector protein comprises an amino acid sequence having at least 80% sequence homology to a Type VI effector protein consensus sequence, including but not limited to the consensus sequence described herein.

[0155] According to the present invention, consensus sequences can be generated from multiple C2c2 orthologs, which can help locate conserved amino acid residues, and motifs, including but not limited to catalytic residues and HEPN motifs in C2C2 orthologs that mediate C2C2 function. One such consensus sequence generated from the 33 orthologs mentioned above using gene alignment is: SEQ ID NO: 32.

[0156] In another non-limiting example, a sequence alignment tool that assists in the generation of consensus sequences and the identification of conserved residues is the MUSCLE alignment tool ( www.ebi.ac.uk / Tools / msa / muscle / ). For example, using MUSCLE, the following amino acid positions that are conserved in C2c2 orthologs can be identified in Leptotrichia wadei C2c2: K2; K5; V6; E301; L331; I335; N341; G351; K352; E375; L392; L396; D403; F446; I466; I470; R474 (HEPN); H475; H479 (HEPN), E508; P556; L561; I595; Y596; F600; Y669; I673; F681; L685; Y761; L676; L779; Y782; L836; D847; Y863; L869; 61; Y965; E970; R971; D972; R1046 (HEPN), H1051 (HEPN), Y1075; D1076;

[0157] In certain exemplary embodiments, the RNA targeting effector protein is a type VIB effector protein, such as Cas13b and a protein of group 29 or group 30. In certain exemplary embodiments, the RNA targeting effector protein comprises one or more HEPN domains. In certain exemplary embodiments, the RNA targeting effector protein comprises a C-terminal HEPN domain, an N-terminal HEPN domain, or both. For exemplary VI-B effector proteins that can be used in the context of the present invention, reference is made to U.S. Application No. 15 / 331,792, filed October 21, 2016, entitled “Novel CRISPR Enzymes and Systems,” International Patent Application No. PCT / US2016 / 058302, filed October 16, 2016, entitled “Novel CRISPR Enzymes and Systems,” and Smargon et al., “Cas13b is a Type VI-B CRISPR-associated RNA-Guided RNase differentially regulated by accessory proteins Csx27 and Csx28,” Molecular Cell, 65, 1-13 (2017); dx.doi.org / 10.1016 / j.molcel.2016.12.023, and U.S. Provisional Application No. to be designated, filed March 15, 2017, entitled “Novel Cas13b Orthologues CRISPR Enzymes andSystem". In a specific embodiment, the Cas13b enzyme is from Bergeyella zoohelcum. In certain other exemplary embodiments, the detection effector protein is or comprises an amino acid sequence having at least 80% sequence homology to any sequence listed in Table 3.

[0158] Table 3

[0159]

[0160]

[0161]

[0162]

[0163] Guide sequence

[0164] As used herein, the term "crRNA" or "guide RNA" or "single guide RNA", "gRNA" refers to a polynucleotide comprising any polynucleotide sequence that has sufficient complementarity to a target nucleic acid sequence to hybridize with the target nucleic acid sequence, and guides the sequence-specific binding of an nRNA targeting complex comprising a gRNA and a CRISPR effector protein to the target nucleic acid sequence. Generally, a gRNA can be any polynucleotide sequence that (i) is capable of forming a complex with a CRISPR effector protein, and (ii) comprises a sequence that has sufficient complementarity to a target polynucleotide sequence to hybridize with the target sequence and guides the sequence-specific binding of a CRISPR complex to the target sequence. As used herein, the term "capable of forming a complex with a CRISPR effector protein" means that the gRNA has a structure that allows the CRISPR effector protein to specifically bind to the gRNA so as to form a complex that can bind to the target RNA in a sequence-specific manner and can function on the target RNA. The structural components of the gRNA may include a direct repeat sequence and a guide sequence (or spacer). Sequence-specific binding to the target RNA is mediated by a portion of the gRNA that is complementary to the target RNA ("guide sequence") In an embodiment of the present invention, the term guide RNA, i.e., RNA capable of guiding Cas to a target locus, is used in previously cited documents such as WO2014 / 093622 (PCT / US2013 / 074667). As used herein, the term "wherein the guide sequence is capable of hybridizing" refers to a subsection of the gRNA having sufficient complementarity with the target sequence to hybridize therewith and mediate the binding of the CRISPR complex to the target RNA. Typically, the guide sequence is any polynucleotide sequence that has sufficient complementarity with the target nucleic acid sequence to hybridize with the target nucleic acid sequence and guide the sequence-specific binding of the CRISPR complex to the target sequence. In some embodiments, when optimally aligned using a suitable alignment algorithm, the degree of complementarity between the guide sequence and its corresponding target sequence is about or greater than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.Optimal alignment can be determined using any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler transform (e.g., Burrows WheelerAligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available from www.novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available from soap.genomics.org.cn), and Maq (available from maq.sourceforge.net).

[0165] In certain embodiments, the CRISPR system provided herein may utilize crRNA or similar polynucleotides comprising a guide sequence, wherein the polynucleotide is a mixture of RNA, DNA, or RNA and DNA, and / or wherein the polynucleotide comprises one or more nucleotide analogs. The sequence may comprise any structure, including but not limited to the structure of natural crRNA, such as a bulge, a hairpin, or a stem-loop structure. In certain embodiments, the polynucleotide comprising a guide sequence forms a duplex with a second polynucleotide sequence that may be an RNA or DNA sequence.

[0166] In some embodiments, a chemically modified guide RNA is used. Examples of guide RNA chemical modification include, but are not limited to, introducing 2'-O-methyl (M), 2'-O-methyl 3' thiophosphate (MS) or 2'-O-methyl 3' thio PACE (MSP) at one or more terminal nucleotides. Such chemically modified guide RNAs can include increased stability and increased activity compared to unmodified guide RNAs, although the specificity of the target relative to the off-target is not predictable. (See, Hendel, 2015, Nat Biotechnol. 33 (9): 985-9, doi: 10.1038 / nbt.3290, published online on June 29, 2015). Chemically modified guide RNAs also include, but are not limited to, RNAs with locked nucleic acid (LNA) nucleotides having a phosphorothioate bond and a methylene bridge between the 2' and 4' carbons of the ribose ring.

[0167] In some embodiments, the length of the guide sequence is about or greater than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75 or more nucleotides. In some embodiments, the length of the guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12 or less nucleotides. Preferably, the guide sequence is 10 to 30 nucleotides long. The ability of the guide sequence to direct sequence-specific binding of the CRISPR complex to the target sequence can be assessed by any suitable assay. For example, components of a CRISPR system sufficient to form a CRISPR complex, including the guide sequence to be tested, can be provided to a host cell having a corresponding target sequence, such as by transfection with a vector encoding the components of the CRISPR sequence, and then assessing preferential cleavage within the target sequence, such as by the Surveyor assay described herein. Similarly, cleavage of a target RNA can be assessed in a test tube by providing a target sequence, components of a CRISPR complex, including a guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing the binding or cleavage rates at the target sequence between the test and control guide sequence reactions. Other assays are possible and will occur to those skilled in the art.

[0168] Guide sequence, and therefore nucleic acid targeting guide RNA can be selected to target any target nucleic acid sequence. In the context of the formation of CRISPR complex, "target sequence" refers to a sequence to which the guide sequence is designed to have complementarity, wherein the hybridization between the target sequence and the guide sequence promotes the formation of CRISPR complex. The target sequence may include RNA polynucleotides. The term "target RNA" refers to an RNA polynucleotide that is or comprises a target sequence. In other words, the target RNA may be a part of a gRNA (i.e., a guide sequence) designed to have complementarity with it and directed to an RNA polynucleotide or a part of an RNA polynucleotide mediated by a complex comprising a CRISPR effector protein and a gRNA. In some embodiments, the target sequence is located in the nucleus or cytoplasm of a cell. The target sequence may be DNA. The target sequence may be any RNA sequence. In some embodiments, the target sequence can be a sequence within an RNA molecule selected from emissive RNA (mRNA), pre-mRNA, ribosomal RNA (rRNA), transfer RNA (tRNA), microRNA (miRNA), small interfering RNA (siRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), double-stranded RNA (dsRNA), non-coding RNA (ncRNA), long non-coding RNA (lncRNA) and small cytoplasmic RNA (scRNA). In some preferred embodiments, the target sequence can be a sequence within an RNA molecule selected from mRNA, pre-mRNA and rRNA. In some preferred embodiments, the target sequence can be a sequence within an RNA molecule selected from ncRNA and lncRNA. In some more preferred embodiments, the target sequence can be a sequence within an mRNA molecule or a pre-mRNA molecule.

[0169] In some embodiments, the nucleic acid targeting guide RNA is selected to reduce the degree of secondary structure within the RNA targeting guide RNA. In some embodiments, about or less than about 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less of the nucleotides of the nucleic acid targeting guide RNA participate in self-complementary base pairing when optimally folded. Optimal folding can be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimum Gibbs free energy. As described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148), an example of such an algorithm is mFold. Another exemplary folding algorithm is RNAfold, an online web server developed at the Institute of Theoretical Chemistry, University of Vienna, using a centroid structure prediction algorithm (see, for example, ARGruber et al., 2008, Cell 106 (1): 23-24; and PACarr and GM Church, 2009, Nature Biotechnology 27 (12): 1151-62).

[0170] In certain embodiments, the guide RNA or crRNA may include a direct repeat (DR) sequence and a guide sequence or a spacer sequence, consisting essentially of or consisting of the above. In certain embodiments, the guide RNA or crRNA may include a direct repeat sequence fused or connected to a guide sequence or a spacer sequence, consisting essentially of or consisting of the above. In certain embodiments, the direct repeat sequence may be located upstream (i.e., 5') of the guide sequence or the spacer sequence. In other embodiments, the direct repeat sequence may be located downstream (i.e., 3') of the guide sequence or the spacer sequence.

[0171] In certain embodiments, the crRNA comprises a stem loop, preferably a single stem loop. In certain embodiments, the direct repeat sequence forms a stem loop, preferably a single stem loop.

[0172] In some embodiments, the spacer length of the guide RNA is 15 to 35 nt. In some embodiments, the spacer length of the guide RNA is at least 15 nucleotides, preferably at least 18 nt, such as at least 19, 20, 21, 22 or more nt. In some embodiments, the spacer length is 15 to 17nt, such as 15, 16 or 17nt, 17 to 20nt, such as 17, 18, 19 or 20nt, 20 to 24nt, such as 20, 21, 22, 23 or 24nt, 23 to 25nt, such as 23, 24 or 25nt, 24 to 27nt, such as 24, 25, 26 or 27nt, 27 to 30nt, such as 27, 28, 29 or 30nt, 30 to 35nt, such as 30, 31, 32, 33, 34 or 35nt, or 35nt or longer.

[0173] In some embodiments, the spacer length of the guide RNA is less than 28 nucleotides. In some embodiments, the spacer length of the guide RNA is at least 18 nucleotides and less than 28 nucleotides. In some embodiments, the spacer length of the guide RNA is 19 to 28 nucleotides. In some embodiments, the spacer length of the guide RNA is 19 to 25 nucleotides. In some embodiments, the spacer length of the guide RNA is 20 nucleotides. In some embodiments, the spacer length of the guide RNA is 23 nucleotides. In some embodiments, the spacer length of the guide RNA is 25 nucleotides.

[0174] In a classical CRISPR-Cas system, the degree of complementarity between a guide sequence and its corresponding target sequence can be about or greater than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or 100%; the length of the guide or RNA or sgRNA can be about or greater than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27. 28, 29, 30, 35, 40, 45, 50, 75 or more nucleotides; or the length of the guide or RNA or sgRNA can be less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12 or fewer nucleotides. However, one aspect of the invention is to reduce off-target interactions, for example, to reduce the interaction of the guide with a target sequence having low complementarity. Indeed, in the Examples, it is shown that the invention relates to mutations that result in the CRISPR-Cas system being able to distinguish between a target sequence and an off-target sequence having greater than 80% to about 95% complementarity, such as 83%-84% or 88-89% or 94-95% complementarity (e.g., distinguishing a target having 18 nucleotides from an off-target having 18 nucleotides with 1, 2 or 3 mismatches). Thus, in the context of the present invention, the degree of complementarity between a guide sequence and its corresponding target sequence is greater than 94.5% or 95% or 95.5% or 96% or 96.5% or 97% or 97.5% or 98% or 98.5% or 99% or 99.5% or 99.9%, or 100%. An off-target is less than 100% or 99.9% or 99.5% or 99% or 99% or 98.5% or 98% or 97.5% or 97% or 96.5% or 96% or 95.5% or 95% or 94.5% or 94% or 93% or 92% or 91% or 90% or 89% or 88% or 87% or 86% or 85% or 84% or 83% or 82% or 81% or 80% complementarity between the sequence and the guide, advantageously an off-target is 100% or 99.9% or 99.5% or 99% or 99% or 98.5% or 98% or 97.5% or 97% or 96.5% or 96% or 95.5% or 95% or 94.5% complementarity between the sequence and the guide.

[0175] In certain embodiments, the regulation of cutting efficiency can be achieved by introducing mismatches, such as 1 or more mismatches, such as 1 or 2 mismatches, between the spacer sequence and the target sequence, including the position of the mismatch along the spacer / target. For example, the more central the double mismatch is (i.e., not 3' or 5'), the more the cutting efficiency is affected. Therefore, by selecting the position of the mismatch along the spacer, the cutting efficiency can be adjusted. For example, if less than 100% target cutting is desired (e.g., in a cell population), 1 or more, such as preferably 2 mismatches, between the spacer and the target sequence can be introduced in the spacer sequence. The more central the mismatch position is along the spacer, the lower the percentage of cutting.

[0176] In certain exemplary embodiments, the cutting efficiency can be utilized to design a single guide for two or more targets that can distinguish single nucleotide changes, such as single nucleotide polymorphisms (SNPs), variations, or (point) mutations. The CRISPR effector can have a reduced sensitivity to SNPs (or other single nucleotide variations), and continue to cut the SNP target with a certain level of efficiency. Therefore, for two targets, or a target group, a guide RNA having a nucleotide sequence complementary to one of the targets, i.e., the target SNP, can be designed. The guide RNA is further designed to have a synthetic mismatch. As used herein, "synthetic mismatch" refers to a non-natural mismatch introduced upstream or downstream of a naturally occurring SNP, such as 5 nucleotides upstream or downstream at most, such as 4, 3, 2 or 1 nucleotides upstream or downstream, preferably 3 nucleotides upstream or downstream at most, more preferably 2 nucleotides upstream or downstream at most, and most preferably 1 nucleotide upstream or downstream (i.e., adjacent to SNP). When the CRISPR effector is combined with the target SNP, only a single mismatch will be formed with the synthetic mismatch, and the CRISPR effector will continue to be activated, and a detectable signal will be generated. When the guide RNA hybridizes to the off-target SNP, two mismatches will be formed, the mismatch from the SNP and the synthetic mismatch, and no detectable signal will be generated. Therefore, the system disclosed herein can be designed to distinguish SNPs within a population. For example, the system disclosed herein can be used to distinguish pathogenic strains that differ by a single SNP or detect certain disease-specific SNPs, such as but not limited to disease-associated SNPs, such as but not limited to cancer-associated SNPs.

[0177] In certain embodiments, the guide RNA is designed such that the SNP is located at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 of the spacer sequence (starting from the 5' end). In certain embodiments, the guide RNA is designed such that the SNP is located at position 1, 2, 3, 4, 5, 6, 7, 8 or 9 of the spacer sequence (starting from the 5' end). In certain embodiments, the guide RNA is designed such that the SNP is located at position 2, 3, 4, 5, 6 or 7 of the spacer sequence (starting from the 5' end). In certain embodiments, the guide RNA is designed such that the SNP is located at position 3, 4, 5 or 6 of the spacer sequence (starting from the 5' end). In certain embodiments, the guide RNA is designed such that the SNP is located at position 3 of the spacer sequence (starting from the 5' end).

[0178] In certain embodiments, the guide RNA is designed such that the mismatch (e.g., synthetic mismatch, i.e., additional mutation other than the SNP) is located at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the spacer sequence (starting from the 5' end). In certain embodiments, the guide RNA is designed such that the mismatch is located at position 1, 2, 3, 4, 5, 6, 7, 8, or 9 of the spacer sequence (starting from the 5' end). In certain embodiments, the guide RNA is designed such that the mismatch is located at position 4, 5, 6, or 7 of the spacer sequence (starting from the 5' end). In certain embodiments, the guide RNA is designed such that the mismatch is located at position 5 of the spacer sequence (starting from the 5' end).

[0179] In certain embodiments, the guide RNA is designed such that the mismatch is located 2 nucleotides upstream of the SNP (ie, one intervening nucleotide).

[0180] In certain embodiments, the guide RNA is designed such that the mismatch is located 2 nucleotides downstream of the SNP (ie, one intervening nucleotide).

[0181] In certain embodiments, the guide RNA is designed such that the mismatch is located at position 5 of the spacer sequence (starting from the 5' end) and the SNP is located at position 3 of the spacer sequence (starting from the 5' end).

[0182] Embodiments described herein include inducing one or more nucleotide modifications in eukaryotic cells discussed herein (in vitro, i.e., in isolated eukaryotic cells), including delivering a vector as discussed herein to the cell. The mutation may include introducing, deleting, or replacing one or more nucleotides at each target sequence of the cell by a guide RNA. The mutation may include introducing, deleting, or replacing 1-75 nucleotides at each target sequence of the cell by a guide RNA. The mutation may include introducing, deleting, or replacing 1, 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides at each target sequence of the cell by a guide RNA. The mutations may comprise introducing, deleting or replacing 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or 75 nucleotides at each target sequence of the cell by a guide RNA. The mutations comprise introducing, deleting or replacing 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or 75 nucleotides at each target sequence of the cell by a guide RNA. The mutation may comprise introducing, deleting or replacing 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or 75 nucleotides at each target sequence of the cell by the guide RNA. The mutation may comprise introducing, deleting or replacing 40, 45, 50, 75, 100, 200, 300, 400 or 500 nucleotides at each target sequence of the cell by the guide RNA.

[0183] Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage within or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs from the target sequence), but may depend, for example, on secondary structure, particularly in the case of RNA targets.

[0184] Signal Amplification CRISPR Effector Proteins

[0185] In certain exemplary embodiments, the signal amplification CRISPR effector protein is a type III-A CRISPR-Cas system effector protein. In certain exemplary embodiments, the type III-A CRISPR-Cas effector protein is Csm6. Csm6 functions with the multiprotein Csm effector complex but is not part of the complex (see, e.g., US20170198286A1; WO2016035044A1; M. Kazlauskiene et al., Science 10.1126 / science.aao0100 (2017); and Niewoehner et al., 2017, bioRxiv preprint first published online on June 23, 2017; doi: dx.doi.org / 10.1101 / 153262).

[0186] In Staphylococcus epidermidis, the Csm complex (SeCsm) comprises Cas10, Csm2, Csm3, Csm4, and Csm5 proteins. Using the Csm complex of Streptococcus thermophilus (St), it was demonstrated that the type III-A CRISPR-Cas system has RNA cleavage activity both in vitro and in cells (see, e.g., US20170198286A1).

[0187] Type III-A CRISPR-Cas systems include Streptococcus thermophilus (GenBank KM222358), DGCC7710 (GenBank AWVZ01000003), LMD-9 (GenBank NC008532), Staphylococcus epidermidis RP62a (GenBank NC002976), Enterococcus italicum DSM15952 (GenBank AEPV01000074), Lactococcus lactis DGCC7167 (GenBank JX524189), and Sulfolobus solfataricus P2 (GenBank AE006641). The type III-A system of DGCC8004 contains 10 cas genes flanking the CRISPR2 array, including cast, cas2, cas6, cas10, csm2, csm3, csm4, csm5, csm6, and csm6' genes. The DGCC8004 CRISPR2 locus shares a similar gene arrangement with the loci of DGCC7710 (GenBank AWVZ00000000, (Horvath and Barrangou, 2010)) and LMD-9 (GenBank NC_008532, (Makarova et al., 2006)). The main difference is the additional csm6' gene in DGCC8004. The Csm6' protein in DGCC8004 contains 386 amino acids and has 34% amino acid identity with the 428 amino acid Csm6 protein, suggesting a possible ancient gene duplication event followed by sequence divergence. In contrast, DGCC7710 contains only a short 117-nt ORF in front of csm6. The CRISPR2-associated Cas / Csm proteins in DGCC8004 are homologous to the corresponding proteins in DGCC7710 and LMD-9 (more than 90% amino acid identity, except for the Csm2 protein, which shares about 70% identity). Other experimentally characterized type III-A systems include Staphylococcus epidermidis RP62a (GenBank NC002976, (Marraffini and Sontheimer, 2008)), Enterococcus italicum DSM15952 (GenBank AEPV01000074, (Millen et al., 2012)), and Lactococcus lactis DGCC7167 (GenBank JX524189, (Millen et al., 2012)). They share the conserved arrangement of the cas10-csm2-csm3-csm4-csm5-csm6 gene cluster with DGCC8004, whereas the positions of the cas6 and cast / cas2 genes vary in some strains.The type III-A CRISPR-Cas locus in Sulfolobus solfataricus P2 (GenBank AE006641) has a different gene organization, showing low protein sequence similarity to the Cas / Csm orthologs in DGCC8004. Notably, the Csm3 protein is the most conserved among the Cas / Csm proteins in different strains, and 5 copies of Csm3 paralogues are present in Sulfolobus solfataricus. The repeat sequences in Staphylococcus epidermidis, Enterococcus italicum, and Lactococcus lactis have the same length (36nt), however nucleotide conservation is limited to the palindromic portion and 3'-end of the repeat sequence. The 8-nt 3′-end sequence of the repeat, which may contribute to the crRNA 5′-handle, showed ACGRRAAC consensus between S. thermophilus, S. epidermidis, E. italicum, and L. lactis, but differed from that of S. solfataricus (AUUGAAG (Rouillon et al., 2013)).

[0188] Csm6 has been shown to be a ssRNA-specific endoribonuclease, and the structural basis for this activity has been determined (Niewoehner and Jinek, 2016, Structural basis for the endoribonuclease activity of the type III-A CRISPR-associated protein Csm6. RNA 22:318–329).

[0189] In some embodiments, one or more elements of the nucleic acid targeting system of the present invention are derived from a specific organism that contains an endogenous CRISPR RNA targeting system. In certain embodiments, the CRISPR RNA targeting system comprises a Csm6 protein, a Csm6 ortholog, or a Csm6-like protein. As used herein, discussion of Csm6 also relates to a Csm6 protein, a Csm6 ortholog, or a Csm6-like protein. Csm6 orthologs can be found in organisms described herein and known in the art (see, e.g., WO2016035044A1 and Niewoehner and Jinek, 2016). Exemplary Csm6 orthologs include, but are not limited to, Thermus thermophilus (T. thermophilus) (TtCsm6, GI: 55978335), Staphylococcus epidermidis (SeCsm6, GI: 488416649), Streptococcus mutans (SmCsm6, GI: 24379650), Streptococcus thermophilus (StCsm6, GI: 585230687), and P. furiosus Csx1 (PfCsx1, GI: 33359545). In certain embodiments, the Csm6 protein useful in the present invention comprises at least one N-terminal CARF (CRISPR-associated Rossman fold) domain and at least one C-terminal HEPN domain (higher eukaryotic and prokaryotic nucleotide binding domain). In certain embodiments, the Csm6 protein forms a dimer. In certain embodiments, dimerization of the HEPN domain results in the formation of a ribonuclease active site. In certain embodiments, the dimer interface of the CARF domain includes an electropositive pocket. Without being bound by theory, this pocket may function as a ligand binding site for allosteric control of ribonuclease activity.

[0190] In certain exemplary embodiments, the CRISPR-based detection system described herein comprises a Csm6 protein comprising at least one HEPN domain, including but not limited to the HEPN domains described herein, HEPN domains known in the art (Niewoehner and Jinek, 2016), and domains that are considered to be HEPN domains by comparison with consensus sequence motifs. A variety of such domains are provided herein. In a non-limiting example, the consensus sequence can be derived from the sequence of a C2c2 or Cas13b ortholog provided herein. In certain exemplary embodiments, the Csm6 protein comprises a single HEPN domain. In certain other exemplary embodiments, the Csm6 protein comprises two HEPN domains.

[0191] In an exemplary embodiment, the Csm6 protein comprises one or more HEPN domains comprising an RxxxxH motif sequence. The RxxxxH motif sequence can be, but is not limited to, from a HEPN domain described herein or a HEPN domain known in the art. The RxxxxH motif sequence also includes a motif sequence generated by combining portions of two or more HEPN domains. As noted, the consensus sequence can be derived from the sequence of an ortholog disclosed herein. In certain embodiments, the HEPN domain comprises a conserved R-X4-6-H motif (Anantharaman et al., Biol Direct.., 2013 Jun 15; 8:15; and Kim et al., Proteins, 2013 Feb; 81(2):261-70).

[0192] In one embodiment of the invention, the HEPN domain comprises at least one RxxxxH motif comprising the sequence of R{N / H / K}X1X2X3H (SEQ ID NO: 571). In one embodiment of the invention, the HEPN domain comprises a RxxxxH motif comprising the sequence of R{N / H}X1X2X3H (SEQ ID NO: 572). In one embodiment of the invention, the HEPN domain comprises the sequence of R{N / K}X1X2X3H (SEQ ID NO: 573). In certain embodiments, X1 is R, S, D, E, Q, N, G, Y or H. In certain embodiments, X2 is I, S, T, V or L. In certain embodiments, X3 is L, F, N, Y, V, I, S, D, E or A.

[0193] CARF domains and consensus sequences of CARF domains have been described (see, e.g., Makarova et al., Front Genet., 2014; 5: 102). In certain embodiments, Csm6 comprises at least one CARF domain comprising a core domain comprising a six-stranded Rossmann-like fold, with core strands 5 and 6 forming a β-hairpin. The main region of sequence conservation is associated with strands 1 and 4 of the core domain. In certain embodiments, the terminus of strand 1 is characterized by polar residues, typically with alcoholic side chains (S / T). In certain embodiments, immediately downstream of strand 4 are highly conserved basic residues (K / R), which are preferably associated with the [DN]X[ST]XXX[RK] (SEQ ID NO: 574) signature. In certain embodiments, Csm6 is truncated to remove the N-terminal CARF domain (e.g., amino acids 1-190 of TtCsm6 or equivalent residues in orthologous Csm6 proteins).

[0194] In certain embodiments, Csm6 comprises at least one 6H domain (Niewoehner and Jinek, 2016). The 6H domain (residues 191-292) of the TtCsm6 polypeptide chain consists of five alpha helices forming a right-handed solenoid domain. Without being bound by theory, since some orthologs may not have a 6H domain, this domain is not required for the activity of the Csm6 protein of the present invention.

[0195] Csm6 has been shown to contribute to interference by acting as an independent ribonuclease that degrades invader RNA transcripts. The Csm6 protein is activated by second messengers generated by the type III interference complex. After the target RNA is bound by the type III interference complex, the Cas10 subunit converts ATP into a cyclic oligoadenylate product, which allosterically activates Csm6 by binding to its CARF domain. CARF domain mutants that eliminate allosteric activation inhibit Csm6 activity in vivo, and mutations in the Cas10 Palm domain of Csm6 phenocopy loss of function (M. Kazlauskiene et al., 2017; and Niewoehner et al., 2017).

[0196] In certain exemplary embodiments, when the activated CRISPR detection protein cuts the activation sequence, the signal amplification CRISPR effector protein is activated. The activation sequence is described in further detail below. The cleavage product of the activation sequence activates the individual activity of the signal amplification CRISPR effector protein, such as RNA nuclease activity. For example, once Csm6 is activated, it cuts RNA indiscriminately similar to the incidental effect of the Cas13 enzyme. Therefore, in addition to the modification of the detection effector of the reporter construct, the activated signal amplification CRISPR effector protein also modifies the reporter construct to further enhance signal generation. In certain embodiments, when provided in combination with another CRISPR enzyme (e.g., Cas13), Csm6 is activated. In certain embodiments, Csm6 can produce a synergistic effect when used in combination with Cas13, so that the incidental activity of Cas13 is greatly improved. Without being bound by theory, when Csm6 is also included in the assay (e.g., a point-of-care assay), the concentration of Cas13 can be greatly reduced in the assay. Therefore, the addition of Csm6 to the Cas13 diagnostic assay can be used to increase the sensitivity of the assay and reduce costs.

[0197] In certain exemplary embodiments, one or more signal amplification effector proteins are selected from Table 4.

[0198] Table 4

[0199]

[0200]

[0201] Activation Sequence

[0202] The activation sequence is used in conjunction with the CRISPR signal amplification effector protein. In certain exemplary embodiments, once the CRISPR detection effector protein is activated, the activation sequence is cut by the CRISPR detection effector protein. The cutting of the activation sequence produces a cut fragment that activates the CRISPR signal amplification effector protein. As described above, in certain exemplary embodiments, the activation of the CRISPR signal amplification effector protein results in the coordinated production of a detectable signal. In certain exemplary embodiments, the activation sequence is a homopolymer oligonucleotide. In certain exemplary embodiments, the cutting of the homopolymer oligonucleotide produces at least one cutting product with a 3'2,3 cyclic phosphate, which stimulates the activation of the CRISPR signal amplification effector protein. In certain exemplary embodiments, the homopolymer is a poly A oligonucleotide. In certain exemplary embodiments, the length of the activation sequence is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides. In certain exemplary embodiments, the activation sequence is 5 to 10 nucleotides in length, 5 to 15 nucleotides in length, 5 to 20 nucleotides in length, 5 to 25 nucleotides in length, 5 to 30 nucleotides in length, 10 to 15 nucleotides in length, 10 to 20 nucleotides in length, 10 to 25 nucleotides in length, 10 to 30 nucleotides in length, 15 to 20 nucleotides in length, 15 to 25 nucleotides in length, 15 to 30 nucleotides in length, 20 to 25 nucleotides in length, 20 to 30 nucleotides in length, or 25 to 30 nucleotides in length.

[0203] Exemplary activation sequences are shown in Table 5.

[0204] Table 5

[0205] rArArArArA 5A-3OH rArArArArA / 3Phos / 5A-3P rArArArArArA 6A-3OH rArArArArArA / 3Phos / 6A-3P rArArArArArArA 7A-3OH rArArArArArArA / 3Phos / 7A-3P

[0206] Reporter constructs

[0207] As used herein, "reporter construct" refers to a molecule that can be cut or otherwise inactivated by an activated CRISPR system effector protein as described herein. The term "reporter construct" may also be referred to as a "detection construct" or "masking construct" alternatively. In certain exemplary embodiments, the reporter construct is an RNA-based reporter construct. The reporter construct is configured so that the generation or detection of a positive detectable signal is not achieved until the CRISPR effector system is activated. A positive detectable signal may be any signal that can be detected using optical, fluorescent, chemiluminescent, electrochemical or other detection methods known in the art. The reporter construct may prevent the generation of a detectable positive signal or mask the presence of a detectable positive signal until the reporter construct is modified by the CRISPR effector protein activity. The term "positive detectable signal" is used to distinguish from other detectable signals that may be detectable in the presence of a reporter construct. For example, in certain embodiments, a first signal (i.e., a negative detectable signal) may be detected when there is an unmodified reporter construct, which is then converted into a second signal (e.g., a positive detectable signal) after the activated CRISPR effector protein modifies the reporter construct.

[0208] In certain exemplary embodiments, the masking construct can inhibit the generation of a gene product. The gene product can be encoded by a reporter construct added to the sample. The masking construct can be an interfering RNA that participates in an RNA interference pathway, such as shRHN or siRNA. The masking construct can also include microRNA (miRNA). When present, the masking construct inhibits the expression of the gene product. The gene product can be a fluorescent protein or other RNA transcript or protein that can be detected by a labeled probe or antibody when the masking construct is not present. After activating the effector protein, the masking construct is cut or otherwise silenced to allow expression and detection of the gene product as a positive detectable signal.

[0209] In certain exemplary embodiments, the masking construct can chelate one or more reagents required to produce a detectable positive signal, so that the release of one or more reagents from the masking construct leads to the generation of a detectable positive signal. One or more reagents can be combined to produce a colorimetric signal, a chemiluminescent signal, a fluorescent signal, or any other detectable signal, and can include any reagent known to be suitable for such a purpose. In certain exemplary embodiments, one or more reagents are chelated by RNA aptamers that bind to the one or more reagents. When the effector protein is activated after the target molecule is detected, the one or more reagents are released. In certain exemplary embodiments, one or more reagents are proteins that can promote the generation of detectable signals, such as colorimetric, chemiluminescent or fluorescent signals, such as enzymes, which are inhibited or chelated so that the protein cannot generate a detectable signal by binding to the protein by one or more RNA aptamers. After activating the effector protein disclosed herein, the RNA aptamer is cut or degraded to the extent that they no longer inhibit the ability of the protein to produce a detectable signal. In certain exemplary embodiments, the aptamer is a thrombin inhibitor aptamer. In certain exemplary embodiments, the thrombin inhibitor aptamer has a sequence of GGGAACAAAGCUGAAGUACUUACCC (SEQ ID NO: 131). When the aptamer is cut, thrombin will become active and will cut a peptide colorimetric or fluorescent substrate. In some exemplary embodiments, the colorimetric substrate is p-nitroaniline (pNA) covalently linked to a peptide substrate for thrombin. After being cut by thrombin, pNA is released and becomes yellow and is easily seen by the eyes. In some exemplary embodiments, the fluorescent substrate is 7-amino-4-methylcoumarin, which is a blue fluorophore that can be detected using a fluorescence detector. Inhibitory aptamers can also be used for horseradish peroxidase (HRP), beta-galactosidase or calf alkaline phosphatase (CAP) within the above general principles.

[0210] In certain embodiments, RNA enzyme activity is detected by cutting of enzyme inhibitory aptamers with colorimetry. A potential mode for converting RNA enzyme activity into a colorimetric signal is to combine the cutting of RNA aptamers with the reactivation of an enzyme that can produce a colorimetric output. In the absence of RNA cutting, the complete aptamer will bind to the enzyme target and inhibit its activity. The advantage of this readout system is that the enzyme provides an additional amplification step: once released from the aptamer by incidental activity (e.g., Cas13a incidental activity), the colorimetric enzyme will continue to produce a colorimetric product, resulting in an increase in the signal.

[0211] In some embodiments, an existing aptamer that inhibits an enzyme with a colorimetric readout is used. There are multiple aptamer / enzyme pairs with a colorimetric readout, such as thrombin, protein C, neutrophil elastase, and subtilisin. These proteases have a colorimetric substrate based on pNA and are commercially available. In some embodiments, a novel aptamer targeting a common colorimetric enzyme is used. Common and robust enzymes, such as beta-galactosidase, horseradish peroxidase, or calf intestinal alkaline phosphatase, can be targeted by an engineered aptamer designed by a selection strategy (such as SELEX). Such a strategy allows rapid selection of aptamers with nanomolar binding efficiency, and can be used to develop other enzyme / aptamer pairs for colorimetric readout.

[0212] In certain embodiments, RNA enzyme activity is detected by colorimetric cleavage of RNA-tethered inhibitors. Many common colorimetric enzymes have competitive reversible inhibitors: for example, β-galactosidase can be inhibited by galactose. Many of these inhibitors are weak, but their effects can be increased by increasing local concentrations. By linking the local concentration of inhibitors to RNA enzyme activity, colorimetric enzymes and inhibitor pairs can be engineered into RNA enzyme sensors. Colorimetric RNA enzyme sensors based on small molecule inhibitors involve three components: a colorimetric enzyme, an inhibitor, and a bridging RNA that is covalently linked to both the inhibitor and the enzyme and tethers the inhibitor to the enzyme. In the uncut configuration, the enzyme is inhibited by small molecules at increased local concentrations; when the RNA is cut (e.g., by Cas13a incidental cutting), the inhibitor will be released and the colorimetric enzyme will be activated.

[0213] In certain embodiments, RNase activity is detected by the formation and / or activation of G-quadruplexes by colorimetry. The G-quadruplex in DNA can be complexed with heme (iron (III)-protoporphyrin IX) to form a DNA enzyme (DNAzyme) with peroxidase activity. When a peroxidase substrate (e.g., ABTS: (2,2'-azabis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt)) is supplied, the G-quadruplex-heme complex causes oxidation of the substrate in the presence of hydrogen peroxide, which then forms a green color in solution. An example of a G-quadruplex-forming DNA sequence is: GGGTAGGGCGGGTTGGGA (SEQ ID NO: 132). By hybridizing an RNA sequence with the DNA aptamer, the formation of a G-quadruplex structure will be limited. After the RNA enzyme is incidentally activated (e.g., C2c2-complex incidentally activated), the RNA short chain will be cut, thereby allowing the G-quadruplex to form and the heme to bind. This strategy is particularly attractive because the color formation is enzymatic, which means that there is additional amplification beyond the RNase activation.

[0214] In certain exemplary embodiments, the masking construct can be immobilized on a solid substrate in individual discrete volumes (defined further below) and chelate a single agent. For example, the agent can be a bead containing a dye. When the immobilized agent is chelated, the individual beads are too diffuse to produce a detectable signal, but can produce a detectable signal after being released from the masking construct, for example by aggregation or a simple increase in solution concentration. In certain exemplary embodiments, the immobilized masking agent is an RNA-based aptamer, which can be cleaved by an activated effector protein upon detection of a target molecule.

[0215] In certain other exemplary embodiments, the masking construct binds to a fixed reagent in the solution, thereby blocking the ability of the reagent to bind to a free, separate labeled binding partner in the solution. Therefore, when a washing step is applied to the sample, the labeled binding partner can be washed out of the sample in the absence of a target molecule. However, if the effector protein is activated, the masking construct is cut to a degree sufficient to interfere with the ability of the masking construct to bind to the reagent, thereby allowing the labeled binding partner to bind to the fixed reagent. Therefore, the labeled binding partner is retained after the washing step, indicating that the target molecule is present in the sample. In some aspects, the masking construct bound to the fixed reagent is an RNA aptamer. The fixed reagent can be a protein, and the labeled binding partner can be a labeled antibody. Alternatively, the fixed reagent can be streptavidin, and the labeled binding partner can be a labeled biotin. The label on the binding partner used in the above embodiments can be any detectable label known in the art. In addition, other known binding partners can be used according to the overall design described herein.

[0216] In certain exemplary embodiments, the masking construct may include a ribozyme. A ribozyme is an RNA molecule with catalytic properties. Both natural ribozymes and engineered ribozymes contain RNA that can be targeted by the effector protein disclosed herein or consist of the above. Ribozymes can be selected or engineered to catalyze reactions that produce negative detectable signals or prevent the production of positive control signals. After the ribozyme is inactivated by an activated effector protein molecule, the reaction that produces a negative control signal or prevents the production of a positive detectable signal is removed, thereby allowing a positive detectable signal to be detected. In an exemplary embodiment, the ribozyme can catalyze a colorimetric reaction, causing the solution to display a first color. When the ribozyme is inactivated, the solution turns a second color, and the second color is a detectable positive signal. Zhao et al. "Signal amplification of glucosamine-6-phosphate based on ribozyme glmS," Biosens Bioelectron. 2014; 16: 337-42 describes an example of how ribozymes are used to catalyze colorimetric reactions, and provides an example of how such a system can be modified to work in the context of the embodiments disclosed herein. Alternatively, the ribozyme, when present, can produce, for example, a cleavage product of an RNA transcript. Thus, detection of a positive detectable signal can include detection of uncleaved RNA transcripts produced only in the absence of a ribozyme.

[0217] In one exemplary embodiment, the masking construct comprises a detection agent that changes color depending on whether the detection agent is aggregated or dispersed in a solution. For example, certain nanoparticles, such as colloidal gold, undergo a visible purple to red color shift when they move from aggregates to dispersed particles. Therefore, in certain exemplary embodiments, such detection agents can be aggregated by one or more bridge molecules. At least a portion of the bridge molecule comprises RNA. After activating the effector protein disclosed herein, the RNA portion of the bridge molecule is cut, allowing the detection agent to disperse and causing a corresponding color change. In certain exemplary embodiments, the bridge molecule is an RNA molecule. In certain exemplary embodiments, the detection agent is a colloidal metal. Colloidal metal materials may include water-insoluble metal particles or metal compounds dispersed in a liquid, a hydrosol or a metal sol. Colloidal metals may be selected from metals of groups IA, IB, IIB and IIIB in the periodic table, as well as transition metals, especially those of group VIII. Preferred metals include gold, silver, aluminum, ruthenium, zinc, iron, nickel and calcium. Other suitable metals include the following in their various oxidation states: lithium, sodium, magnesium, potassium, scandium, titanium, vanadium, chromium, manganese, cobalt, copper, gallium, strontium, niobium, molybdenum, palladium, indium, tin, tungsten, rhenium, platinum and gadolinium. The metal is preferably provided in ionic form, derived from a suitable metal compound, such as Al3+, Ru3+, Zn2+, Fe3+, Ni2+ and Ca2+ ions.

[0218] In certain other exemplary embodiments, the masking construct may comprise an RNA oligonucleotide to which a detectable label is attached and a masking agent for the detectable label. Examples of such detectable label / masking agent pairs are fluorophores and quenchers for the fluorophores. Quenching of the fluorophore may occur due to the formation of a non-fluorescent complex between the fluorophore and another fluorophore or a non-fluorescent molecule. This mechanism is called ground state complex formation, static quenching, or contact quenching. Therefore, the RNA oligonucleotide can be designed so that the fluorophore and the quencher are close enough for contact quenching to occur. Fluorophores and their associated quenchers are known in the art and can be selected by a person of ordinary skill in the art for this purpose. The specific fluorophore / quencher is not important in the context of the present invention, only the selection of the fluorophore / quencher pair can ensure the shielding of the fluorophore. After activating the effector protein disclosed herein, the RNA oligonucleotide is cleaved, thereby cutting off the proximity between the fluorophore and the quencher required to maintain the contact quenching effect. Therefore, the detection of the fluorophore can be used to determine the presence of the target molecule in the sample.

[0219] In certain other exemplary embodiments, the masking construct may include one or more RNA oligonucleotides to which one or more metal nanoparticles, such as gold particles, are attached. In some embodiments, the masking construct includes a variety of metal nanoparticles cross-linked by a variety of RNA oligonucleotides forming a closed loop. In one embodiment, the masking construct includes three gold nanoparticles cross-linked by three RNA oligonucleotides forming a closed loop. In some embodiments, the CRISPR effector protein cleaves the RNA oligonucleotide resulting in a detectable signal generated by the metal nanoparticles.

[0220] In certain other exemplary embodiments, the masking construct may comprise one or more RNA oligonucleotides to which one or more quantum dots are attached. In some embodiments, cleavage of the RNA oligonucleotide by the CRISPR effector protein results in a detectable signal generated by the quantum dots.

[0221] In an exemplary embodiment, the masking construct may comprise a quantum dot. The quantum dot may have a plurality of linker molecules attached to the surface. At least a portion of the linker molecule comprises RNA. The linker molecule is attached to the quantum dot at one end and to one or more quenchers along the length or end of the linker so that the quencher remains close enough for quenching of the quantum dot to occur. The linker may be branched. As described above, the quantum dot / quencher pair is not important, only the selection of the quantum dot / quencher pair can ensure the masking of the fluorophore. Quantum dots and their associated quenchers are known in the art and can be selected for this purpose by a person of ordinary skill in the art after activation of the effector protein disclosed herein, and the RNA portion of the linker molecule is cleaved, thereby eliminating the proximity between the quantum dot and one or more quenchers required to maintain the quenching effect. In certain exemplary embodiments, the quantum dot is streptavidin-conjugated. The RNA is attached via a biotin linker and recruits a quenching molecule with the sequence / 5Biosg / UCUCGUACGUUC / 3IAbRQSp / (SEQ ID NO. 133) or / 5Biosg / UCUCGUACGUUCUCUCGUACGUUC / 3IAbRQSp / (SEQ ID NO. 134), wherein / 5Biosg / is a biotin tag and / 3lAbRQSp / is an Iowa black quencher. After cleavage, the quantum dots will visibly fluoresce through the activated effectors disclosed herein.

[0222] In a similar manner, fluorescence energy transfer (FRET) can be used to generate a detectable positive signal. FRET is a non-radiative process by which photons from an energy-excited fluorophore (i.e., a "donor fluorophore") raise the energy state of an electron in another molecule (i.e., an "acceptor") to a higher vibrational level of an excited singlet state. The donor fluorophore returns to the ground state without emitting the fluorescent characteristic of the fluorophore. The acceptor can be another fluorophore or a non-fluorescent molecule. If the acceptor is a fluorophore, the transferred energy is emitted as a fluorescent characteristic of the fluorophore. If the acceptor is a non-fluorescent molecule, the absorbed energy is lost as heat. Therefore, in the context of the embodiments as disclosed herein, the fluorophore / quencher pair is replaced by a donor fluorophore / acceptor pair attached to an oligonucleotide molecule. When intact, the masking construct generates a first signal (negative detectable signal) as detected by fluorescence or heat emitted by the acceptor. After activating the effector protein disclosed herein, the RNA oligonucleotide is cut and FRET is destroyed, so that the fluorescence of the donor fluorophore (positive detectable signal) is now detected.

[0223] In certain exemplary embodiments, the masking construct includes the use of an intercalating dye that changes its absorbance in response to cleavage of long RNAs into short nucleotides. There are a variety of such dyes. For example, pyranose-Y will complex with RNA and form a complex with an absorbance at 572 nm. Cleavage of RNA results in a loss of absorbance and a color change. Methylene blue can be used in a similar manner, with a change in absorbance at 688 nm following RNA cleavage. Thus, in certain exemplary embodiments, the masking construct includes RNA and an intercalating dye complex that changes absorbance when RNA is cleaved by an effector protein disclosed herein.

[0224] Amplification

[0225] In certain exemplary embodiments, the target RNA and / or DNA can be amplified before activating the CRISPR effector protein. Any suitable RNA or DNA amplification technique can be used. In certain exemplary embodiments, RNA or DNA amplification is isothermal amplification. In certain exemplary embodiments, isothermal amplification can be nucleic acid sequencing-based amplification (NASBA), recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), helicase-dependent amplification (HDA), or nickase amplification reaction (NEAR). In certain exemplary embodiments, non-isothermal amplification methods can be used, including but not limited to PCR, multiple displacement amplification (MDA), rolling circle amplification (RCA), ligase chain reaction (LCR), or derivative amplification method (RAM).

[0226] In certain exemplary embodiments, amplification based on RNA or DNA amplification nucleic acid sequences is NASBA, which begins with reverse transcription of the target RNA by a sequence-specific reverse primer to produce an RNA / DNA duplex. The RNA template is then degraded using RNase H, allowing a forward primer containing a promoter (e.g., a T7 promoter) to bind and initiate extension of the complementary chain, producing a double-stranded DNA product. RNA polymerase promoter-mediated transcription of the DNA template then produces a copy of the target RNA sequence. Importantly, each of the new target RNAs can be detected by the guide RNA, thereby further enhancing the sensitivity of the assay. Then, the binding of the guide RNA to the target RNA results in the activation of the CRISPR effector protein, and the method is performed as described above. The NASBA reaction has the additional advantage of being able to be performed under moderate isothermal conditions, for example, at about 41°C, making it suitable for systems and devices for early and direct detection on-site and away from clinical laboratories.

[0227] In certain other exemplary embodiments, a recombinase polymerase amplification (RPA) reaction can be used to amplify a target nucleic acid. The RPA reaction uses a recombinase that can pair a sequence-specific primer with a homologous sequence in a duplex DNA. If the target DNA is present, DNA amplification is initiated, and no other sample manipulation, such as thermal cycling or chemical melting, is required. The entire RPA amplification system is stable as a dry preparation and can be safely transported without refrigeration. The RPA reaction can also be performed at an isothermal temperature at an optimal reaction temperature of 37-42°C. Sequence-specific primers are designed to amplify sequences containing target nucleic acid sequences to be detected. In certain exemplary embodiments, an RNA polymerase promoter (e.g., a T7 promoter) is added to one of the primers. This results in a double-stranded DNA product containing amplification of the target sequence and the RNA polymerase promoter. After or during the RPA reaction, an RNA polymerase that will produce RNA from a double-stranded DNA template is added. The amplified target RNA can then be detected by a CRISPR effector system. In this way, the target DNA can be detected using the embodiments disclosed herein. The RPA reaction can also be used to amplify the target RNA. The target RNA is first converted to cDNA using reverse transcriptase, followed by second strand DNA synthesis, at which point the RPA reaction is performed as described above.

[0228] Therefore, in certain exemplary embodiments, the system disclosed herein may include an amplification reagent. This paper describes different components or reagents that can be used for amplification of nucleic acids. For example, an amplification reagent as described herein may include a buffer, such as a Tris buffer. The Tris buffer may be used in any concentration suitable for a desired application or use, such as, but not limited to, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 25 mM, 50 mM, 75 mM, 1 M, etc. A person skilled in the art will be able to determine the appropriate concentration of a buffer such as Tris for the present invention.

[0229] Salts, such as magnesium chloride (MgCl 2 ), potassium chloride (KCl) or sodium chloride (NaCl), can be included in amplification reactions such as PCR to improve the amplification of nucleic acid fragments. Although the salt concentration will depend on the specific reaction and application, in some embodiments, nucleic acid fragments of a specific size can produce optimal results at a specific salt concentration. Larger products may require a change in salt concentration, typically a lower salt, to produce the desired results, while amplification of smaller products can produce better results at a higher salt concentration. Those skilled in the art will appreciate that the presence and / or concentration of salts and changes in salt concentrations can change the stringency of biological or chemical reactions, and therefore any salt that provides appropriate conditions for the present invention and reactions as described herein can be used.

[0230] Other components of biological or chemical reactions may include cell lysis components that break open or lyse cells for analysis of the material therein. Cell lysis components may include, but are not limited to, detergents, salts such as NaCl, KCl, ammonium sulfate [(NH 4 ) 2 SO 4 ] and the like. Detergents applicable to the present invention may include TritonX-100, sodium dodecyl sulfate (SDS), CHAPS (3-[(3-cholealkylpropyl) dimethylammonium]-1-propanesulfonate), ethyltrimethylammonium bromide, nonylphenoxypolyethoxyethanol (NP-40). The concentration of the detergent may depend on the specific application and may be specific to the reaction in some cases. The amplification reaction may include dNTPs and nucleic acid primers used at any concentration suitable for the present invention, for example including but not limited to 100nM, 150nM, 200nM, 250nM, 300nM, 350nM, 400nM, 450nM, 500nM, 550nM, 600nM, 650nM, 700nM, 750nM, 800nM, 850nM, 900nM, 9 In some embodiments, the polymerase used in the present invention may be a concentration of 50nM, 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, 80mM, 90mM, 100mM, 150mM, 200mM, 250mM, 300mM, 350mM, 400mM, 450mM, 500mM, etc. Likewise, the polymerase useful in accordance with the present invention may be any specific or universal polymerase known in the art and useful for the present invention, including Taq polymerase, Q5 polymerase, etc.

[0231] In some embodiments, amplification reagents as described herein may be applicable to hot start amplification. In some embodiments, hot start amplification may be beneficial to reduce or eliminate dimerization of adapter molecules or oligomers, or otherwise prevent unwanted amplification products or artifacts and obtain optimal amplification of desired products. Many components described herein for amplification may also be used for hot start amplification. In some embodiments, reagents or components suitable for use with hot start amplification may be appropriately used to replace one or more composition components. For example, polymerases or other reagents that exhibit desired activity under specific temperatures or other reaction conditions may be used. In some embodiments, reagents designed or optimized for hot start amplification may be used, for example, polymerases may be activated after transposition or after reaching a specific temperature. Such polymerases may be antibody-based or aptamer-based. Polymerases as described herein are known in the art. Examples of such reagents may include, but are not limited to, hot start polymerases, hot start dNTPs, and photo-caged dNTPs. Such reagents are known in the art and are available. Those skilled in the art will be able to determine the optimal temperature for individual reagents.

[0232] Amplification of nucleic acid can be performed using specific thermal cycle machinery or devices, and can be performed in a single reaction or in large quantities so that any desired number of reactions can be performed simultaneously. In some embodiments, microfluidics or robotic devices can be used to amplify, or manual changes in temperature can be used to amplify to achieve desired amplification. In some embodiments, optimization can be performed to obtain the best reaction conditions for a particular application or material. Those skilled in the art will understand and be able to optimize reaction conditions to obtain enough amplifications.

[0233] In certain embodiments, detection of DNA using a method or system of the invention requires transcription of the (amplified) DNA into RNA prior to detection.

[0234] Signal amplification based on guided release and target generation

[0235] In certain exemplary embodiments, the compositions, systems, and methods disclosed herein may further include adding a second target. The second target is different from the primary target and may be universal in the assay. The second target may be added to each assay at a high concentration. A guide sequence corresponding to the second target is contained in each assay volume. The secondary target guide sequence is protected so that it cannot bind to the secondary target or detect the CRISPR effector protein, such as the Cas13 protein. The protective group or structure is configured so that it can be cut after the activation of the detection CRISPR effector protein. Once the protective group or structure is removed, the released guide sequence is able to form a complex with the detection CRISPR effector protein in the solution and trigger further activation of the detection CRISPR effector protein, thereby causing further generation of a detectable signal by modification of the reporter construct.

[0236] Alternatively, a second guide sequence can be added to each assay volume along with the protected target. Cleavage of the protector group or structure from the target by the activated detection CRISPR effector protein would allow additional CRISPR effector protein / guide sequence / second target sequence complexes to form, further increasing collateral effects.

[0237] In certain exemplary embodiments, the protective group or structure may be a blocking second structural ring that is cleaved off by the incidental activity.

[0238] In another aspect, the activated side effect can cleave the protected or circularized primer, which is released to perform an amplification reaction on the template for the guide sequence, the target sequence, or both. In certain exemplary embodiments, the amplification reaction is an isothermal amplification reaction, such as a recombinase polymerase amplification or a rolling circle amplification. Subsequent transcription of the amplified template will produce more guide sequences and / or targets, thereby allowing additional detection of CRISPR effector protein activation.

[0239] Target RNA / DNA enrichment

[0240] In certain exemplary embodiments, the target RNA or DNA may be first enriched before detection or amplification. In certain exemplary embodiments, such enrichment may be achieved by binding the target nucleic acid through a CRISPR effector system.

[0241] Current target-specific enrichment schemes require single-stranded nucleic acids prior to hybridization with probes. Among the various advantages, embodiments of the present invention can skip this step and can directly target double-stranded DNA (partially or completely double-stranded). In addition, embodiments disclosed herein are enzyme-driven targeting methods that provide faster kinetics and easier workflows that allow isothermal enrichment. In certain exemplary embodiments, enrichment can occur between 20-37°C. In certain exemplary embodiments, guide RNA groups for different target nucleic acids are used in a single assay, allowing detection of multiple targets and / or multiple variants of a single target.

[0242] In certain exemplary embodiments, the dead CRISPR effector protein can bind to a target nucleic acid in a solution and then be separated from the solution. For example, a dead CRISPR effector protein bound to a target nucleic acid can be separated from a solution using an antibody or other molecule (e.g., an aptamer) that specifically binds to the dead CRISPR effector protein.

[0243] In other exemplary embodiments, the death CRISPR effector protein can be bound to a solid substrate. The fixed substrate can refer to any material that is suitable or can be modified to be suitable for the attachment of polypeptides or polynucleotides. Possible substrates include, but are not limited to, glass and modified functionalized glass, plastics (including acrylic resins, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethane, Teflon TMIn some embodiments, the solid support comprises a patterned surface suitable for fixing molecules in an ordered pattern. In certain embodiments, the patterned surface refers to the arrangement of different regions in or on the exposed layer of the solid carrier. In some embodiments, the solid support comprises an array of holes or depressions in the surface. The composition and geometry of the solid support can vary with its use. In some embodiments, the solid support is a planar structure, such as a glass slide, a chip, a microchip and / or an array. In this way, the surface of the matrix can be in the form of a planar layer. In some embodiments, the solid support comprises one or more surfaces of a flow cell. The term "flow cell" used herein refers to a chamber comprising a solid surface over which one or more fluid reagents can flow. For example, exemplary flow cells and related fluid systems and detection platforms that can be easily used in the methods of the present disclosure are described in Bentley et al. Nature 456:53-59 (2008), WO 04 / 0918497, US7,057,026; WO 91 / 06678; WO 07 / 123744; US 7,329,492; US 7,211,414; US7,315,019; US7,405,281, and US 2008 / 0108082. In some embodiments, the solid support or its surface is non-planar, such as the inner or outer surface of a tube or container. In some embodiments, the solid support includes microspheres or beads. "Microspheres", "beads", "particles" are intended to represent small discrete particles made of various materials in the context of solid substrates, including but not limited to plastics, ceramics, glass and polystyrene. In certain embodiments, the microspheres are magnetic microspheres or beads. Alternatively or additionally, the beads may be porous.The beads may range in size from nanometers (eg 100 nm) to millimeters (eg 1 mm).

[0244] The sample containing or suspected of containing the target nucleic acid can then be exposed to a matrix to allow binding of the target nucleic acid to the bound dead CRISPR effector protein. Non-target molecules can then be washed away. In certain exemplary embodiments, the target nucleic acid can then be released from the CRISPR effector protein / guide RNA complex for further detection using methods disclosed herein. In certain exemplary embodiments, the target nucleic acid can first be amplified as described herein.

[0245] In certain exemplary embodiments, the CRISPR effector can be labeled with a binding tag. In certain exemplary embodiments, the CRISPR effector can be chemically tagged. For example, the CRISPR effector can be chemically biotinylated. In another exemplary embodiment, a fusion can be generated by adding an additional sequence encoding the fusion to the CRISPR effector. An example of such a fusion is AviTag TM , which employs highly targeted enzymatic conjugation of a single biotin on a unique 15 amino acid peptide tag. In certain embodiments, the CRISPR effector can be labeled with a capture tag, such as but not limited to GST, Myc, hemagglutinin (HA), green fluorescent protein (GFP), flag, His tag, TAP tag, and Fc tag. Whether a fusion, chemical tag, or capture tag, the binding tag can be used to pull down the CRISPR effector system once it has bound to the target nucleic acid or immobilized the CRISPR effector system on a solid substrate.

[0246] In certain exemplary embodiments, the guide RNA can be labeled with a binding tag. In certain exemplary embodiments, the entire guide RNA can be labeled using in vitro transcription (IVT) that introduces one or more biotinylated nucleotides (e.g., biotinylated uracil). In some embodiments, biotin can be added to the guide RNA chemically or enzymatically, for example, one or more biotin groups are added to the 3' end of the guide RNA. The binding tag can be used to pull down the guide RNA / target nucleic acid complex after binding occurs, for example, by exposing the guide RNA / target nucleic acid to a streptavidin-coated solid substrate.

[0247] Therefore, in certain exemplary embodiments, engineered or non-naturally occurring CRISPR effectors can be used for enrichment purposes. In one embodiment, the modification may include mutations of one or more amino acid residues of the effector protein. One or more mutations may be in one or more catalytically active domains of the effector protein. The effector protein may have reduced or eliminated nuclease activity compared to the effector protein lacking the one or more mutations. The effector protein may not guide the cutting of the RNA chain at the target locus. In a preferred embodiment, one or more mutations may include two mutations. In a preferred embodiment, one or more amino acid residues are modified in a C2c2 effector protein (e.g., an engineered or non-naturally occurring effector protein or C2c2). In a specific embodiment, one or more modified or mutated amino acid residues are those corresponding to R597, H602, R1278 and H1283 in C2c2, such as mutations R597A, H602A, R1278A and H1283A (reference LshC2c2 amino acids), or corresponding amino acid residues in LshC2c2 orthologs.

[0248] In a specific embodiment, the one or more modified or mutated amino acid residues are C2c2 corresponding to K2, K39, V40, E479, L514, V518, N524, G534, K535, E580, L597, V602, D630, F676, L709, I713, R717 (HEPN), N718, H722 (HEPN), E773, P823, V828, I879, Y880, F884, Y997, L1001, F1009, L1013 , Y1093, L1099, L1111, Y1114, L1203, D1222, Y1244, L1250, L1253, K1261, 1134, L1355, L1359, R1362, Y1366, E1371, R1372, D1373, R1509 (HEPN), H1514 (HEPN), Y1543, D1544, K1546, K1548, V1551, 11558 (numbered in common with C2c2). In certain embodiments, the one or more modified or mutated amino acid residues are one or more of those corresponding to R717 and R1509 in C2c2. In certain embodiments, the one or more modified or mutated amino acid residues are one or more of those corresponding to K2, K39, K535, K1261, R1362, R1372, K1546 and K1548 in C2c2. In certain embodiments, the mutation results in a protein with an altered or modified activity. In certain embodiments, the mutation results in a protein with reduced activity, such as reduced specificity. In certain embodiments, the mutation results in a protein without catalytic activity (i.e., a "dead" C2c2). In embodiments, the amino acid residues correspond to LshC2c2 amino acid residues, or corresponding amino acid residues of C2c2 proteins from different species. Devices that can facilitate these steps.

[0249] The above-described enrichment system can also be used to deplete samples of certain nucleic acids. For example, guide RNAs can be designed to bind to non-target RNAs to remove non-target RNAs from a sample. In an exemplary embodiment, guide RNAs can be designed to bind to nucleic acids that do carry a specific nucleic acid variation. For example, a higher copy number of non-variant nucleic acids can be expected in a given sample. Therefore, the embodiments disclosed herein can be used to remove non-variant nucleic acids from a sample to increase the efficiency with which a CRISPR effector system can detect target variant sequences in a given sample.

[0250] Protein detection

[0251] In addition to detecting nucleic acids, the systems, devices and methods disclosed herein can also be suitable for detecting polypeptides (or other molecules) by incorporating polypeptide detection aptamers of specific configurations. Polypeptide detection aptamers are different from the masking construct aptamers discussed above. First, the aptamer is designed to specifically bind to one or more target molecules. In an exemplary embodiment, the target molecule is a target polypeptide. In another exemplary embodiment, the target molecule is a target chemical compound, such as a targeted therapeutic molecule. Methods for designing and selecting aptamers that are specific to a given target, such as SELEX, are known in the art. In addition to specificity to a given target, the aptamer is further designed to introduce an RNA polymerase promoter binding site. In certain exemplary embodiments, the RNA polymerase promoter is a T7 promoter. Before binding to the target, the RNA polymerase site cannot be approached or otherwise recognized by the RNA polymerase. However, the aptamer is configured so that after binding to the target, the structure of the aptamer undergoes a conformational change, so that the RNA polymerase promoter is exposed. The aptamer sequence downstream of the RNA polymerase promoter serves as a template for generating a trigger RNA oligonucleotide by RNA polymerase. Thus, the template portion of the aptamer can further incorporate a barcode or other recognition sequence that recognizes a given aptamer and its target. Guide RNAs as described above can then be designed to recognize these specific trigger oligonucleotide sequences. Binding of the guide RNA to the trigger oligonucleotide activates the CRISPR effector protein, which proceeds to inactivate the masking construct and generate a positive detectable signal as previously described.

[0252] Thus, in certain exemplary embodiments, the methods disclosed herein include the additional steps of allocating a sample or sample group into a group of individual discrete volumes, each of the individual discrete volumes comprising a peptide detection aptamer, a CRISPR effector protein, one or more guide RNAs, a masking construct, and incubating the sample or sample group under conditions sufficient to allow the peptide detection aptamer to bind to one or more target molecules, wherein binding of the aptamer to the corresponding target exposes the RNA polymerase promoter binding site, resulting in the synthesis of a trigger RNA through the binding of the RNA polymerase to the RNA polymerase promoter binding site.

[0253] In another exemplary embodiment, the binding of the aptamer can expose the primer binding site after the aptamer binds to the target polypeptide. For example, the aptamer can expose the RPA primer binding site. Therefore, the addition or inclusion of the primer will enter the amplification reaction, such as the RPA reaction outlined above.

[0254] Device

[0255] System as described herein can be embodied on diagnostic device.Many substrates and configurations of the device that can limit multiple individual discrete volumes in device can be used.As used herein, "individual discrete volume" refers to discrete space, such as container (container), container (receptacle) or can be by preventing and / or suppressing the volume or space of other arbitrary limits of the property limit of target molecule migration, such as by physical property such as volume or space limited by wall, such as the surface of the wall of hole, pipe or droplet, it can be impermeable or semi-permeable, or by other means such as chemistry, diffusion rate limitation, electromagnetic or light irradiation or its any combination limit that can contain target molecule and indexable nucleic acid identifier (such as nucleic acid barcode). "Diffusion rate limited" (such as diffusion limited volume) refers to that only some molecules or reactions can be approached, because diffusion constraint effectively limits space or volume, as wherein diffusion will limit the situation of two parallel laminar flows of the migration of target molecules from one flow to another flow. A "chemically" defined volume or space refers to a space where only certain target molecules can exist due to their chemical or molecular properties (e.g., size), such as through the surface charge of the beads, the size of the matrix, or other physical properties that can allow selection of species that can enter the interior of the beads, where, for example, gel beads can exclude certain species from entering the beads rather than other species. An "electro-magnetic" defined volume or space refers to a space where the electromagnetic properties (e.g., charge or magnetism) of the target molecule or its support can be used to define certain areas in the space (e.g., in a magnetic field or directly on a magnet to capture magnetic particles). An "optically" defined volume refers to any spatial region that can be defined by irradiating it with visible light, ultraviolet light, infrared light, or other wavelengths of light, so that only target molecules within the defined space or volume can be labeled. An advantage of using non-walled or semi-permeable discrete volumes is that some reagents, such as buffers, chemical activators, or other reagents can pass through the discrete volumes, while other materials, such as target molecules, can remain in the discrete volumes or spaces. Typically, the discrete volumes will include a fluid medium (e.g., an aqueous solution, an oil, a buffer, and / or a culture medium capable of supporting cell growth) suitable for labeling target molecules with a transposable nucleic acid identifier under conditions that allow labeling. Exemplary discrete volumes or spaces useful in the disclosed methods include droplets (e.g., microfluidic droplets and / or emulsion droplets), hydrogel beads or other polymer structures (e.g., polyethylene glycol diacrylate beads or agarose beads), tissue slides (e.g., fixed formalin paraffin-embedded tissue slides having specific areas, volumes, or spaces defined by chemical, optical, or physical means), microscope slides having areas defined by deposited reagents in an ordered array or random pattern, tubes (e.g., centrifuge tubes, microcentrifuge tubes, test tubes, cuvettes, conical tubes, etc.), bottles (e.g., glass bottles, plastic bottles, ceramic bottles, conical bottles, scintillation vials, etc.), wells (e.g., wells in a plate), plates, pipettes or pipette tips, etc. In certain embodiments, the compartment is an aqueous droplet in a water-in-oil emulsion.In certain embodiments, any application, method, or system described herein that requires precise or uniform volumes may use an acoustic liquid dispenser.

[0256] In certain exemplary embodiments, the device includes a flexible material substrate on which a plurality of spots can be defined. Flexible substrate materials suitable for diagnosis and biosensing are known in the art. Flexible substrate materials can be made of plant-derived fibers, such as cellulose fibers, or can be made of flexible polymers, such as flexible polyester films and other polymer types. In each defined spot, the reagents of the system described herein are applied to individual spots. Each spot can contain the same reagent, except for different guide RNA or guide RNA groups, or, where applicable, different detection aptamers, to screen multiple targets at one time. Therefore, the systems and devices herein can be able to screen for the presence of the same target or a limited number of targets in samples from multiple sources (e.g., multiple clinical samples from different individuals), or screen for the presence of multiple different targets in aliquots of a single sample (or multiple samples from the same source). In certain exemplary embodiments, the elements of the system described herein are freeze-dried onto a paper or cloth substrate. Pardee et al. Cell. 2016, 165 (5): 1255-66 and Pardee et al. Cell. 2014, 159 (4): 950-54 Pardee discloses an exemplary substrate based on flexible materials that can be used for certain exemplary devices. In Shevkoplyas et al., entitled "Paper based diagnostic test" International Patent Application Publication No. WO / 2013 / 071301, Siegel et al., entitled "Paper-based microfluidic systems" U.S. Patent Application Publication No. 2011 / 0111517, and Shafiee et al. "Paper and Flexible Substrates as Materials for Biosensing Platforms to Detect Multiple Biotargets" Scientific Reports 5: 8719 (2015), suitable substrates based on flexible materials for use with biological fluids (including blood) are disclosed. Wang et al. "Flexible Substrate-Based Devices for Point-of-Care Diagnostics" Cell 34 (11): 909-21 (2016) discloses additional flexible-based materials, including those suitable for wearable diagnostic devices. Other flexible-based materials may include nitrocellulose, polycarbonate, methyl ethyl cellulose, polyvinylidene fluoride (PVDF), polystyrene or glass (see, for example, US20120238008). In some embodiments, the discrete volumes are separated by a hydrophobic surface, such as, but not limited to, wax, photoresist or solid ink.

[0257] In some embodiments, a dosimeter or badge that acts as a sensor or indicator can be provided that notifies the wearer of exposure to certain microorganisms or other agents. For example, the systems described herein can be used to detect specific pathogens. Similarly, the aptamer-based embodiments disclosed above can be used to detect both polypeptides and other agents (e.g., chemical agents) to which specific aptamers can bind. Such devices can be used to monitor soldiers or other military personnel, as well as clinicians, researchers, hospital staff, etc., in order to provide information related to exposure to potentially dangerous microorganisms as quickly as possible, such as for biological or chemical warfare agent detection. In other embodiments, such monitoring badges can be used to prevent exposure to dangerous microorganisms or pathogens in immunocompromised patients, burn patients, patients undergoing chemotherapy, children, or the elderly.

[0258] The sample sources that can be analyzed using the systems and devices described herein include biological samples of subjects or environmental samples. Environmental samples can include surfaces or fluids. Biological samples can include, but are not limited to, saliva, blood, plasma, serum, feces, urine, sputum, mucus, lymph, synovial fluid, spinal fluid, cerebrospinal fluid, swabs of skin or mucous membranes, or combinations thereof. In an exemplary embodiment, the environmental sample is taken from a solid surface, such as a surface for preparing food or other sensitive compositions and materials.

[0259] In other exemplary embodiments, the elements of the system described herein can be placed on a disposable substrate, such as a swab or cloth for wiping a surface or sample fluid. For example, the system can be used to test the presence of pathogens on food by wiping the surface of food (such as fruit or vegetables). Similarly, the disposable substrate can be used to wipe other surfaces to detect certain microorganisms or reagents, such as for security screening. The disposable substrate can also have applications in evidence collection, where the CRISPR system is designed to detect, such as identifying DNA SNPs or certain tissue or cell markers that can be used to identify suspects to determine the type of biological substances present in the sample. Similarly, the disposable substrate can be used to collect samples from patients-such as saliva samples from the mouth-or swabs of the skin. In other embodiments, samples or swabs can be taken out from meat products to detect whether there are contaminants on or in meat products.

[0260] Near real-time microbial diagnostics are required in food, clinical, industrial and other environmental settings (see, e.g., LuTK, BowersJ and KoerisMS., Trends Biotechnol. 2013Jun; 31(6):325-7). In certain embodiments, the present invention is used to rapidly detect foodborne pathogens using guide RNAs specific for pathogens (e.g., Campylobacter jejuni, Clostridium perfringens, Salmonella, Escherichia coli, Bacillus cereus, Listeria monocytogenes, Shigella, Staphylococcus aureus, Staphylococcus aureus Enteritidis, Streptococcus, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia enterocolitica and Yersinia pseudotuberculosis, Brucella, Corynebacterium ulcerans, Plasmodium berghei or Plesiomonas shigelloides).

[0261] In some embodiments, the device is a flow strip or includes a flow strip. For example, a lateral flow strip allows the detection of RNA enzymes (such as C2c2) by color. The RNA reporter is modified to have a first molecule (such as FITC) connected to the 5' end and a second molecule (such as biotin) connected to the 3' end (or vice versa). The lateral flow strip is designed to have two capture lines, an anti-first molecule antibody (such as anti-FITC) hybridized at the first line and an anti-second molecule (such as anti-biotin) antibody hybridized at the second downstream line. When the SHERLOCK reaction flows down along the strip, the uncut reporter will bind the anti-first molecule antibody at the first capture line, and the cut reporter will release the second molecule and allow the second molecule to be bound at the second capture line. The second molecule sandwich antibody, such as conjugated with nanoparticles, such as gold nanoparticles, will bind any second molecule at the first or second line and cause a strong readout / signal (such as color). As more reporters are cut, more signals will accumulate at the second capture line, and fewer signals will appear at the first line. In some aspects, the present invention relates to the use of a flow strip as described herein for detecting nucleic acids or polypeptides. In certain aspects, the invention relates to a method for detecting a nucleic acid or a polypeptide using a flow strip as defined herein, such as a (lateral) flow test or a (lateral) flow immunochromatographic assay.

[0262] In certain exemplary embodiments, the device is a microfluidic device (i.e., individual discrete volumes) that produces and / or merges different droplets. For example, a first group of droplets containing a sample to be screened can be formed, and a second group of droplets containing elements of the system described herein can be formed. The first group and the second group of droplets are then merged, and the diagnostic method as described herein is then performed on the merged droplet group. The microfluidic device disclosed herein can be a silicone-based chip and can be manufactured using a variety of techniques, including but not limited to hot embossing, elastomer molding, injection molding, LIGA, soft lithography, silicon manufacturing, and related thin film processing techniques. Suitable materials for manufacturing microfluidic devices include but are not limited to cyclic olefin copolymers (COC), polycarbonate, poly (dimethylsiloxane) (PDMS) and poly (methacrylate) (PMMA). In one embodiment, soft lithography in PDMS can be used to prepare microfluidic devices. For example, a mold can be manufactured using photolithography that defines the position of flow channels, valves, and filters in a substrate. The matrix material is poured into the mold and allowed to solidify to form a stamp. The stamp is then sealed to a solid support, such as but not limited to glass. Due to the hydrophobic nature of some polymers such as PDMS that absorb some proteins and can inhibit certain biological processes, a passivating agent may be necessary (Schoffner et al. Nucleic Acids Research, 1996, 24: 375-379). Suitable passivating agents are known in the art and include, but are not limited to, silanes, polyparaxylene, n-dodecyl-bD-mannoside (DDM), pluronic, Tween-20, other similar surfactants, polyethylene glycol (PEG), albumin, collagen, and other similar proteins and polypeptides.

[0263] In certain exemplary embodiments, the system and / or device may be suitable for conversion to flow cytometry readout and / or allow sensitive and quantitative measurement of millions of cells in a single experiment, and improve existing flow-based methods, such as PrimeFlow assays. In certain exemplary embodiments, cells may be formed into droplets containing unpolymerized gel monomers, which are then formed into single-cell droplets suitable for analysis by flow cytometry. A detection construct comprising a fluorescent detectable marker may be cast into a droplet comprising unpolymerized gel monomers. When the gel monomers are polymerized, beads are formed in the droplets. Because gel polymerization is formed by free radicals, fluorescent reporters become covalently bound to the gel. The detection construct may be further modified to include a linker, such as an amine. A quencher may be added after gel formation and combined with a reporter construct via a linker. Therefore, when the reporter is cut by a CRISPR effector protein, the quencher is not bound to the gel and diffuses freely. Amplification of the signal in the droplet may be achieved by coupling a detection construct amplified by a hybridization chain reaction (HCR initiator). DNA / RNA hybrid hairpins can be introduced into a hairpin loop gel that can contain an RNase-sensitive domain. By protecting the strand displacement site within the hairpin loop with an RNase-sensitive domain, the HCR initiator can be selectively deprotected after the CRISPR effector protein cuts the hairpin loop. After the HCR initiator is deprotected by site-mediated strand displacement, the fluorescent HCR monomer can be washed into the gel to amplify the signal, wherein the initiator is deprotected.

[0264] Examples of microfluidic devices that can be used in the context of the present invention are described in Hour et al. “Direct Detection and drug-resistance profiling of bacteremias using inertial microfluidics” Lap Chip. 15(10): 2297-2307 (2016).

[0265] The system described herein can be further incorporated into a wearable medical device that evaluates biological samples (e.g., biofluids) of subjects outside of a clinical setting, and remotely reports the results of the assay to a central server accessible to a healthcare professional. The device can have the ability to automatically sample blood, such as the devices described in U.S. Patent Application Publication No. 2015 / 0342509 entitled “Needle-free Blood Draw” by Peeters et al. and U.S. Patent Application Publication No. 2015 / 0065821 entitled “Nanoparticle Phoresis” by Andrew Conrad.

[0266] In certain exemplary embodiments, the device may include individual wells, such as microplate wells. The size of the microplate wells may be the size of a standard 6, 24, 96, 384, 1536, 33456 or 9600 size well. In certain exemplary embodiments, the elements of the systems described herein may be freeze dried and applied to the surface of the wells prior to distribution and use.

[0267] Device disclosed herein may also include inlet and outlet ports, or openings, which in turn may be connected to valves, tubes, channels, chambers and syringes and / or pumps for introducing fluids into the device and extracting fluids from the device. These devices may be connected to fluid flow actuators that allow fluids to be directed and moved in microfluidic devices. Exemplary actuators include, but are not limited to, syringe pumps, mechanically actuated recirculation pumps, electroosmotic pumps, bulbs, bellows, diaphragms or bubbles intended to force fluid motion. In certain exemplary embodiments, the device is connected to a controller having a programmable valve that works together to move fluids through the device. In certain exemplary embodiments, the device is connected to a controller discussed in further detail below. These devices may be connected to flow actuators, controllers and sample loading devices by terminating in a metal pin to insert a pipeline at an inlet port on the device.

[0268] The elements of the system as shown herein are stable when freeze-dried, and therefore embodiments that do not require a support device are also contemplated, i.e., the system can be applied to any surface or fluid that supports the reactions disclosed herein and allows for detection of a positive detectable signal from a surface or solution. In addition to freeze-drying, the system can also be stably stored and used in a granular form. Polymers for forming suitable granulated forms are known in the art.

[0269] In some embodiments, the CRISPR effector protein is combined with an individual discrete volume in the device. The individual discrete volume may contain different guide RNAs specific for different target molecules. In some embodiments, the sample is exposed to a solid matrix comprising more than one discrete volume, each of which contains a guide RNA specific for the target molecule. Without being bound by theory, each guide RNA will capture its target molecule from the sample, and the sample does not need to be divided into separate assays. Therefore, valuable samples can be retained. The effector protein can be a fusion protein comprising an affinity tag. Affinity tags are well known in the art (e.g., HA tags, Myc tags, Flag tags, His tags, biotin). The effector protein can be connected to a biotin molecule, and the discrete volume can contain streptavidin. In other embodiments, the CRISPR effector protein is bound by an antibody specific for the effector protein. Methods for binding CRISPR enzymes have been previously described (see, e.g., US20140356867A1).

[0270] The devices disclosed herein may also include devices known in the art for analyzing the elements of the point of care (POC) of the sample by other methods. See, for example, St John and Price, "Existing and Emerging Technologies for Point-of-Care Testing" (Clin Biochem Rev. 2014 Aug; 35(3): 155-167).

[0271] The present invention can be used with wireless lab-on-a-chip (LOC) diagnostic sensor systems (see, e.g., U.S. Pat. No. 9,470,699, "Diagnostic radio frequency identification sensors and applications thereof"). In certain embodiments, the present invention is performed in a LOC controlled by a wireless device (e.g., a cell phone, a personal digital assistant (PDA), a tablet), and the results are reported to the device.

[0272] Radio frequency identification (RFID) tag systems include RFID tags that transmit data for reception by RFID readers (also known as interrogators). In a typical RFID system, a single object (e.g., a store item) is equipped with a relatively small tag that contains a transponder. The transponder has a memory chip that is assigned a unique electronic product code. The RFID reader sends a signal that activates the transponder within the tag using a communication protocol. As a result, the RFID reader is able to read and write data from the tag. In addition, the RFID tag reader processes the data according to the RFID tag system application. Currently, there are passive and active RFID tags. Passive RFID tags do not contain an internal power source, but are powered by radio frequency signals received from the RFID reader. Alternatively, active RFID tags contain an internal power source, which gives the active RFID tags a larger transmission range and storage capacity. The use of passive tags versus active tags depends on the specific application.

[0273] Lab-on-a-chip technology is well described in the scientific literature and consists of multiple microfluidic channels, input or chemical wells. The reaction in the well can be measured using radio frequency identification (RFID) tag technology because the conductive leads from the RFID electronic chip can be directly connected to each test well. The antenna can be printed or mounted in another layer of the electronic chip or directly mounted on the back of the device. In addition, the leads, antenna and electronic chip can be embedded in the LOC chip to prevent short circuits of electrodes or electronic devices. Since LOC allows complex sample separation and analysis, this technology allows LOC testing to be completed independently of complex or expensive readers. Instead, a simple wireless device such as a cellular phone or PDA can be used. In one embodiment, the wireless device also controls the separation and control of the microfluidic channels for more complex LOC analysis. In one embodiment, LEDs and other electronic measurement or sensing devices are included in the LOC-RFID chip. Without being bound by theory, this technology is disposable, allowing complex tests that require separation and mixing to be performed outside the laboratory.

[0274] In a preferred embodiment, the LOC can be a microfluidic device. The LOC can be a passive chip, wherein the chip is powered and controlled by a wireless device. In certain embodiments, the LOC includes a microfluidic channel for holding reagents and a channel for introducing samples. In certain embodiments, a signal from a wireless device transfers power to the LOC and activates the mixing of the sample and the assay reagent. Specifically, in the case of the present invention, the system may include a masking agent, a CRISPR effector protein, and a guide RNA specific to a target molecule. After activating the LOC, the microfluidic device can mix the sample and the assay reagent. During mixing, the sensor detects the signal and sends the result to the wireless device. In certain embodiments, the masking agent is a conductive RNA molecule. The conductive RNA molecule can be attached to a conductive material. The conductive molecule can be a conductive nanoparticle, a conductive protein, a metal particle attached to a protein or latex or other conductive beads. In certain embodiments, if DNA or RNA is used, the conductive molecule can be directly connected to a matching DNA or RNA chain. The release of the conductive molecule can be detected on the sensor. The assay can be a one-step process.

[0275] Since the conductivity of a surface area can be precisely measured, quantitative results can be obtained in a disposable wireless RFID electrical assay. In addition, the test area can be very small, allowing more tests to be performed in a given area, thus saving costs. In certain embodiments, separate sensors each bound to a different CRISPR effector protein and guide RNA immobilized on the sensor are used to detect multiple target molecules. Without being bound by theory, the activation of different sensors can be distinguished by wireless means.

[0276] In addition to the conductive methods described herein, other methods that rely on RFID or Bluetooth as a basic low-cost communication and power platform for disposable RFID assays can be used. For example, optical devices can be used to assess the presence and level of a given target molecule. In certain embodiments, an optical sensor detects the demasking of a fluorescent masking agent.

[0277] In certain embodiments, the devices of the invention may comprise handheld portable devices for reading diagnostic assays (see, e.g., Vashist et al., Commercial Smartphone-Based Devices and Smart Applications for Personalized Healthcare Monitoring and Management, Diagnostics 2014, 4(3), 104-128; mReader from Mobile Assay; and Holomic Rapid Diagnostic Test Reader).

[0278] As noted herein, certain embodiments allow for detection by colorimetric changes, which has certain attendant benefits when the embodiments are used in a POC situation or in a resource-poor environment where access to more sophisticated detection devices to read out signals may be limited. However, the portable embodiments disclosed herein may also be combined with a handheld spectrophotometer capable of detecting signals outside the visible light range. Das et al. "Ultra-portable, wireless smartphone spectrophotometer for rapid, non-destructive testing of fruit ripeness." Nature Scientific Reports. 2016, 6: 32504, DOI: 10.1038 / srep32504 describes an example of a handheld spectrophotometer device that can be used in conjunction with the present invention. Finally, in certain embodiments utilizing a quantum dot-based masking construct, due to the near-complete quantum yield provided by the quantum dots, a handheld UV light or other suitable device can be successfully used to detect the signal.

[0279] Example methods and applications

[0280] The low cost and adaptability of the assay platform lend themselves to many applications, including (i) general RNA / DNA / protein quantification, (ii) rapid, multiplexed RNA / DNA and protein expression detection, and (iii) sensitive detection of target nucleic acids, peptides, and proteins of clinical and environmental samples. In addition, the systems disclosed herein can be adapted to detect transcripts in biological environments, such as cells. Given the high specificity of the CRISPR effectors described herein, allele-specific expression of transcripts or disease-associated mutations in living cells can be tracked.

[0281] In certain exemplary embodiments, a single guide RNA specific for a single target is placed in a separate volume. Each volume can then receive aliquots of different samples or the same sample. In certain exemplary embodiments, multiple guide RNAs, each directed to a separate target, can be placed in a single well so that multiple targets can be screened in different wells. In order to detect multiple guide RNAs in a single volume, in certain exemplary embodiments, multiple effector proteins with different specificities can be used. For example, different orthologs with different sequence specificities can be used. For example, one ortholog can preferentially cut A, while others preferentially cut C, U, or T. Therefore, guide RNAs that are all single nucleotides or contain most of a single nucleotide can be produced, each with a different fluorophore. In this way, up to four different targets can be screened in a single individual discrete volume.

[0282] As demonstrated herein, the CRISPR effector system is capable of detecting target molecules at concentrations as low as attomole. See, for example, the Examples described below. Due to the sensitivity of the system, many applications requiring rapid and sensitive detection may benefit from the embodiments disclosed herein and are considered within the scope of the present invention. Example assays and applications are described in further detail below.

[0283] Microbiological Applications

[0284] In certain exemplary embodiments, the systems, devices and methods disclosed herein relate to the presence of one or more microbial agents in a detection sample (e.g., a biological sample obtained from a subject). In certain exemplary embodiments, the microorganism may be a bacterium, a fungus, a yeast, a protozoa, a parasite or a virus. Therefore, the methods disclosed herein may be applicable to other methods (or combinations) that require rapid identification of microbial species, monitoring of the presence of microbial proteins (antigens), antibodies, antibody genes, detection of certain phenotypes (e.g., bacterial drug resistance), monitoring of disease progression and / or disease outbreaks, and antibiotic screening. Due to the rapid and sensitive diagnostic capabilities of the embodiments disclosed herein, the detection of microbial species as low as single nucleotide differences, and the ability to be deployed as a POC device, the embodiments disclosed herein may be used to guide treatment regimens, such as as appropriate antibiotic or antiviral selection. The embodiments disclosed herein may also be used to screen for the presence of microbial contamination in environmental samples (air, water, surfaces, food, etc.).

[0285] Methods for identifying microbial species, such as bacteria, viruses, fungi, yeasts, or parasites, are disclosed. Specific embodiments disclosed herein describe methods and systems for identifying and distinguishing microbial species within a single sample or in multiple samples, allowing many different microorganisms to be identified. The present method allows the detection of pathogens in biological or environmental samples by detecting the presence of target nucleic acid sequences in samples and distinguishing two or more species of one or more organisms (e.g., bacteria, viruses, yeasts, protozoa, and fungi or a combination thereof). A positive signal obtained from a sample indicates the presence of a microorganism. By using more than one effector protein, multiple microorganisms can be identified simultaneously using the methods and systems of the present invention, wherein each effector protein targets a specific microbial target sequence. In this way, a multi-level analysis can be performed on a specific subject, wherein any number of microorganisms can be detected at one time. In some embodiments, a probe set that can identify one or more microbial species can be used for simultaneous detection of multiple microorganisms.

[0286] Multiplex analysis of samples allows for large-scale testing of samples, reducing the time and cost of analysis. However, multiplex analysis is often limited by the availability of biological samples. However, according to the present invention, an alternative to multiplex analysis can be performed, such that multiple effector proteins can be added to a single sample, and the masking constructs can each be combined with a separate quenching dye. In this case, a positive signal can be obtained from each quenching dye separately to perform multiple tests in a single sample.

[0287] Disclosed herein is a method for distinguishing two or more species of one or more organisms in a sample. The method is also suitable for detecting one or more species of one or more organisms in a sample.

[0288] Microbiological testing

[0289] In some embodiments, a method for detecting a microorganism in a sample is provided, comprising distributing a sample or sample group into one or more individual discrete volumes, the individual discrete volumes comprising a CRISPR system as described herein; incubating the sample or sample group under conditions sufficient to allow one or more guide RNAs to bind to one or more microorganism-specific targets; activating the CRISPR effector protein by binding one or more guide RNAs to one or more target molecules, wherein activation of the CRISPR effector protein results in modification of an RNA-based masking construct, thereby generating a detectable positive signal; detecting a detectable positive signal, wherein detection of a detectable positive signal indicates the presence of one or more target molecules in the sample. One or more target molecules may be mRNA, gDNA (coding or non-coding), trRNA, or RNA, comprising a target nucleotide tide sequence that can be used to distinguish two or more microbial species / strains from each other. Guide RNAs can be designed to detect target sequences. The embodiments disclosed herein may also utilize certain steps to improve hybridization between guide RNA and target RNA sequences. Methods for enhancing ribonucleic acid hybridization are disclosed in WO2015 / 085194 entitled "Enhanced Methods of Ribonucleic Acid Hybridization", which is incorporated herein by reference. The microorganism specific target can be RNA or DNA or protein. The DNA method can further include the use of a DNA primer that introduces an RNA polymerase promoter as described herein. If the target is a protein, the method will utilize an aptamer and a protein detection specific step as described herein.

[0290] Detection of single nucleotide variants

[0291] In some embodiments, guide RNAs that are specific for and bind to target sequences described herein can be used to detect one or more identified target sequences. The systems and methods of the present invention can even distinguish single nucleotide polymorphisms that exist between different microbial species, and thus, the use of multiple guide RNAs in accordance with the present invention can further expand or improve the number of target sequences that can be used to distinguish between species. For example, in some embodiments, one or more guide RNAs can distinguish between species, genera, families, orders, classes, phyla, kingdoms, or phenotypes or combinations thereof of microorganisms.

[0292] rRNA sequence-based detection

[0293] In certain exemplary embodiments, the devices, systems and methods disclosed herein can be used to distinguish multiple microbial species in a sample. In certain exemplary embodiments, identification can be based on ribosomal RNA sequences, including 16S, 23S and 5S subunits. Methods for identifying related rRNA sequences are disclosed in U.S. Patent Application Publication No. 2017 / 0029872. In certain exemplary embodiments, the guide RNA group can be designed to distinguish each species by a variable region unique to each species or strain. Guide RNA can also be designed to target RNA genes that distinguish microorganisms at the genus, family, order, class, phylum, kingdom level or a combination thereof. In certain exemplary embodiments using amplification, the amplification primer set can be designed to flank the constant region of the ribosomal RNA sequence, and the guide RNA can be designed to distinguish each species by a variable internal region. In certain exemplary embodiments, primers and guide RNAs can be designed to be conserved and variable regions in the 16S subunit, respectively. Other genes or genomic regions that are uniquely variable in species or species subsets can also be used, such as the RecA gene family and the RNA polymerase β subunit. Other suitable phylogenetic markers and methods for their identification are discussed, for example, in Wu et al. arXiv:1307.8690 [q-bio.GN].

[0294] In certain exemplary embodiments, methods or diagnostics are designed to simultaneously screen microorganisms across multiple phylogenetic and / or phenotypic levels. For example, the method or diagnostic may include the use of multiple CRISPR systems with different guide RNAs. The first group of guide RNAs can distinguish, for example, mycobacteria, gram-positive bacteria, and gram-negative bacteria. These general categories can be further subdivided. For example, guide RNAs can be designed and used in methods or diagnostics to distinguish between intestinal and non-intestinal tracts in gram-negative bacteria. A second group of guide RNAs can be designed to distinguish microorganisms at the genus or species level. Therefore, a matrix that identifies all mycobacteria, gram-positive, gram-negative (further divided into intestinal and non-intestinal tracts) can be produced, wherein the genus of each bacterial species identified in a given sample falls into one of these categories. The foregoing is for illustrative purposes only. Other means for classifying other types of microorganisms are also contemplated, and they will follow the above-mentioned overall structure.

[0295] Screening for drug resistance

[0296] In certain exemplary embodiments, the devices, systems, and methods disclosed herein can be used to screen for microbial genes of interest, such as antibiotic and / or antiviral resistance genes. Guide RNAs can be designed to distinguish known genes of interest. Samples, including clinical samples, can then be screened using the embodiments disclosed herein for detecting these genes. The ability to screen for drug resistance at the POC will have tremendous benefits in selecting appropriate treatment options. In certain exemplary embodiments, the antibiotic resistance gene is a carbapenemase, including KPC, NDM1, CTX-M15, OXA-48. Other antibiotic resistance genes are known and can be found, for example, in the Comprehensive Antibiotic Resistance Database (Jia et al. "CARD 2017: expansion and model-centric curation of the ComprehensiveAntibiotic Resistance Database." Nucleic Acids Research, 45, D566-573).

[0297] Ribavirin is an effective antiviral drug that protects against many RNA viruses. Several clinically important viruses have evolved resistance to ribavirin, including foot-and-mouth disease virus (DOI: 10.1128 / JVI.03594-13); poliovirus (Pfeifer and Kirkegaard. PNAS, 100(12):7289-7294, 2003); and hepatitis C virus (Pfeiffer and Kirkegaard. PNAS, 100(12):7289-7294, 2003). Kirkegaard, J. Virol. 79(4):2346-2355, 2005). Many other persistent RNA viruses, such as hepatitis and HIV, have evolved resistance to existing antiviral drugs: hepatitis B virus (lamivudine, tenofovir, entecavir) doi:10 / 1002 / hep22900; hepatitis C virus (telaprevir, BILN2061, ITMN-191, SCh6, boceprevir, AG-021541, ACH-806) doi:10.1002 / hep.22549; and HIV (many drug resistance mutations) hivb.standford.edu. The embodiments disclosed herein can be used to detect such variants, etc.

[0298] In addition to drug resistance, there are many clinically relevant mutations that can be detected using the embodiments disclosed herein, such as persistent versus acute infection in LCMV (doi: 10.1073 / pnas.1019304108), and increased infectivity in Ebola (Diehl et al. Cell. 2016, 167(4): 1088-1098).

[0299] As described elsewhere herein, closely related microbial species can be distinguished by introducing synthetic mismatches in the gRNA (e.g., having only a single nucleotide difference in a given target sequence).

[0300] Group Coverage Method

[0301] In a specific embodiment, a guide RNA group is designed that can identify all microbial species in a microorganism of a limited group, for example. Such a method is described in certain exemplary embodiments, and the method for producing guide RNA as described herein can be compared with the method disclosed in WO2017 / 040316, which is incorporated herein by reference. As described in WO2017040316, the group coverage solution can identify the minimum number of target sequence probes or guide RNAs required to cover the entire target sequence or target sequence group (e.g., genomic sequence group). Group coverage methods have previously been used to identify primers and / or microarray probes, typically within the range of 20 to 50 base pairs. See, e.g., Pearson et al. cs.virginia.edu / ~robins / papers / primers_dam11_final.pdf., Jabado et al. Nucleic Acids Res. 2006 34(22):6605-11, Jabado et al. Nucleic Acids Res. 2008, 36(1):e3 doi10.1093 / nar / gkm1106, Duitama et al. Nucleic Acids Res. 2009, 37(8):2483-2492, Phillippy et al. BMC Bioinformatics. 2009, 10:293 doi:10.1186 / 1471-2105-10-293. However, such methods generally involve treating each primer / probe as a k-mer and using a suffix array to search for exact matches or allow for inexact matches. Additionally, the methods typically employ a binary approach to detect hybridization by selecting primers or probes such that each input sequence need only be bound by one primer or probe, and the position of that binding along the sequence is irrelevant. Alternative approaches may divide the target genome into predefined windows, and effectively treat each window as a separate input sequence under a binary approach—i.e., they determine whether a given probe or guide RNA binds within each window, and require that all windows be bound by the state of certain probes or guide RNAs. In effect, these methods treat each element that is “universal” in the group coverage problem as the entire input sequence or a predefined window of the input sequence, and each element is considered “covered” if the start of the probe or guide RNA binds within the element. These approaches limit the fluidity that allows different probe or guide RNA designs to cover a given target sequence.

[0302] In contrast, embodiments disclosed herein relate to detecting longer probe or guide RNA lengths, for example, in the range of 70bp to 200bp suitable for hybridization selection sequencing. In addition, the methods disclosed herein can be applied to a pan-target sequence method that can define a probe or guide RNA group, which can identify and facilitate the detection sequencing of all species and / or strain sequences in a large and / or variable target sequence group. For example, the methods disclosed herein can be used to identify all variants of a given virus or a variety of different viruses in a single assay. In addition, the methods disclosed herein treat each element that is "universal" in the group coverage problem as a nucleotide of the target sequence, and as long as the probe or guide RNA is bound to some segments of the target genome containing the element, each element is considered to be "covered". These types of group coverage methods can be used to replace the binary methods of the previous methods, and the methods disclosed herein better simulate how the probe or guide RNA hybridizes with the target sequence. Rather than simply asking whether a given guide RNA sequence binds to a given window, these methods can be used to detect hybridization patterns—i.e., where a given probe or guide RNA binds to one or more target sequences—and then determine from these hybridization patterns the minimum number of probes or guide RNAs required to cover the set of target sequences to an extent sufficient to both enrich the sample and sequence any and all target sequences. These hybridization patterns can be determined by defining certain parameters that minimize a loss function, thereby enabling the identification of minimal sets of probes or guide RNAs in a manner that allows the parameters to vary for each species (e.g., to reflect the diversity of each species) and in a computationally efficient manner that is not achievable using direct application of set coverage solutions (e.g., those previously applied in the context of probe or guide RNA design).

[0303] The ability to detect the abundance of multiple transcripts can allow the generation of unique microbial signatures that indicate a specific phenotype. Genetic tags can be derived using various machine learning techniques. Therefore, the guide RNA of the CRISPR system can be used to identify and / or quantify the relative levels of biomarkers defined by the gene tags to detect certain phenotypes. In certain exemplary embodiments, the gene tags represent sensitivity to antibiotics, resistance to antibiotics, or a combination thereof.

[0304] In one aspect of the present invention, the method includes detecting one or more pathogens. In this way, it is possible to obtain a distinction between the infection of an individual microorganism to a subject. In some embodiments, such a distinction can enable clinicians to detect or diagnose a specific disease, such as different variants of a disease. Preferably, the pathogen sequence is a genome or a fragment thereof of a pathogen. The method may also include determining the evolution of the pathogen. Determining the evolution of the pathogen may include identifying pathogen mutations, such as nucleotide deletions, nucleotide insertions, nucleotide substitutions. In the latter, there are non-synonymous, synonymous, and non-coding substitutions. During an outbreak, mutations are more common in non-synonymous. The method may further include determining the substitution rate between the two pathogen sequences analyzed as described above. Whether the mutation is harmful or adaptive, functional analysis is required, however, the incidence of non-synonymous mutations indicates that the continued development of this epidemic may provide opportunities for the adaptation of the pathogen, emphasizing the necessity of rapid containment. Therefore, the method may further include assessing the risk of viral adaptation, wherein the number of non-synonymous mutations is determined. (Gire, et al., Science 345, 1369, 2014).

[0305] Monitoring microbial outbreaks

[0306] In some embodiments, a CRISPR system as described herein or a method of using it can be used to determine the evolution of a pathogen outbreak. The method can include detecting one or more target sequences from multiple samples from one or more subjects, wherein the target sequence is a sequence from a microorganism that causes an outbreak. Such a method can further include determining a pattern of pathogen transmission, or a mechanism involved in a disease outbreak caused by a pathogen.

[0307] The pattern of pathogen transmission can include continuous new transmission from the natural host of the pathogen or subject-to-subject transmission (e.g., person-to-person transmission) after a single transmission from a natural reservoir or a mixture of the two. In one embodiment, pathogen transmission can be bacterial or viral transmission, in which case the target sequence is preferably a microbial genome or a fragment thereof. In one embodiment, the pattern of pathogen transmission is an early pattern of pathogen transmission, i.e., at the beginning of a pathogen outbreak. Determining the pattern of pathogen transmission at the beginning of an outbreak increases the possibility of stopping the epidemic as soon as possible, thereby reducing the possibility of national and international transmission.

[0308] Determining the pattern of pathogen transmission can include detecting pathogen sequences according to the methods described herein. Determining the pattern of pathogen transmission can further include detecting shared intra-host variation of pathogen sequences between subjects, and determining whether the shared intra-host variation shows a temporal pattern. The observed patterns of intra-host and inter-host variation provide important insights into transmission and epidemiology (Gire, et al., 2014).

[0309] Detection of shared intra-host variation between subjects showing a temporal pattern is an indication of a transmission link between subjects (particularly between humans) because it can be explained by infection of subjects from multiple sources (repeated infection), repeated mutation of sample contamination (with or without balancing selection to enhance mutations), or co-transmission of slightly different viruses arising from mutations that occurred earlier in the transmission chain (Park et al., Cell 161(7): 1516-1526, 2015). Detection of shared intra-host variation between subjects can include detection of intra-host variants located at common single nucleotide polymorphism (SNP) positions. Positive detection of intra-host variants located at common (SNP) positions indicates repeated infection and contamination as the main explanation for intra-host variants. Repeated infection and contamination can be separated based on the SNP frequency that appears as inter-host variants (Park et al., 2015). Otherwise, repeated infection and contamination can be excluded. In the latter case, detection of shared intra-host variation between subjects can further include evaluating the frequency of synonymous and non-synonymous variants and comparing the frequencies of synonymous and non-synonymous variants to each other. Non-synonymous mutations are mutations that change the amino acids of a protein, which may lead to biological changes in microorganisms that are subject to natural selection. Synonymous substitutions do not change the amino acid sequence. Equal frequencies of synonymous and non-synonymous variants indicate neutral evolution of variants within the host. If the frequencies of synonymous and non-synonymous variants are different, the variants within the host may be maintained by balancing selection. If the frequencies of synonymous and non-synonymous variants are low, recurrent mutations are indicated. If the frequencies of synonymous and non-synonymous variants are high, co-transmission is indicated (Park et al., 2015).

[0310] Like Ebola virus, Lassa virus (LASV) can cause hemorrhagic fever with high mortality. Andersen et al. generated a genome catalog of nearly 200 LASV sequences from clinical and rodent reservoir samples (Andersen et al., Cell Volume 162, Issue 4, p738-750, August 13, 2015). Andersen et al. showed that the EVD epidemic in 2013-2015 was driven by human-to-human transmission, while LASV infection was mainly due to reservoir-to-human infection. Andersen et al. explained the spread of LASV in West Africa and showed that this migration was accompanied by changes in LASV genome abundance, mortality, codon adaptation and conversion efficiency. The method may further include phylogenetically comparing the first pathogen sequence with the second pathogen sequence, and determining whether there is a phylogenetic relationship between the first and second pathogen sequences. The second pathogen sequence may be an earlier reference sequence. If there is a phylogenetic association, the method may further include rooting the phylogeny of the first pathogen sequence in the second pathogen sequence. Therefore, a pedigree of the first pathogen sequence can be constructed. (Park et al., 2015).

[0311] The method may further include determining whether the mutation is deleterious or adaptive. Deleterious mutations indicate transmission-impaired viruses and dead-end infections and are therefore typically present only in individual subjects. Mutations unique to an individual subject are mutations that occur on the outer branches of the phylogenetic tree, while internal branch mutations are mutations that are present in multiple samples (i.e., in multiple subjects). Higher rates of non-synonymous substitutions are characteristic of the outer branches of the phylogenetic tree (Park et al., 2015).

[0312] In internal branches of a phylogenetic tree, selection has more opportunities to filter out deleterious mutants. By definition, internal branches have produced multiple descendant lineages and are therefore less likely to contain mutations with fitness costs. Thus, a lower rate of nonsynonymous substitutions indicates internal branches (Park et al., 2015).

[0313] Synonymous mutations that are likely to have minor effects on fitness occur at comparable frequencies on internal and external branches (Park et al., 2015).

[0314] By analyzing sequenced target sequences, such as viral genomes, it is possible to uncover mechanisms that contribute to the severity of epidemic episodes, such as during the 2014 Ebola outbreak. For example, Gire et al. performed a phylogenetic comparison of the genomes from the 2014 outbreak with all 20 genomes from earlier outbreaks, suggesting that the 2014 West African virus may have spread from Central Africa in the past decade. Rooting the phylogeny using divergence from other Ebola virus genomes is problematic. However, rooting the tree on the oldest outbreak showed a strong correlation between sample date and root tip distance, with a substitution rate of 8 × 10-4 per site per year. This suggests that lineages from the three most recent outbreaks diverged from a common ancestor at roughly the same time, around 2004, supporting the hypothesis that each outbreak represents an independent zoonotic event from the same genetically diverse viral population in a natural reservoir. They also found that the 2014 EBOV outbreak may have resulted from a single transmission from a natural reservoir, followed by human-to-human transmission during the outbreak. Their results also suggested that the epidemic in Sierra Leone may have resulted from the simultaneous introduction of two genetically distinct viruses from Guinea (Gire et al., 2014).

[0315] It is also possible to determine how Lassa virus spread from its point of origin, particularly due to human-to-human transmission, even going back 400 years in history (Andersen et al., Cell 162(4):738-50, 2015).

[0316] With regard to the work required during the 2013-2015 EBOV outbreak and the difficulties encountered by medical personnel at the outbreak site, and more generally, the methods of the present invention make it possible to use a smaller selection of probes for sequencing, making it possible to accelerate sequencing, thereby shortening the time required from sampling to result procurement. In addition, the kits and systems can be designed to be used in the field, so that the diagnosis of patients can be easily performed without the need to send or transport the samples to another part of the country or the world.

[0317] In any of the above methods, sequencing the target sequence or a fragment thereof may use any of the above sequencing processes. In addition, sequencing the target sequence or a fragment thereof may be near real-time sequencing. The sequencing of the target sequence or a fragment thereof may be performed according to previously described methods (experimental procedures: Matranga et al., 2014; and Gire et al., 2014). Sequencing the target sequence or a fragment thereof may include parallel sequencing of multiple target sequences. Sequencing the target sequence or a fragment thereof may include Illumina sequencing.

[0318] Analysis of a target sequence or fragment thereof that hybridizes to one or more selected probes can be an identification assay, wherein hybridization of a selected probe to a target sequence or fragment thereof indicates the presence of the target sequence within the sample.

[0319] Currently, primary diagnosis is based on the patient's symptoms. However, various diseases may have the same symptoms, so diagnosis relies on statistics. For example, malaria causes flu-like symptoms: headache, fever, shivering, joint pain, vomiting, hemolytic anemia, jaundice, hemoglobin in the urine, retinal damage and convulsions. These symptoms are also common in sepsis, gastroenteritis and viral diseases. Among the latter, Ebola hemorrhagic fever has the following symptoms: fever, sore throat, muscle pain, headache, vomiting, diarrhea, rash, decreased liver and kidney function, internal and external bleeding.

[0320] When a patient is presented to a medical unit, for example in tropical Africa, the basic diagnosis will end up being malaria, because statistically, malaria is the most likely disease within that region of Africa. Therefore, the patient is treated for malaria, although the patient may not actually be infected with the disease and the patient ends up not being treated correctly. Lack of correct treatment can be life-threatening, especially when the disease the patient is infected with exhibits rapid evolution. It may be too late before the medical staff realizes that the treatment given to the patient is ineffective and makes a correct diagnosis and treats the patient appropriately.

[0321] The method of the present invention provides a solution to this situation. In fact, because the number of guide RNAs can be significantly reduced, this makes it possible to provide selected probes divided into groups (each group is specific for a disease) on a single chip, so that multiple diseases such as viral infections can be diagnosed at the same time. Due to the present invention, more than 3 diseases, preferably more than 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 diseases can be diagnosed on a single chip at the same time, preferably the most common diseases in the population of a given geographical area. Since the probe selected in each group is specific to one of the diagnosed diseases, a more accurate diagnosis can be made, thereby reducing the risk of incorrectly treating the patient.

[0322] In other cases, an illness such as a viral infection may not cause any symptoms, or may cause symptoms but they disappear before the patient is presented to medical personnel. In such cases, the patient does not seek any medical help, or the diagnosis is complicated by the absence of symptoms on the day of presentation.

[0323] The invention can also be used in conjunction with other methods to diagnose disease, identify pathogens and optimize treatments based on the detection of nucleic acids, such as mRNA in crude, unpurified samples.

[0324] The method of the present invention also provides a powerful tool to solve this situation. In fact, since multiple sets of selected guide RNAs, each specific to one of the most common diseases occurring within a population in a given area, are contained in a single diagnostic, medical personnel only need to contact the biological sample taken from the patient with the chip. Reading the chip can find out the disease that the patient is infected with.

[0325] In some cases, patients present to medical personnel with a diagnosis for specific symptoms. The method of the present invention can not only identify which disease is causing these symptoms, but also determine whether the patient has another disease that he is not aware of.

[0326] This information is perhaps the most important when searching for the mechanisms of an outbreak. In fact, groups of patients with the same virus also showed temporal patterns, suggesting subject-to-subject transmission links.

[0327] Screening for microbial genetic perturbations

[0328] In certain exemplary embodiments, the CRISPR system disclosed herein can be used to screen for microbial genetic perturbations. Such methods can be useful, for example, for mapping microbial pathways and functional networks. Microbial cells can be genetically modified and then screened under different experimental conditions. As described above, the embodiments disclosed herein can screen multiple target molecules in a single sample in a multiplex manner, or a single target in a single individual discrete volume. Genetically modified microorganisms can be modified to include identification of specific genetically modified nucleic acid barcode sequences carried by specific microbial cells or microbial cell groups. Barcodes are short nucleotide sequences (e.g., DNA, RNA, or a combination thereof) used as identifiers. Nucleic acid barcodes can have a length of 4-100 nucleotides and can be single-stranded or double-stranded. Methods for identifying cells with barcodes are known in the art. Therefore, the guide RNA of the CRISPR effect system described herein can be used to detect barcodes. Detection of a positive detectable signal indicates the presence of a specific genetic modification in the sample. The methods disclosed herein can be combined with other methods for detecting complementary genotypes or phenotypic readings (indicating the effects of genetic modifications under the experimental conditions of the test). The genetic modifications to be screened may include, but are not limited to, gene knock-in, gene knock-out, inversion, translocation, transposition, or one or more nucleotide insertions, deletions, substitutions, mutations, or additions of nucleic acids encoding epitopes with functional consequences, such as altered protein stability or detection. In a similar manner, the methods described herein can be used in synthetic biology applications to screen for the function of specific arrangements of gene regulatory elements and gene expression modules.

[0329] In certain exemplary embodiments, the method can be used to screen for hypoalleles. The hypoalleles generated and their use in identifying key bacterial functional genes and identifying new antibiotic therapeutic agents are disclosed in PCT / US2016 / 060730, entitled "Multiplex High-Resolution Detection of Micro-organism Strains, Related Kits, Diagnostic Methods and Screening Assays", filed on November 4, 2016, which is incorporated herein by reference.

[0330] Different experimental conditions can include exposing the microbial cells to different chemicals, combinations of chemicals, different concentrations of chemicals or combinations of chemicals, different durations of exposure to chemicals or combinations of chemicals, different physical parameters, or both. In certain exemplary embodiments, the chemical is an antibiotic or an antiviral agent. The different physical parameters to be screened can include different temperatures, atmospheric pressures, different atmospheric and non-atmospheric gas concentrations, different pH levels, different culture medium compositions, or combinations thereof.

[0331] Screening environmental samples

[0332] The methods disclosed herein can also be used to screen environmental samples for contaminants by detecting the presence of target nucleic acids or polypeptides. For example, in some embodiments, the present invention provides a method for detecting microorganisms, comprising: exposing a CRISPR system as described herein to a sample; activating an RNA effector protein by binding one or more guide RNAs to one or more microorganism-specific target RNAs or one or more trigger RNAs, thereby generating a detectable positive signal. A positive signal can be detected and indicates the presence of one or more microorganisms in a sample. In some embodiments, the CRISPR system can be on a substrate as described herein, and the substrate can be exposed to a sample. In other embodiments, the same CRISPR system and / or different CRISPR systems can be applied to multiple discrete locations on a substrate. In other embodiments, different CRISPR systems can detect different microorganisms at each location. As described in further detail above, the substrate can be a flexible material substrate, for example, including but not limited to a paper substrate, a fabric substrate, or a flexible polymer substrate.

[0333] According to the present invention, the matrix can be passively exposed to the sample by temporarily dipping the matrix in the fluid to be sampled, by applying the fluid to be tested to the matrix, or by contacting the matrix with the surface to be tested. Any method for introducing the sample into the matrix can be appropriately used.

[0334] As described herein, the sample used in the present invention can be a biological or environmental sample, such as a food sample (fresh fruit or vegetables, meat), a beverage sample, a paper surface, a fabric surface, a metal surface, a wood surface, a plastic surface, a soil sample, a fresh water sample, a wastewater sample, a salt water sample, an exposure to atmosphere or other gas samples or a combination thereof. For example, a household / commercial / industrial surface made of any material can be wiped, including but not limited to metal, wood, plastic, rubber, etc., and a pollutant can be tested. Whether there are pathogenic bacteria or parasites or other microorganisms in a soil sample can be tested for environmental purposes and / or for human, animal or plant disease testing. A water sample, such as a fresh water sample, a wastewater sample or a salt water sample, cleanliness and safety and / or potability can be assessed to detect the presence of, for example, Cryptosporidium parvum, Giardia lamblia or other microbial contaminants. In other embodiments, biological sample can be obtained from following source, include but not limited to tissue sample, saliva, blood, blood plasma, serum, feces, urine, sputum, mucus, lymph, synovial fluid, cerebrospinal fluid, ascites, pleural effusion, seroma, pus or skin or mucosal surface swab.In some specific embodiments, environmental sample or biological sample can be rough sample and / or can not purify or increase one or more target molecules from sample before using this method.The identification of microorganism may be useful and / or required for any number of applications, therefore can use according to the present invention from those skilled in the art think that any type of sample in any source is suitable.

[0335] In some embodiments, food is inspected for bacterial contamination (e.g., E. coli) in restaurants or other food providers; food surfaces; moisture is tested for pathogens such as Salmonella, Campylobacter, or E. coli; food quality is also inspected by manufacturers and regulatory agencies to determine the purity of meat sources; air contamination with pathogens such as Legionella is identified; beer is inspected for contamination or spoilage with pathogens such as Pediatrics and Lactobacillus; and pasteurized or unpasteurized cheese is contaminated with bacteria or fungi during the manufacturing process.

[0336] Microorganisms according to the present invention can be pathogenic microorganisms or microorganisms that cause food or consumer products to go bad. Pathogenic microorganisms may be pathogenic or unfavorable to humans, animals or plants. For human or animal purposes, microorganisms may cause disease or cause illness. Animal or veterinary applications of the present invention can identify animals infected by microorganisms. For example, the method and system of the present invention can identify companion animals with pathogens, including but not limited to kennel cough, rabies virus and heartworm. In other embodiments, the method and system of the present invention can be used for parentage testing for breeding purposes. Plant microorganisms may cause plants to be injured or diseased, yield reduction or change in properties, such as fruit flavor, taste, consistency, smell, food or consumer product contamination purposes, and microorganisms may have adverse effects on the taste, smell, color, consistency or other commercial properties of food or consumer products. In certain exemplary embodiments, the microorganism is a bacterial species. The bacterium can be a psychotroph, Escherichia coli, lactic acid bacteria, or spore-forming bacteria. In certain exemplary embodiments, the bacterium can be any bacterial species that causes disease or illness, or otherwise causes undesirable products or properties. The bacterium according to the present invention can be pathogenic to humans, animals or plants.

[0337] Sample type

[0338] Suitable samples for the methods disclosed herein include any conventional biological samples obtained from an organism or part thereof, such as plants, animals, bacteria, etc. In a specific embodiment, the biological sample is obtained from an animal subject, such as a human subject. A biological sample is any solid or fluid sample obtained, excreted or secreted from any organism, including but not limited to single-cell organisms, such as bacteria, yeast, protozoa and amoeba, etc., multicellular organisms (e.g., plants or animals, including samples from healthy or apparently healthy human subjects or human patients affected by a condition or disease to be diagnosed or investigated, such as infection by pathogenic microorganisms such as pathogenic bacteria or viruses). For example, a biological sample can be a biological fluid obtained from, for example, blood, plasma, serum, urine, feces, sputum, mucus, lymph, synovial fluid, bile, ascites, pleural effusion, seroma, saliva, cerebrospinal fluid, aqueous or vitreous humor, or any body secretion, exudate, exudate (e.g., fluid obtained from an abscess or any other site of infection or inflammation) or fluid obtained from a joint (e.g., a normal joint or a joint affected by a disease, such as rheumatoid arthritis, osteoarthritis, gout, or septic arthritis), or a swab of the skin or mucosal surface.

[0339] Sample can also be a sample obtained from any organ or tissue (including biopsy or autopsy specimens, such as tumor biopsy) or can include cells (primary cells or cultured cells) or culture medium conditioned by any cell, tissue or organ. Exemplary samples include, but are not limited to, cells, cell lysates, blood smears, cell centrifugation preparations, cytological smears, body fluids (such as blood, plasma, serum, saliva, sputum, urine, bronchoalveolar lavage, semen, etc.), tissue biopsy (such as tumor biopsy), fine needle aspirates and / or tissue sections (such as cryostat tissue sections and / or paraffin-embedded tissue sections). In other examples, sample includes circulating tumor cells (which can be identified by cell surface markers). In a specific example, sample is directly used (such as fresh or frozen), or can be operated before use, such as by fixing (such as using formalin) and / or embedding in wax (such as formalin-fixed paraffin-embedded (FFPE) tissue samples). It should be understood that any method of obtaining tissue from a subject may be used, and the choice of method used will depend on various factors, such as the type of tissue, the age of the subject, or the procedures available to the practitioner. Standard techniques for obtaining such samples are available in the art. See, e.g., Schluger et al., J. Exp. Med. 176: 1327-33 (1992); Bigby et al., Am. Rev. Respir. Dis. 133: 515-18 (1986); Kovacs et al., NEJM 318: 589-93 (1988); and Ognibene et al., Am. Rev. Respir. Dis. 129: 929-32 (1984).

[0340] In other embodiments, the sample can be an environmental sample, such as water, soil, or as an industrial or medical surface. In some embodiments, the method disclosed in U.S. Patent Publication No. 2013 / 0190196 can be used to detect nucleic acid tags, particularly RNA levels, directly from a crude cell sample with high sensitivity and specificity. The coding sequence from the pathogen of interest and all coding sequences in other organisms can be identified or selected to be specific to each pathogen of interest by BLAST software comparison.

[0341] Various embodiments of the present disclosure involve the use of procedures and methods known in the art to successfully fractionate clinical blood samples. See, for example, Han Wei Hou et al., Microfluidic Devices for Blood Fractionation, Micromachines 2011, 2, 319-343; Ali Asgar S. Bhagat et al., Dean Flow Fractionation (DFF) Isolation of Circulating Tumor Cells (CTCs) from Blood, 15 th International Conference on Miniaturized Systems for Chemistry and Life Sciences, October 2-6, 2011, Seattle, WA; and procedures disclosed in International Patent Publication No. WO2011109762, the entire disclosure of which is incorporated herein by reference. Blood samples are typically expanded in culture to increase sample size for testing purposes. In some embodiments of the invention, blood or other biological samples can be used in the methods described herein without the need for expansion in culture.

[0342] In addition, various embodiments of the present disclosure relate to the successful isolation of pathogens from whole blood using spiral microchannels using procedures and methods known in the art, such as described in Han Wei Hou et al., Pathogen Isolation from Whole Blood Using Spiral Microchannel, Case No. 15995 JR, Massachusetts Institute of Technology. The manuscript is in preparation, the entire disclosure of which is incorporated herein by reference.

[0343] Due to the increased sensitivity of the embodiments disclosed herein, in certain exemplary embodiments, the assays and methods can be performed in crude samples or samples in which the target molecule to be detected is not further fractionated or purified from the sample.

[0344] Exemplary Microorganisms

[0345] The embodiments disclosed herein can be used to detect many different microorganisms. The term microorganism as used herein includes bacteria, fungi, protozoa, parasites and viruses.

[0346] bacteria

[0347] Provided below is an example list of types of microorganisms that may be detected using the embodiments disclosed herein.In certain exemplary embodiments, the microorganism is a bacterium. Examples of bacteria that can be detected according to the disclosed methods include, but are not limited to, one or more of the following (or a combination thereof): Acinetobacter baumanii, Actinobacillus species, Actinomycetes species, Actinomyces species (e.g., Actinomyces israelii and Actinomyces naeslundii), Aeromonas species (e.g., Aeromonas hydrophila, Aeromonas veronii biovar sobria (Aeromonas sobria), and Aeromonas caviae), Anaplasma phagocytophilum, Anaplasma marginale Alcaligenes xylosoxidans, Acinetobacter baumanii, Actinobacillus actinomycetemcomitans, Bacillus species (e.g., Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacillus thuringiensis and Bacillus stearothermophilus), Bacteriodes species (e.g., Bacteroides fragilis), Bartonella species (e.g., Bartonella bacilliformis and Bartonella henselae, Bifidobacterium species, Bordetella species (e.g., Bordetella pertussis, Bordetella parapertussis, and Bordetellabronchiseptica), Borrelia species (e.g., Borrelia recurrentis and Borrelia burgdorferi), Brucella species (e.g., Brucella abortus, Brucella canis, Brucella melintensis, and Brucellasuis), Burkholderia species (e.g., Burkholderia pseudomallei and Burkholderia cepacia), Campylobacter species (e.g., Campylobacter jejuni, Campylobacter coli, Campylobacter lari and Campylobacter fetus), Capnocytophaga species, Cardiobacterium hominis, Chlamydia trachomatis, Chlamydophila pneumoniae, Chlamydophila psittaci, Citrobacter sp. Coxiella burnetii, Corynbacterium species (e.g., Corynebacterium diphtheriae, Corynebacterium jeikeum and Corynebacterium), Clostridium species (e.g., Clostridium perfringens, Clostridium difficile, Clostridium botulinum and Clostridium tetani), Eikenella corrodens, Enterobacter species (e.g., Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter cloacae, and Escherichia coli, including opportunistic E. coli, such as enterotoxigenic E. coli, enteroinvasive E. coli, enteropathogenic E. coli, enterohemorrhagic E. coli, enteroaggregative E. coli, and uropathogenic E. coli), Enterococcus species (e.g., Enterococcus faecalis and Enterococcus faecium), Ehrlichia species (e.g., Ehrlichia chafeensia and Ehrlichia canis), Epidermophyton floccosum, Erysipelothrixrhusiopathiae, Eubacterium species, Francisella tularensis, Fusobacterium nucleatum, Gardnerella vaginalis, Gemella morbillorum, Haemophilus species (e.g., Haemophilus influenzae, Haemophilus ducreyi, Haemophilus aegyptius, Haemophilus parainfluenzae, Haemophilus haemolyticus, and Haemophilus parahaemolyticus, Helicobacter species (e.g., Helicobacter pylori, Helicobacter cinaedi, and Helicobacterfennelliae), Kingella kingii, Klebsiella species (e.g., Klebsiella pneumoniae, Klebsiella granulomatis, and Klebsiella oxytoca), Lactobacillus species, Listeria monocytogenes, Leptospira interrogans, Legionellapneumophila, Leptospira interrogans, Peptostreptococcus species, Mannheimia hemolytica, Microsporum canis, Moraxella catarrhalis, Morganell species, Mobiluncus species, Micrococcus species, Mycobacterium species (e.g., Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium paratuberculosis, Mycobacterium intracellulare, Mycobacterium avium, Mycobacterium bovis, and Mycobacterium marinum), Mycoplasma species (e.g., Mycoplasma pneumoniae, Mycoplasmahominis, and Mycoplasma genitalium), Nocardia species (e.g., Nocardia asteroides, Nocardia cyriacigeorgica, and Nocardia brasiliensis), Neisseria species (e.g., Neisseria gonorrhoeae and Neisseria meningitidis), Pasteurella multocida, Pityrosporum orbiculare (Malasseziafurfur), Plesiomonas shigelloides. Prevotella sp., Porphyromonas sp., Prevotellamelaninogenica, Proteus species (e.g., Proteus vulgaris and Proteus mirabilis), Providencia species (e.g., Providencia alcalifaciens, Providencia rettgeri, and Providencia stuartii), Pseudomonas aeruginosa, Propionibacterium acnes, Rhodococcus equi, Rickettsia sp. (e.g. Rickettsia rickettsii, Rickettsia akari and Rickettsia prowazekii, Orientia tsutsugamushi (formerly: Rickettsia tsutsugamushi) and Rickettsia typhi), Rhodococcus species, Serratia marcescens, Stenotrophomonas maltophilia, Salmonella species (e.g. Salmonella enterica, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Salmonella cholerasuis and Salmonella typhimurium), Serratia species (e.g. Serratia marcesans and Serratia liquifaciens), Shigella species (e.g. Shigella dysenteriae, Shigellaflexneri, Shigella boydii and Shigella sonnei), Staphylococcus species (e.g., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hemolyticus, Staphylococcus saprophyticus), Streptococcus species (e.g., Streptococcus pneumoniae (e.g., chloramphenicol-resistant serotype 4 Streptococcus pneumoniae, spectinomycin-resistant serotype 6B Streptococcus pneumoniae, streptomycin-resistant serotype 9V Streptococcus pneumoniae, erythromycin-resistant serotype 14 Streptococcus pneumoniae, optoxin-resistant serotype 14 Streptococcus pneumoniae, rifampicin-resistant serotype 18C Streptococcus pneumoniae, tetracycline-resistant serotype 1 9F Streptococcus pneumoniae, penicillin-resistant serotype 19F Streptococcus pneumoniae, and trimethoprim-resistant serotype 23F Streptococcus pneumoniae, chloramphenicol-resistant serotype 4 Streptococcus pneumoniae, spectinomycin-resistant serotype 6B Streptococcus pneumoniae, streptomycin-resistant serotype 9V Streptococcus pneumoniae, optoxin-resistant serotype 14 Streptococcus pneumoniae, rifampicin-resistant serotype 18C Streptococcus pneumoniae, penicillin-resistant serotype 19F Streptococcus pneumoniae, or trimethoprim-resistant serotype 23F Streptococcus pneumoniae), Streptococcus agalactiae, Streptococcus mutans, Streptococcus pyogenes, Group A Streptococcus, Streptococcus pyogenes, Group B Streptococcus, Streptococcus agalactiae, Group C Streptococcus, Streptococcus anginosus, Streptococcus equismilis, Group D Streptococcus, Streptococcus bovis, Group F Streptococcus, and Streptococcus anginosus Group G Streptococcus), Spirillum minus, Streptobacillus moniliformi, Treponema species (e.g., Treponema carateum, Treponema petenue, Treponema pallidum, and Treponema endemicum, Trichophyton rubrum, T. mentagrophytes, Tropheryma whippelii, Ureaplasma urealyticum, Veillonella species, Vibrio species (e.g., Vibriocholerae, Vibrio parahemolyticus, Vibrio vulnificus, Vibrio parahaemolyticus, Vibrio vulnificus, Vibrio alginolyticus, Vibriomimicus, Vibrio hollisae, Vibrio fluvialis, Vibrio metchnikovii, Vibrio damsela, and Vibrio furnisii), Yersinia species (e.g., Yersinia enterocolitica, Yersinia pestis, and Yersinia pseudotuberculosis), and Xanthomonas maltophilia, among others.

[0348] Fungi

[0349] In certain exemplary embodiments, the microorganism is a fungus or a fungal species. Examples of fungi that can be detected according to the disclosed methods include, but are not limited to, any one or more of the following (or any combination): Aspergillus, Blastomyces, Candidiasis, Coccidiodomycosis, Cryptococcus neoformans, Cryptococcus gatti, Histoplasma (e.g., Histoplasma capsulatum), Pneumocystis (e.g., Pneumocystis jirovecii), Stachybotrys (e.g., Stachybotrys chartarum), Mucroymcosis, Sporothrix, fungal eye infections ringworm), Exserohilum, Cladosporium, in certain exemplary embodiments, the fungus is a yeast. Examples of yeasts that can be detected according to the disclosed method include, but are not limited to, one or more of the following (or any combination): Aspergillus species (e.g., Aspergillus fumigatus, Aspergillus flavus, and Aspergillus clavatus), Cryptococcus species (e.g., Cryptococcus neoformans, Cryptococcus gati, Cryptococcus laurentii, and Cryptococcus albidus), Geotrichum species, Saccharomyces species, Hansenula species, Candida species (e.g., Candida albicans), Kluyveromyces species, Debaryomyces species, Pichia species. In certain exemplary embodiments, the fungus is a mold. Exemplary molds include, but are not limited to, Penicillium species, Cladosporium species, Mycosporium species, or a combination thereof.

[0350] Protozoa

[0351] In certain exemplary embodiments, the microorganism is a protozoan. Examples of protozoa that can be detected according to the disclosed methods and devices include, but are not limited to, any one or more (or any combination) of the following: Euglenozoa, Heterolobosea, Diplomonadida, Amoebozoa, Blastocystic, Apicomplexa. Exemplary Euglenozoa include, but are not limited to, Trypanosoma cruzi (Chagas disease), T. brucei gambiense, T. brucei rhodesiense, Leishmania braziliensis, L. infantum, L. mexicana, L. major, L. tropica, L. donovani. Exemplary Heterolobosea include, but are not limited to, Naegleria fowleri. Exemplary Diplomonas include, but are not limited to, Giardia intestinalis (G. lamblia, G. duodenalis). Exemplary Amoeba include, but are not limited to, canthamoeba castellanii, Balamuthia madrillaris, Entamoeba histolytica. Exemplary Blastocystis include, but are not limited to, Blastocystic hominis. Exemplary Apicomplexa include, but are not limited to, Babesia microti, Cryptosporidium parvum, Cyclospora cayetanensis, Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and Toxoplasma gondii.

[0352] parasites

[0353] In certain exemplary embodiments, the microorganism is a parasite. Examples of parasites that can be detected according to the disclosed methods include, but are not limited to, one or more (or any combination) of Onchocerca species and Plasmodium species.

[0354] Virus

[0355] In certain exemplary embodiments, the systems, devices and methods disclosed herein relate to detecting viruses in samples. The embodiments disclosed herein can be used to detect viral infections (e.g., subjects or plants), or to determine viral strains, including viral strains that differ due to single nucleotide polymorphisms. The virus can be a DNA virus, an RNA virus, or a retrovirus. Non-limiting examples of viruses that can be used in the present invention include, but are not limited to, Ebola, measles, SARS, chikungunya, hepatitis, Marburg, yellow fever, MERS, dengue, Lassa, influenza, rhabdoviruses, or HIV. Hepatitis viruses can include hepatitis A, hepatitis B, or hepatitis C. Influenza viruses can include, for example, influenza A or influenza B. HIV may include HIV 1 or HIV 2. In certain exemplary embodiments, the viral sequence can be human respiratory syncytial virus, Sudan ebolavirus, Bundibugyo virus, Tai Forest ebolavirus, Reston ebolavirus, Achimota, Aedes flavivirus, Aguacate virus, Akabane virus, Alethinophid reptarenavirus, Allpahuayo mammarenavirus, Amaparimmarenavirus, Andes virus, Apoi virus, Aravan virus, Aroa virus, Arumwot virus, Atlantic salmon paramyxovirus, Australian bat lyssavirus, Avian bornavirus, Avian metapneumovirus, Avianparamyxoviruses, Penguin or Falkland Islands virus, BK polyomavirus, Bagaza virus, Banna virus, bat herpesvirus, Bat sapovirus, Bear Canon mammarenavirus, Beilong virus, Betacoronavirus, Betapapillomavirus 1-6, Bhanja virus, Bokeloh bat lyssavirus, Bovine disease virus, Bourbon virus, Bovine hepacivirus, Bovine parainfluenza virus 3, Bovine respiratory syncytial virus, Brazoran virus, Bunyamwera virus, Caliciviridae virus. California encephalitis virus, Candiru virus, Canine distemper virus, Canine pneumovirus, Cedar virus, Cell fusion virus, Cetaceanmorbillivirus, Chandipura virus, Chaoyang virus, Chaparemammarenavirus, Chikungunya virus, Colobus monkey papillomavirus, Colorado tick fever virus, Cowpox virus, Crimean-Congo hemorrhagic fever virus, Culex flavivirus, Cupixi mammarenavirus, dengue virus, Dobrava-Belgrade virus, Donggang virus, Dugbe virus, Duvenhage virus, Easternequine encephalitis virus, Entebbe bat virus, Enterovirus AD, European batlyssavirus 1-2, Eyach virus, Feline morbillivirus, Fer-de-Lance paramyxovirus, Fitzroy River virus, Flaviviridae virus, Flexal mammarenavirus, GB virus C, Gairo virus, Gemycircularvirus, Goose paramyxovirus SF02, Great Island virus, Guanaritomammarenavirus, Hantaan virus, Hantavirus Z10, Heartland virus, Hendra virus, Hepatitis A / B / C / E, Hepatitis delta virus, Human bocavirus, Human coronavirus, Human endogenous retrovirus K, Human enteric coronavirus, Human genital-associated circular DNA virus-1, Human herpes 1-8, Human immunodeficiency virus 1 / 2, Humanmastadenovirus AG, Human papillomavirus, Human parainfluenza virus 1-4, Human paraechovirus, Humanpicornavirus, Human smacovirus, Ikoma lyssavirus, Ilheus virus, Influenza AC, Ippymammarenavirus, Irkut virus, J-virus, JC polyomavirus, Japanese encephalitis virus, Junin mammarenavirus, KI polyomavirus, Kadipiro virus, Kamiti River virus, Kedougou virus, Khujand virus, Kokobera virus, Kyasanur forest disease virus, Lagosbat virus, Langat virus, Lassa mammarenavirus, Latino mammarenavirus, Leopards Hill virus, Liao ning virus, Ljungan virus, Lloviu virus, Louping ill virus, Lujo mammarenavirus, Lunamammarenavirus, Lunk virus, Lymphocytic choriomeningitis mammarenavirus, Lyssavirus Ozernoe, MSSI2\.225 virus, Machupo mammarenavirus, Mamastrovirus 1, Manzanilla virus, Mapuera virus, Marburg virus, Mayaro virus, Measles virus, Menangle virus, Mercadeo virus, Merkel cell polyomavirus, Middle East respiratory syndrome coronavirus, Mobalamammarenavirus, Modoc virus, Moijang virus, Mokolo virus, Monkeypox virus, Montana myotisleukoenchalitis virus, Mopeia lassa virus reassortant 29, Mopeia mammarenavirus, Morogoro virus, Mossman virus, Mumps virus, Murine pneumonia virus, Murray Valleyencephalitis virus, Nariva virus, Newcastledisease virus, Nipah virus, Norwalk virus, Norwayrat hepacivirus, Ntaya virus, O'nyong-nyong virus, Oliveros mammarenavirus, Omskhemorrhagic fever virus, Oropouche virus, Parainfluenza virus 5, Parana mammarenavirus, Parramatta River virus, Peste-des-petits-ruminants virus, Pichande mammarenavirus, Picornaviridae virus, Pirital mammarenavirus, Piscihepevirus A, swine parainfluenza virus 1, porcinerubulavirus, Powassan virus, primate T-cell leukemia virus 1-2, Primateerythroparvovirus 1, Punta Toro virus, Puumala virus, Quang Binh virus, Rabies virus, Razdan virus, Reptile bornavirus 1, Rhinovirus AB, Rift Valley fever virus, Rinderpest virus, Rio Bravo virus, Rodent Torque Teno virus, Rodent hepacivirus, RossRiver virus, Rotavirus AI, Royal Farm virus, Rubella virus, Sabia mammarenavirus, Salem virus, Sandfly fever Naples virus, Sandfly fever Sicilian virus, Sapporo virus, Sathuperi virus, Seal anellovirus, Semliki Forest virus, Sendai virus, Seoul virus, Sepik virus, severe acute respiratory syndrome-related coronavirus, severe fever with thrombocytopenia syndrome virus, Shamonda virus, Shimoni bat virus, Shuni virus, Simbu virus, Simian torque teno virus, Simian virus 40-41, Sin Nombre virus, Sindbis virus, Small anellovirus, Sosuga virus, Spanish goatencephalitis virus, Spondweni virus, St.Louis encephalitis virus, Sunshine virus, TTV-like mini virus, Tacaribe mammarenavirus, Taila virus, Tamana bat virus, Tamamimammarenavirus, Tembusu virus, Thogoto virus, Thottapalayam virus, Tick-borneencephalitis virus, Tioman virus, Togaviridae virus, Torque teno canis virus, Torque tenodouroucouli virus, Torque teno felis virus, Torque teno midi virus, Torque teno sus virus, Torque teno tamarin virus, Torque teno virus, Torque tenozalophus virus, Tuhoko virus, Tula virus, Tupaia paramyxovirus, Usutu virus, Uukuniemi virus, Vaccinia virus, Variola virus, Venezuelan equine encephalitis virus, Vesicular stomatitis Indiana virus, WUPolyomavirus, Wesselsbron virus, West Caucasian bat virus, West Nile virus, Westernequine encephalitis virus, Whitewater Arroyo mammarenavirus, yellow fever virus, Yokose virus, Yug Bogdanovac virus, Zaire ebolavirus, Zika virus, or Zygosaccharomyces bailiivirus Zviral sequence. Examples of RNA viruses that can be detected include one or more (or any combination) of the following: Coronaviridae, Picornaviridae, Caliciviridae, Flaviviridae, Togaviridae, Bornaviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, or Deltavirus. In certain embodiments, the virus is a coronavirus, SARS, poliovirus, rhinovirus, hepatitis A, Norwalk virus, yellow fever virus, West Nile virus, hepatitis C virus, dengue fever virus, Zika virus, Rubella virus, Ross River virus, Sindbis virus,virus, Chikungunyavirus, Borna disease virus, Ebola virus, Marburg virus, Measles virus, Mumps virus, Nipah virus, Hendra virus, Newcastle disease virus, Human respiratory syncytial virus, Rabies virus, Lassa virus, Hantavirus, Crimean-Congo hemorrhagic fever virus, Influenza, or Hepatitis D virus

[0356] In certain exemplary embodiments, the virus can be a plant virus selected from the group consisting of tobacco mosaic virus (TMV), tomato spotted wilt virus (TSWV), cucumber mosaic virus (CMV), potato virus Y (PVY), RT virus cauliflower mosaic virus (CaMV), plum pox virus (PPV), brome mosaic virus (BMV), potato virus X (PVX), citrus tristeza virus (CTV), barley yellow dwarf virus (BYDV), potato leafroll virus (PLRV), tomato bushy stunt virus (TBSV), rice bulb virus (RTSV), rice yellow mottle virus (RYMV ), rice hoar virus (RHBV), maize rhabdovirus (MRFV), maize dwarf mosaic virus (MDMV), sugarcane mosaic virus (SCMV), sweet potato feather mottle virus (SPFMV), sweet potato settling vein nematode virus (SPSVV), grape fan leaf virus (GFLV), grape virus A (GVA), grape virus B (GVB), grape mottle virus (GFkV), grape leaf roll virus-related virus-1, -2 and -3, (GLRaV-1, -2 and -3), Arabidopsis mosaic virus (ArMV), or larch stem pockmark-related virus (RSPaV). In a preferred embodiment, the target RNA molecule is part of the pathogen or is transcribed from a DNA molecule of the pathogen. For example, the target sequence may be contained in the genome of an RNA virus. If the pathogen infects or has infected the plant, it is further preferred that the CRISPR effector protein hydrolyzes the target RNA molecule of the pathogen in the plant. Therefore, when a CRISPR system (or the parts thereof required for its implementation) is used therapeutically, it is preferred that the CRISPR system is able to cleave the target RNA molecule from the plant pathogen, i.e. after infection has occurred, or prevent, i.e. before infection occurs.

[0357] In certain exemplary embodiments, the virus can be a retrovirus. Examples of retroviruses that can be detected using the embodiments disclosed herein include one or more or any combination of viruses of the genera Alpharetrovirus, Betaretrovirus, Gammaretrovirus, Deltaretrovirus, Epsilonretrovirus, Lentivirus, Spumavirus or Metaviridae, Pseudoviridae and Retroviridae (including HIV), Hepadnaviridae (including hepatitis B virus) and Caulimoviridae (including cauliflower mosaic virus).

[0358] In certain exemplary embodiments, the virus is a DNA virus. Example DNA viruses that can be detected using the embodiments disclosed herein include one or more of the following viruses (or any combination): Family Myoviridae, Podoviridae, Siphoviridae, Alloherpesviridae, Herpesviridae (including human herpesvirus and Varicella Zozter virus), Malocoherpesviridae, Lipoviridae, Rudiviridae, Adenovirus, Ampullaviridae, Vesicular Viridae, African Swine Fever Viridae (including African Swine Fever Virus), Baculovirus, Cicaudaviridae, Clavaviridae, Corticoviridae, Microspindle-shaped Bacteriophage Family, Globuloviridae, Tropoviridae, Hytrosaviridae, Iridoviridae, Maseilleviridae, Mimiviridae, Nu diviridae, Nimaviridae, Pandoraviridae, Papillomavirus, Algal DNA Viridae, Plasmaviridae, Polydnaviruses, Polyomaviridae (including Simian virus 40, JC virus, BK virus), Poxviridae (including cowpox and smallpox), Sphaerolipoviridae, Tectiviridae, Turriviridae, Dinodnavirus, Salterprovirus, Rhizidovirus, etc. In some embodiments, a method of diagnosing a species-specific bacterial infection in a subject suspected of having a bacterial infection is described as obtaining a sample comprising bacterial ribosomal ribonucleic acid from the subject; contacting the sample with one or more of the probes, and detecting hybridization between bacterial ribosomal ribonucleic acid sequences present in the sample and the probes, wherein detection of hybridization indicates that the subject is infected with Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter baumannii, Candida albicans, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Proteus mirabilis, Streptococcus agalactiae, or Staphylococcus maltophilia, or a combination thereof.

[0359] Malaria detection and surveillance

[0360] Malaria is a mosquito-borne pathology caused by Plasmodium parasites. The parasite is transmitted to people through the bite of infected female Anopheles mosquitoes. Five Plasmodium species cause human malaria: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi. Of these, Plasmodium falciparum and Plasmodium vivax are responsible for the greatest threat, according to the World Health Organization (WHO). Plasmodium falciparum is the most prevalent malaria parasite on the African continent and is responsible for most malaria-related deaths worldwide. Plasmodium vivax is the predominant malaria parasite in most countries outside of sub-Saharan Africa.

[0361] In 2015, 91 countries and territories experienced persistent malaria transmission. According to the latest WHO estimates, there were 212 million cases of malaria and 429,000 deaths in 2015. In areas with high malaria transmission, children under 5 years of age are particularly vulnerable to infection, illness and death; more than two-thirds (70%) of malaria deaths occur in this age group. Globally, under-5 malaria mortality rates fell by 29% between 2010 and 2015. However, malaria remains the leading killer of children under five, claiming the life of one child every two minutes.

[0362] As described by the WHO, malaria is an acute febrile illness. In non-immune individuals, symptoms develop seven or more days after the bite of an infective mosquito. The initial symptoms - fever, headache, chills and vomiting - may be mild and difficult to recognize as malaria, but if not treated within 24 hours, Plasmodium falciparum malaria can progress to severe illness, often resulting in death.

[0363] Children with severe malaria often develop one or more of the following: severe anemia, respiratory distress due to metabolic acidosis, or cerebral malaria. In adults, multiorgan involvement is also common. In areas where malaria is endemic, people may develop partial immunity, resulting in asymptomatic infection.

[0364] The development of rapid and effective diagnostic tests is highly relevant to public health. Indeed, early diagnosis and treatment of malaria not only reduces illness and prevents death, but also helps reduce the spread of malaria. According to the World Health Organization's recommendations, all suspected malaria cases should be confirmed using parasite-based diagnostic tests (particularly using rapid diagnostic tests) before receiving treatment (see "WHO Guidelines for the treatment of malaria", third edition, published in April 2015)).

[0365] Resistance to antimalarial therapy has become a key health problem, which greatly reduces treatment strategies. In fact, as reported on the World Health Organization website, resistance of Plasmodium falciparum to previous generations of drugs such as chloroquine and sulfadoxine / pyrimethamine (SP) became common in the 1950s and 1960s, undermining malaria control efforts and reversing the growth of child survival. Therefore, the World Health Organization recommends routine monitoring of resistance to antimalarial drugs. In fact, accurate diagnosis can avoid inappropriate treatment and limit the extension of resistance to antimalarial drugs.

[0366] In this context, the WHO Technical Strategy for Malaria 2016-2030, adopted by the World Health Assembly in May 2015, provides a technical framework for all malaria-endemic countries. It is designed to guide and support regional and national plans as they work towards malaria control and elimination. The strategy sets ambitious but achievable global targets, including:

[0367] Reduce the incidence of malaria cases by at least 90% by 2030.

[0368] Reduce malaria mortality by at least 90% by 2030.

[0369] Eliminate malaria in at least 35 countries by 2030.

[0370] Prevent the re-emergence of malaria in all malaria-free countries.

[0371] The strategy is the result of an extensive 2-year consultation process involving more than 400 technical experts from 70 Member States. It is based on 3 key axes:

[0372] Ensure universal access to malaria prevention, diagnosis and treatment;

[0373] Accelerate efforts towards elimination and achieving malaria-free status; and

[0374] Transform malaria surveillance into a core intervention.

[0375] Treatments for Plasmodium include arylamino alcohols such as quinine or quinine derivatives such as chloroquine, amodiaquine, mefloquine, piperaquine, lumihanol, primaquine; lipophilic hydroxynaphthoquinone analogs such as atovaquone; antifolate drugs such as the sulfonamides sulfadoxine, dapsone and pyrimethamine; proguanil; atovaquone / proguanil combinations; artemisinin drugs; and combinations thereof.

[0376] Target sequences for diagnosing the presence of mosquito-borne pathogens include sequences that diagnose the presence of Plasmodium, particularly Plasmodium species that affect humans such as Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and Plasmodium knowlesi, including sequences from their genomes.

[0377] The target sequences are used for diagnostic monitoring of drug resistance against treatment of malarial parasites, particularly malarial parasite species that affect humans such as Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi.

[0378] Additional target sequences include target molecules / nucleic acid molecules encoding proteins involved in essential biological processes of the Plasmodium parasite, in particular transporters, such as proteins from the drug / metabolite transporter family, ATP-binding cassette (ABC) proteins involved in substrate translocation, such as ABC transporter subfamily C or Na + / H + exchange proteins, membrane glutathione S-transferases; proteins involved in the folate pathway, such as dihydropteroate synthetase, dihydrofolate reductase activity or dihydrofolate reductase-thymidylate synthetase; and proteins involved in the transport of protons across the inner mitochondrial membrane, particularly the cytochrome b complex. Additional targets may also include genes encoding heme polymerases.

[0379] Additional target sequences include target molecules / nucleic acid molecules encoding proteins involved in basic biological processes, which can be selected from the Plasmodium falciparum chloroquine resistance transporter gene (pfcrt), Plasmodium falciparum multidrug resistance transporter 1 (pfmdr1), Plasmodium falciparum multidrug resistance-associated protein gene (Pfmrp), Plasmodium falciparum Na+ / H+ exchanger gene (pfnhe), gene encoding Plasmodium falciparum export protein 1, Plasmodium falciparum Ca2+ transporting ATPase 6 (pfatp6); Plasmodium falciparum dihydropterin synthase (pfdhps), dihydrofolate reductase activity (pfdhpr) and dihydrofolate reductase thymidylate synthase (pfdhfr) genes, cytochrome b genes, GTP cyclohydrolase and Kelch13 (K13) genes, as well as their functional heterologous genes in other Plasmodium species.

[0380] Many mutations, particularly single point mutations, have been identified in proteins that are current therapeutic targets and are associated with specific resistance phenotypes.Thus, the present invention allows for the detection of various resistance phenotypes in mosquito-borne parasites such as Plasmodium.

[0381] The present invention allows detection of one or more mutations of a target nucleic acid / molecule, and in particular one or more single nucleotide polymorphisms. Thus, any one of the following mutations or combinations thereof may be used as drug resistance markers and may be detected according to the present invention.

[0382] Single point mutations in Plasmodium falciparum K13 include single point mutations at positions 252, 441, 446, 449, 458, 493, 539, 543, 553, 561, 568, 574, 578, 580, 675, 476, 469, 481, 522, 537, 538, 579, 584 and 719, particularly mutations E252Q, P441 L, F446I, G449A, N458Y, Y493H, R539T, I543T, P553L, R561H, V568G, P574L, A578S, C580Y, A675V, M476I; C469Y; A481V; S522C; N537I; N537D; G538V; M579I; D584V; and H719N. These mutations are usually associated with artemisinin drug resistance phenotypes (Artemisinin and artemisinin-based combination therapy resistance, April 2016 WHO / HTM / GMP / 2016.5).

[0383] In Plasmodium falciparum dihydrofolate reductase (DHFR) (PfDHFR-TS, PFD0830w), important polymorphisms include mutations at positions 108, 51, 59, and 164, particularly 108D, 164L, 51I, and 59R, which mediate resistance to pyrimethamine. Other polymorphisms include 437G, 581G, 540E, 436A, and 613S, which are associated with resistance to sulfadoxine. Additional observed mutations include Ser108Asn, Asn51Ile, Cys59Arg, Ile164Leu, Cys50Arg, Ile164Leu, Asn188Lys, Ser189Arg, and Val213Ala, Ser108Thr, and Ala16Val. Mutations Ser108Asn, Asn51Ile, Cys59Arg, Ile164Leu, Cys50Arg, Ile164Leu are particularly associated with resistance to pyrimethamine-based therapies and / or chloroguanine-dapsone combination therapy. Cycloguanidine resistance appears to be associated with the double mutations Ser108Thr and Ala16Val. Amplification of dhfr may also be highly associated with treatment resistance, especially pyrimethamine resistance.

[0384] In Plasmodium falciparum dihydropyrimidine synthase (DHPS) (PfDHPS, PF08_0095), important polymorphisms include mutations at positions 436, 437, 581 and 613: Ser436Ala / Phe, Ala437Gly, Lys540Glu, Ala581Gly and Ala613Thr / Ser. Polymorphisms at positions 581 and / or 613 are also associated with resistance to sulfadoxine-pyrimethamine therapy.

[0385] In the Plasmodium falciparum chloroquine resistance transporter (PfCRT), polymorphisms at position 76, particularly the mutation Lys76Thr, are associated with resistance to chloroquine. Further polymorphisms include Cys72Ser, Met74Ile, Asn75Glu, Ala220Ser, Gln271Glu, Asn326Ser, Ile356Thr, and Arg371Ile, which may be associated with chloroquine resistance. PfCRT is also phosphorylated at residues S33, S411, and T416, which may modulate the transport activity or specificity of the protein.

[0386] In the Plasmodium falciparum multidrug resistance transporter 1 (PfMDR1) (PFE1150w), polymorphisms at positions 86, 184, 1034, 1042, especially Asn86Tyr, Tyr184-PHE, Ser1034Cys, Asn1042Asp and Asp1246Tyr have been identified and reported to affect sensitivity to lumefantrine, artemisinin, quinine, fluoroquine, halogenated anthraquinones and chloroquine. In addition, amplification of PfMDR1 is associated with reduced sensitivity to lumefantrine, artemisinin, quinine, mefloquine and halogenated anthraquinones, and dysregulation of PfMDR1 leads to increased resistance to chloroquine. Amplification of pfmdr1 can also be detected. The phosphorylation state of PfMDR1 is also highly relevant.

[0387] In the Plasmodium falciparum multidrug resistance-associated protein (PfMRP) (gene reference PFA0590w), polymorphisms at positions 191 and / or 437 such as Y191H and A437S have been identified and are associated with the chloroquine resistance phenotype.

[0388] In the Plasmodium falciparum NA+ / H+ exchange protein (PfNHE) (reference PF13_0019), an increased repeat of DNNND at the microsatellite ms4670 may be a marker for quinine resistance.

[0389] Mutations that alter the ubiquinol binding site of the cytochrome b protein encoded by the cytochrome b gene (Cytb, mal_mito_3) are associated with atovaquone resistance. Mutations at positions 26, 268, 276, 133, and 280, especially Tyr26Asn, Tyr268Ser, M1331, and G280D, may be associated with atovaquone resistance.

[0390] For example, in Plasmodium vivax, mutations in PvMDR1 (a homolog of PfMDR1) have been associated with chloroquine resistance, particularly the polymorphism at position 976, such as the mutation Y976F.

[0391] The above mutations are defined in terms of protein sequences. However, a skilled person will be able to determine corresponding mutations, including SNPs, identified in nucleic acid target sequences.

[0392] Other identified drug resistance markers are known in the art, for example, as described in "Susceptibility of Plasmodium falciparum to antimalarial drugs (1996-2004)"; WHO; Artemisinin and artemisinin-based combination therapy resistance (April 2016 WHO / HTM / GMP / 2016.5); "Drug-resistant malaria: molecular mechanisms and implications for public health" FEBS Lett. 2011 Jun 6; 585(11): 1551-62. doi: 10.1016 / j.febslet.2011.04.042. Epub 2011 Apr 23. Review. PubMed PMID: 21530510; the contents of which are incorporated herein by reference.

[0393] As for the polypeptides detectable according to the present invention, the gene products of all genes mentioned herein can be used as targets. Accordingly, it is expected that such polypeptides can be used for species identification, typing and / or drug resistance detection.

[0394] In certain exemplary embodiments, the systems, devices and methods disclosed herein relate to detecting the presence of one or more mosquito-borne parasites in a sample (e.g., a biological sample obtained from a subject). In certain exemplary embodiments, the parasite may be selected from the species Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, or Plasmodium knowlesi. Therefore, the methods disclosed herein may be applicable to other methods (or combinations) that require rapid identification of parasite species, monitoring of the presence of parasites and parasite forms (e.g., corresponding to various stages of infection and parasite life-cycles, such as exocytic cycle, erythrocytic cycle, sporozoite cycle; parasite forms include merozoites, sporozoites, schizonts, gametocytes); detecting certain phenotypes (e.g., pathogen drug resistance), monitoring disease progression and / or outbreaks, and therapeutic (drug) screening. In addition, in the case of malaria, a long period of time may pass after an infectious bite, i.e., a long incubation period during which the patient does not show symptoms. Similarly, prophylactic treatments may delay the onset of symptoms, and long asymptomatic periods may also be observed before relapse. This delay can easily lead to misdiagnosis or delayed diagnosis, thereby compromising the effectiveness of treatment.

[0395] Due to the rapid and sensitive diagnostic capabilities of the embodiments disclosed herein, the detection of parasite types as low as single nucleotide differences, and the ability to be deployed as a POC device, the embodiments disclosed herein can be used to guide treatment options, such as selecting an appropriate course of treatment. The embodiments disclosed herein can also be used to screen environmental samples (mosquito populations, etc.) to determine the presence and typing of parasites. The embodiments can also be modified to simultaneously detect mosquito-borne parasites and other mosquito-borne pathogens. In some cases, malaria and other mosquito-borne pathogens may initially present similar symptoms. Therefore, the ability to quickly distinguish between infection types can guide important treatment decisions. Other mosquito-borne pathogens that can be detected together with malaria include dengue fever, West Nile virus, chikungunya fever, yellow fever, filariasis, Japanese encephalitis, St. Louis encephalitis, western equine encephalitis, eastern equine encephalitis, Venezuelan equine encephalitis, La Crosse encephalitis and Zika.

[0396] In certain exemplary embodiments, the devices, systems and methods disclosed herein can be used to distinguish mosquito-borne parasite species in samples. In certain exemplary embodiments, identification can be based on ribosomal RNA sequences, including 18S, 16S, 23S and 5S subunits. In certain exemplary embodiments, identification can be based on gene sequences that exist in multiple copies in the genome, such as mitochondrial genes such as CYTB. In certain exemplary embodiments, identification can be based on highly expressed and / or highly conserved gene sequences, such as GAPDH, histone H2B, enolase or LDH. Methods for identifying related rRNA sequences are disclosed in U.S. Patent Application Publication No. 2017 / 0029872. In certain exemplary embodiments, the guide RNA group can be designed to distinguish each species by a variable region unique to each species or strain. The guide RNA can also be designed to target RNA genes or combinations thereof that distinguish microorganisms at the genus, family, order, class, phylum, and kingdom levels. In certain exemplary embodiments using amplification, an amplification primer set can be designed to flank the constant region of the ribosomal RNA sequence and to design a guide RNA for distinguishing each species by a variable internal region. In certain exemplary embodiments, primers and guide RNAs can be designed to conserve and variable regions in the 16S subunit, respectively. Other genes or genomic regions that are uniquely variable in a species or a subset of species can also be used, such as the RecA gene family, RNA polymerase β subunit. Other suitable phylogenetic markers and methods for identifying them are discussed, for example, in Wu et al. arXiv:1307.8690 [q-bio.GN].

[0397] In certain exemplary embodiments, species identification can be performed based on genes present in the genome in multiple copies, such as mitochondrial genes such as CYTB genes. In certain exemplary embodiments, species identification can be performed based on highly expressed and / or highly conserved genes (e.g., GAPDH, histone H2B, enolase, or LDH).

[0398] In certain exemplary embodiments, the method or diagnosis is designed to screen mosquito-borne parasites across multiple phylogenetic and / or phenotypic levels simultaneously. For example, the method or diagnosis may include the use of multiple CRISPR systems with different guide RNAs. A first set of guide RNAs can distinguish, for example, Plasmodium falciparum or Plasmodium vivax. These general classes can be further subdivided. For example, guide RNAs can be designed and used in methods or diagnostics to distinguish drug-resistant strains (generally or for a specific drug or combination of drugs). A second set of guide RNAs can be designed to distinguish microorganisms at the species level. Thus, a matrix that identifies all mosquito-borne parasite species or subspecies can be generated, further divided according to drug resistance. The foregoing is for illustrative purposes only. Other means for classifying other types of mosquito-borne parasites are also contemplated, and they will follow the general structure described above.

[0399] In certain exemplary embodiments, the devices, systems, and methods disclosed herein can be used to screen for mosquito-borne parasite genes of interest, such as drug resistance genes. Guide RNAs can be designed to distinguish known genes of interest. Samples, including clinical samples, can then be screened using the embodiments disclosed herein for detection of one or more such genes. The ability to screen for drug resistance at the POC will have tremendous benefits in selecting appropriate treatment options. In certain exemplary embodiments, the drug resistance gene is a gene encoding a protein, such as a transporter, such as a protein from the drug / metabolite transporter family, an ATP-binding cassette (ABC) protein involved in substrate translocation, such as the ABC transporter C subfamily or Na+ transporter. + / H +exchange proteins; proteins involved in the folate pathway, such as dihydropteroate synthase, dihydrofolate reductase activity or dihydrofolate reductase-thymidylate synthetase; and proteins involved in the transport of protons across the inner mitochondrial membrane, particularly the cytochrome b complex. Additional targets may also include genes encoding heme polymerases. In certain exemplary embodiments, the drug resistance gene is selected from the group consisting of Plasmodium falciparum chloroquine resistance transporter gene (pfcrt), Plasmodium falciparum multidrug resistance transporter 1 (pfmdr1), Plasmodium falciparum multidrug resistance-associated protein gene (Pfmrp), Plasmodium falciparum Na+ / H+ exchanger gene (pfnhe), Plasmodium falciparum Ca2+ transporting ATPase 6 (pfatp6), Plasmodium falciparum dihydropterin synthase (pfdhps), dihydrofolate reductase activity (pfdhpr) and dihydrofolate reductase-thymidylate synthase (pfdhfr) genes, cytochrome b gene, GTP cyclohydrolase and Kelch13 (K13) genes, and their functional heterologous genes in other Plasmodium species. Other identified drug resistance markers are known in the art, for example, as described in "Susceptibility of Plasmodium falciparum to antimalarial drugs (1996–2004)"; WHO; Artemisinin and artemisinin-based combination therapy resistance (April 2016 WHO / HTM / GMP / 2016.5); "Drug-resistant malaria: molecular mechanisms and implications for public health" FEBS Lett. 2011 Jun 6; 585(11): 1551-62. doi: 10.1016 / j.febslet.2011.04.042. Epub 2011 Apr 23. Review. PubMed PMID: 21530510; the contents of which are incorporated herein by reference.

[0400] In some embodiments, the CRISPR systems, detection systems, or methods of using thereof described herein can be used to determine the evolution of a mosquito-borne parasite outbreak. The method can include detecting one or more target sequences from multiple samples from one or more subjects, wherein the target sequence is a sequence from a mosquito-borne parasite that spreads or causes an outbreak. Such methods can further include determining a pattern of transmission of a mosquito-borne parasite, or a mechanism involved in an outbreak of a disease caused by a mosquito-borne parasite. The sample can be derived from one or more humans, and / or derived from one or more mosquitoes.

[0401] The pattern of pathogen transmission can include continued new transmission from the natural reservoir of mosquito-borne parasites or additional transmissions after a single transmission from the natural reservoir or a mixture of both. In one embodiment, the target sequence is preferably a sequence or fragment thereof in the genome of a mosquito-borne parasite. In one embodiment, the pattern of mosquito-borne parasite transmission is an early pattern of mosquito-borne parasite transmission, i.e., at the beginning of an outbreak of mosquito-borne parasites. Determining the pattern of mosquito-borne parasite transmission at the beginning of an outbreak increases the likelihood of stopping the outbreak early, thereby reducing the likelihood of local and international spread.

[0402] Determining the pattern of transmission of a mosquito-borne parasite may include detecting sequences of the mosquito-borne parasite according to the methods described herein. Determining the pattern of pathogen transmission may further include detecting shared intra-host variation in sequences of the mosquito-borne parasite between subjects, and determining whether the shared intra-host variation shows a temporal pattern. The observed patterns of intra-host and inter-host variation provide important insights into transmission and epidemiology (Gire, et al., 2014).

[0403] In addition to other sample types disclosed herein, a sample can be derived from one or more mosquitoes, for example, a sample can comprise mosquito saliva.

[0404] Biomarker detection

[0405] In certain exemplary embodiments, the systems, devices and methods disclosed herein can be used for the detection of biomarkers. For example, the systems, devices and methods disclosed herein can be used for SNP detection and / or genotyping. The systems, devices and methods disclosed herein can also be used to detect any disease state or condition characterized by abnormal gene expression. Abnormal gene expression includes aberrations of expressed genes, the location of expression and the level of expression. A variety of transcripts or protein markers associated with cardiovascular, immune disorders and cancer and other diseases can be detected. In certain exemplary embodiments, the embodiments disclosed herein can be used for cell-free DNA detection of diseases involving lysis, such as liver fibrosis and restrictive / obstructive lung disease. In certain exemplary embodiments, the embodiments can be used for prenatal detection of faster and more portable cell-free DNA. The embodiments disclosed herein can be used to screen for a panel of different SNPs associated with cardiovascular health, lipid / metabolic features, ethnic identification, paternity testing, human ID (e.g., matching suspects with criminal databases of SNP tags). The embodiments disclosed herein can also be used for the detection of cell-free DNA of mutations associated with cancer tumors and released from cancer tumors. Embodiments disclosed herein can also be used to detect meat quality, for example, by providing rapid detection of different animal origins in a given meat product. Embodiments disclosed herein can also be used to detect GMOs or DNA-related gene editing. As described elsewhere herein, closely related genotypes / alleles or biomarkers (e.g., having only a single nucleotide difference in a given target sequence) can be distinguished by introducing synthetic mismatches in gRNA.

[0406] In one aspect, the present invention relates to a method for detecting a target nucleic acid in a sample, comprising:

[0407] a. distributing a sample or sample group into one or more individual discrete volumes, the individual discrete volumes comprising a CRISPR system according to the invention as described herein;

[0408] b. incubating the sample or sample group under conditions sufficient to allow the one or more guide RNAs to bind to one or more target molecules;

[0409] c. activating the CRISPR effector protein by binding of the one or more guide RNAs to the one or more target molecules, wherein activation of the CRISPR effector protein results in modification of the RNA-based masking construct such that a detectable positive signal is generated; and

[0410] d. detecting the detectable positive signal, wherein the detection of the detectable positive signal indicates the presence of one or more target molecules in the sample.

[0411] Biomarker Sample Type

[0412] The sensitivity of the assays described herein is well suited for detecting target nucleic acids in a variety of biological sample types, including sample types where the target nucleic acid is rare or the sample material is limited. Biomarker screening can be performed on many sample types, including but not limited to saliva, urine, blood, feces, sputum, and cerebrospinal fluid. Embodiments disclosed herein can also be used to detect the up-regulation and / or down-regulation of genes. For example, because the sample can be serially diluted, only the overexpressed gene remains above the detection limit threshold of the assay.

[0413] In certain embodiments, the invention provides steps of obtaining a sample of a biological fluid (eg, urine, plasma or serum, sputum, cerebrospinal fluid) and extracting DNA. The mutant nucleotide sequence to be detected may be part of a larger molecule or may initially exist as a discrete molecule.

[0414] In some embodiments, DNA is isolated from the plasma / serum of a cancer patient. For comparison, a DNA sample and a second sample, such as lymphocytes, separated from a tumor tissue can be separated from the non-tumor tissue (control) of the same patient. The non-tumor tissue can be the same type as the tumor tissue or from different organ sources. In some embodiments, a blood sample is collected and immediately separated from blood plasma and blood cells by centrifugation. Serum can be filtered and stored frozen until DNA extraction.

[0415] In certain exemplary embodiments, the target nucleic acid is detected directly from a crude or unprocessed sample, such as blood, serum, saliva, cerebrospinal fluid, sputum, or urine. In certain exemplary embodiments, the target nucleic acid is cell-free DNA.

[0416] Circulating tumor cells

[0417] In one embodiment, the present invention can be used to measure circulating cells (e.g., circulating tumor cells (CTCs)). Isolation of circulating tumor cells (CTCs) for any of the methods described herein can be performed. Exemplary techniques that can be used in the present invention to achieve specific and sensitive detection and capture of circulating cells have been described (Mostert B, et al., Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev. 2009; 35: 463-474; and Talasaz AH, et al., Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci US A. 2009; 106: 3970-3975). As few as one CTC can be found in a background of CTC105-106 peripheral blood mononuclear cells (Ross AA, et al., Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood. 1993, 82: 2605-2610). The platform uses immunomagnetic beads coated with anti-epithelial cell adhesion molecule (EpCAM) antibodies to enrich epithelial cells expressing EPCAM, followed by immunostaining to confirm the presence of cytokeratin staining and the absence of the leukocyte marker CD45 to confirm that the captured cells are epithelial tumor cells (Momburg F, et al., Immunohistochemical study of the expression of a Mr34,000human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 1987; 47: 2883-2891; and Allard WJ, et al., Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10: 6897-6904). The number of captured cells has been prospectively demonstrated to have prognostic significance in patients with breast, colorectal, and prostate cancers with advanced disease (Cohen SJ, et al., J Clin Oncol. 2008; 26: 3213-3221; Cristofanilli M, et al., N Engl J Med. 2004; 351: 781-791; Cristofanilli M, et al., J Clin Oncol. 2005; 23: 1420-1430; and de Bono JS, et al., Clin Cancer Res. 2008; 14: 6302-6309).

[0418] The present invention also provides the isolation of CTCs using CTC-Chip technology. CTC-Chip is a microfluidics-based CTC capture device in which blood flows through a chamber containing thousands of microspheres coated with CTC-binding anti-EpCAM antibodies (Nagrath S, et al. Isolation of rare circulating tumor cells in cancer patients by microchip technology. Nature. 2007; 450: 1235-1239). Compared with the previous system, CTC-Chip significantly improved CTC count and purity (Maheswaran S, et al. Detection of mutations in EGFR incirculating lung-cancer cells, N Engl J Med. 2008; 359: 366-377). Both platforms can be used for downstream molecular analysis.

[0419] Cell-free chromatin

[0420] In certain embodiments, cell-free chromatin fragments are isolated and analyzed according to the present invention.Nucleosomes can be detected in the serum of healthy individuals (Stroun et al. Annals of the New York Academy of Sciences 906:161-168 (2000)) as well as individuals with disease states. In addition, the serum concentration of nucleosomes in patients with benign and malignant diseases (such as cancer and autoimmune diseases) is quite high (Holdenrieder et al. (2001) Int J Cancer 95, 1 14-120, Trejo-Becerril et al (2003) Int J Cancer 104, 663-668; Kuroi et al 1999 Breast Cancer 6, 361-364; Kuroi et al (2001) Int j Oncology 19, 143-148; Amoura et al (1997) Arth Rheum 40, 2217-2225; Williams et al (2001) J Rheumatol 28, 81-94). Without being bound by theory, the high concentration of nucleosomes in patients with tumors originates from apoptosis that occurs spontaneously in proliferating tumors. Nucleosomes circulating in the blood contain unique modified histones. For example, U.S. Patent Publication No. 2005 / 0069931 (March 31, 2005) relates to the use of antibodies directed against specific histone N-terminal modifications as diagnostic markers for disease, using such histone-specific antibodies to separate nucleosomes from a patient's blood or serum sample in order to purify and analyze the accompanying DNA for diagnostic / screening purposes. Thus, the present invention can use chromatin-bound DNA to detect and monitor, for example, tumor mutations. Identification of DNA associated with modified histones can serve as a diagnostic marker for disease and congenital defects.

[0421] Thus, in another embodiment, the isolated chromatin fragments are derived from circulating chromatin, preferably circulating mono- and oligonucleosomes. The isolated chromatin fragments can be derived from a biological sample. The biological sample can be from a subject or a patient in need. The biological sample can be serum, plasma, lymph, blood, blood fractions, urine, synovial fluid, spinal fluid, saliva, circulating tumor cells or mucus.

[0422] Cell-free DNA (cfDNA)

[0423] In certain embodiments, the present invention can be used to detect cell-free DNA (cfDNA). Cell-free DNA in plasma or serum can be used as a non-invasive diagnostic tool. For example, cell-free fetal DNA has been studied and optimized for testing compatible RhD factors, sex determination of X-linked genetic disorders, testing of monogenic disorders, identification of preeclampsia. For example, sequencing the fetal cell fraction of cfDNA in maternal plasma is a reliable method for detecting copy number changes associated with fetal chromosome aneuploidy. Another example, cfDNA isolated from cancer patients has been used to detect mutations in key genes associated with treatment decisions.

[0424] In certain exemplary embodiments, the present disclosure provides for detecting cfDNA directly from a patient sample. In certain other exemplary embodiments, the present disclosure uses the enrichment embodiments disclosed above and provides enriched cfDNA prior to detecting target cfDNA.

[0425] Exosomes

[0426] In one embodiment, exosomes can be measured with the present invention. Exosomes are small extracellular vesicles that have been shown to contain RNA. It is known in the art to separate exosomes by ultracentrifugation, filtration, chemical precipitation, size exclusion chromatography, and microfluidics. In one embodiment, exosomes are purified using exosome biomarkers. Separation and purification of exosomes from biological samples can be performed by any known method (see, for example, WO2016172598A1).

[0427] SNP Detection and Genotyping

[0428] In certain embodiments, the present invention can be used to detect the presence of single nucleotide polymorphisms (SNPs) in biological samples. SNPs may be relevant to maternal testing (e.g., sex determination, fetal defects). They may be relevant to criminal investigations. In one embodiment, suspects in criminal investigations may be identified by the present invention. Not constrained by forensic evidence based on theoretical nucleic acids, the most sensitive assay available may be required to detect the genetic material of a suspect or victim, because the sample tested may be limited.

[0429] In other embodiments, disease-associated SNPs are encompassed by the present invention. Disease-associated SNPs are well known in the art, and one skilled in the art can apply the methods of the present invention to design appropriate guide RNAs (see, e.g., www.ncbi.nlm.nih.gov / clinvar?term=human%5Borgn%5D).

[0430] In one aspect, the invention relates to a method for genotyping, such as SNP genotyping, comprising:

[0431] a) partitioning a sample or set of samples into one or more individual discrete volumes comprising a CRISPR system according to the invention as described herein;

[0432] b) incubating the sample or set of samples under conditions sufficient to allow the one or more guide RNAs to bind to the one or more target molecules;

[0433] c) activating a CRISPR effector protein by binding of the one or more guide RNAs to the one or more target molecules, wherein activation of the CRISPR effector protein results in modification of the RNA-based masking construct such that a detectable positive signal is generated; and

[0434] d) detecting the detectable positive signal, wherein the detection of the detectable positive signal indicates the presence of one or more target molecules characteristic of a particular genotype in the sample.

[0435] In some embodiments, the detectable signal is compared with one or more standard signals (e.g., by comparing signal intensity), preferably a synthetic standard signal. In some embodiments, the standard is or corresponds to a specific genotype. In some embodiments, the standard comprises a specific SNP or other (single) nucleotide variation. In some embodiments, the standard is a (PCR amplified) genotype standard. In some embodiments, the standard is DNA or comprises DNA. In some embodiments, the standard is or comprises RNA. In some embodiments, the standard is or comprises RNA transcribed from DNA. In some embodiments, the standard is or comprises DNA reverse transcribed from RNA. In some embodiments, the detectable signal is compared with one or more standards, each of which corresponds to a known genotype, such as SNP or other (single) nucleotide variation. In some embodiments, the detectable signal is compared with one or more standard signals, and the comparison includes statistical analysis, such as by parametric or non-parametric statistical analysis, such as by one-way or two-way ANOVA, etc. In certain embodiments, the detectable signal is compared to the signal of one or more standards, and when the detectable signal does not deviate (statistically) significantly from the standard, the genotype is determined to correspond to the genotype of the standard.

[0436] In other embodiments, the present invention allows for rapid genotyping for emergency pharmacogenomics. In one embodiment, a single point of care can be used to genotype patients entering the emergency room. The patient may be suspected of having a blood clot and the emergency physician needs to determine the blood thinner dosage management. In an exemplary embodiment, the present invention can provide guidance for the administration of blood thinners during the treatment of myocardial infarction or stroke based on genotyping of markers such as VKORC1, CYP2C9, and CYP2C19. In one embodiment, the blood thinner is the anticoagulant warfarin (Holford, NH (December 1986) "Clinical Pharmacokinetics and Pharmacodynamics of Warfarin Understanding the Dose-Effect Relationship". Clinical Pharmacokinetics. Springer International Publishing. 11 (6): 483–504). Genes related to blood coagulation are known in the art (see, e.g., US20060166239A1; Litin SC, Gastineau DA (1995) "Current concepts in anticoagulant therapy". Mayo Clin. Proc. 70(3): 266–72; and Rusdiana et al., Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol. 2013 Mar; 69(3): 395-405). Specifically, in the VKORC1 1639 (or 3673) single nucleotide polymorphism, the common ("wild type") G allele is replaced by the A allele. People with the A allele (or "A haplotype") produce less VKORC1 than those with the G allele (or "non-A haplotype"). The prevalence of these variants also varies by ethnicity, with 37% of Caucasians and 14% of Africans carrying the A allele. The end result is a reduced amount of clotting factor, and therefore a reduced ability to clot blood.

[0437] In certain exemplary embodiments, the availability of genetic material for detecting SNPs in patients allows detection of SNPs without amplifying DNA or RNA samples. In the case of genotyping, it is easy to obtain biological samples for testing. In certain exemplary embodiments, the incubation time of the present invention can be shortened. The assay can be performed within a period of time required for the enzymatic reaction to occur. Those skilled in the art can perform biochemical reactions within 5 minutes (e.g., 5 minutes connection). The present invention can use an automatic DNA extraction device to obtain DNA from blood. DNA can then be added to the reaction of the target molecule that produces the effector protein. After the target molecule is produced, the masking agent can be cut immediately and the signal detected. In an exemplary embodiment, the present invention allows POC rapid diagnosis to be used to determine the genotype before administering a drug (e.g., a blood thinner). In the case of using an amplification step, all reactions occur in the same reaction in a one-step method. In a preferred embodiment, the POC assay can be performed in less than 1 hour, preferably 10 minutes, 20 minutes, 30 minutes, 40 minutes, or 50 minutes.

[0438] In certain embodiments, the systems, devices and methods disclosed herein can be used to detect the presence or expression level of long noncoding RNA (lncRNA). The expression of certain lncRNAs is associated with disease states and / or drug resistance. In particular, certain lncRNAs (e.g., TCONS_00011252, NR_034078, TCONS_00010506, TCONS_00026344, TCONS_00015940, TCONS_00028298, TCONS_00026380, TCONS_0009861, TCONS_00026521, TCONS_00016127, NR_125939, NR_033834, TCONS_00021026, TCONS_ 00006579, NR_109890 and NR_026873) are associated with resistance to cancer treatment, such as resistance to one or more BRAF inhibitors (e.g., Vemurafenib, Dabrafenib, Sorafenib, GDC-0879, PLX-4720 and LGX818) used to treat melanoma (e.g., nodular melanoma, malignant melanoma, malignant melanoma, acral melanoma, superficial spreading melanoma, mucosal melanoma, polypoid melanoma, desmoplastic melanoma, amelanoma melanoma and soft tissue melanoma). Detection of lncRNA using various embodiments described herein can facilitate disease diagnosis and / or selection of treatment options.

[0439] In one embodiment, the invention can direct DNA or RNA targeted therapies (e.g., CRISPR, TALEs, zinc finger proteins, RNAi), particularly in settings where rapid administration of the therapy is important to the therapeutic outcome.

[0440] LOH detection

[0441] Cancer cells experience a loss of genetic material (DNA) compared to normal cells. This loss of genetic material experienced by almost all (if not all) cancers is called "loss of heterozygosity" (LOH). Loss of heterozygosity (LOH) is a serious chromosomal event that results in the loss of an entire gene and surrounding chromosomal regions. Loss of heterozygosity is a common event in cancer, where it can indicate the absence of functional tumor suppressor genes in the lost region. However, the loss can be silent because there is still a functional gene on the other chromosome of the chromosome pair. The remaining copies of the tumor suppressor gene can be inactivated by point mutations, r...

Claims

1. A nucleic acid detection system, include: a) detecting a CRISPR system, comprising: i. Detection of type VI CRISPR effector proteins with incidental cleavage activity upon activation, ii. one or more guide RNAs designed to hybridize to corresponding target nucleic acid sequences, and b) one or more type IIIa signal amplification CRISPR Csm6 effector proteins with incidental cleavage activity upon activation; and c) one or more RNA-based masking constructs comprising non-target nucleic acid sequences that are inactivated by the incidental cleavage activity of said detection Type VI CRISPR effector protein and / or said one or more Type IIIa signal amplification CRISPR Csm6 effector proteins, wherein complex formation between the detection Type VI CRISPR effector protein and the one or more guide RNAs hybridized to the corresponding target nucleic acid sequence activates the incidental cleavage activity of the detection Type VI CRISPR effector protein; wherein the activated detection Type VI CRISPR effector protein cleaves the activation sequence, and its cleavage product activates the incidental cleavage activity of said one or more Type VIIIa signal amplification CRISPR Csm6 effector proteins; and wherein the incidental cleavage activity of the detection Type VI CRISPR effector protein and the one or more Type IIIa signal amplification CRISPR Csm6 effector proteins act synergistically to inactivate the RNA-based masking construct to produce or mask a detectable signal.

2. The system of claim 1, wherein the Csm6 effector protein is selected from EiCsm6 and LsCsm6.

3. The system of claim 1, wherein the target nucleic acid sequence is a target DNA, and the system further comprises a primer that binds to the target DNA and comprises an RNA polymerase promoter.

4. The system of claim 1, wherein the detection Type VI CRISPR effector protein is an RNA targeting effector protein.

5. The system of claim 4, wherein the RNA targeting effector protein comprises one or more HEPN domains.

6. The system of claim 5, wherein the one or more HEPN domains comprise a RxxxxH motif sequence.

7. The system of claim 6, wherein the RxxxxH motif comprises R{N / H / K}X 1 X 2 X 3 H sequence.

8. The system according to claim 7, wherein X 1 is R, S, D, E, Q, N, G, or Y, and X 2 are independently I, S, T, V or L, and X 3 are independently L, F, N, Y, V, I, S, D, E or A.

9. The system of claim 4, wherein the RNA targeting effector protein is C2c2.

10. The system of claim 9, wherein the C2c2 effector protein is a Leptotrichia wadeiF0279C2c2 effector protein.

11. The system of claim 1, wherein the one or more RNA-based masking constructs comprise RNA aptamers, RNA-tethered inhibitors, interfering RNAs, RNA oligonucleotides, or ribozymes.

12. The system of claim 11, wherein the one or more RNA-based masking constructs inhibit the generation of a detectable positive signal.

13. The system of claim 12, wherein the one or more RNA-based masking constructs inhibit the generation of a detectable positive signal by masking the detectable positive signal or otherwise generating a detectable negative signal.

14. The system of claim 11, wherein the interfering RNA inhibits the production of a gene product encoded by a reporter construct, wherein the gene product produces a detectable positive signal when expressed.

15. The system of claim 11, wherein a ribozyme produces the detectable negative signal, and wherein the detectable positive signal is produced when the ribozyme is inactivated.

16. The system of claim 11, wherein the ribozyme converts a substrate to a first color, and wherein the substrate converts to a second color when the ribozyme is inactivated.

17. The system of claim 11, wherein the aptamer or RNA-tethered inhibitor sequesters an enzyme, wherein the enzyme generates a detectable signal upon release from the aptamer or RNA-tethered inhibitor by acting on a substrate.

18. The system of claim 11, wherein the aptamer is an inhibitory aptamer that inhibits an enzyme and prevents the enzyme from catalyzing the production of a detectable signal from a substrate, or wherein the RNA-tethered inhibitor inhibits an enzyme and prevents the enzyme from catalyzing the production of a detectable signal from a substrate.

19. The system of claim 18, wherein the enzyme is thrombin, protein C, neutrophil elastase, subtilisin, horseradish peroxidase, β-galactosidase, or calf alkaline phosphatase.

20. The system of claim 19, wherein the enzyme is thrombin and the substrate is p-nitroaniline covalently linked to a peptide substrate for thrombin, or 7-amino-4-methylcoumarin covalently linked to a peptide substrate for thrombin.

21. The system of claim 11, wherein the aptamer sequesters a pair of agents that combine to produce a detectable signal when released from the aptamer.

22. The system of claim 11, wherein the one or more RNA-based masking constructs comprise an RNA oligonucleotide to which both a detectable ligand and a masking component are attached.

23. The system of claim 11, wherein the one or more RNA-based masking constructs comprise nanoparticles aggregated by bridge molecules, wherein at least a portion of the bridge molecules comprise RNA, and wherein the solution undergoes a color shift when the nanoparticles are distributed in the solution.

24. The system of claim 23, wherein the nanoparticles are colloidal metals.

25. The system of claim 24, wherein the colloidal metal is colloidal gold.

26. The system of claim 11, wherein the one or more RNA-based masking constructs comprise quantum dots linked to one or more quencher molecules via a linker molecule, wherein at least a portion of the linker molecule comprises RNA.

27. The system of claim 11, wherein the one or more RNA-based masking constructs comprise RNA complexed with an intercalating dye, wherein the intercalating dye changes absorbance upon cleavage of the RNA.

28. The system of claim 27, wherein the intercalating dye is pyronin red-Y or methylene blue.

29. The system of claim 22, wherein the detectable ligand is a fluorophore and the masking component is a quenching molecule.

30. The system of claim 11, wherein the masking construct comprises an RNA oligonucleotide designed to bind to a G-quadruplex forming sequence, wherein a G-quadruplex structure is formed by the G-quadruplex forming sequence upon cleavage of the masking construct, and wherein the G-quadruplex structure produces a detectable positive signal.

31. The system of claim 1, wherein the one or more RNA-based masking constructs are cleaved by the detection Type VI CRISPR effector protein and the one or more Type IIIa signal amplification CRISPR Csm6 effector proteins.

32. The system of claim 31 , wherein the one or more RNA-based masking constructs comprise an RNA-based masking construct that is cleaved by the detection Type VI CRISPR effector protein.

33. The system of claim 31 , wherein the one or more RNA-based masking constructs comprise an RNA-based masking construct that is cleaved by the one or more Type IIIa signal amplification CRISPR Csm6 effector proteins.

34. The system of claim 31 , wherein the one or more RNA-based masking constructs comprise an RNA-based masking construct that is cleaved by the detection Type VI CRISPR effector protein and an RNA-based masking construct that is cleaved by the one or more Type IIIa signal amplification CRISPR Csm6 effector proteins.

35. The system of claim 31 , wherein the RNA-based masking construct cleaved by the one or more Type IIIa signal amplification CRISPR Csm6 effector proteins comprises homopolymeric A-RNA or C-RNA.

36. The system of claim 1, wherein the one or more guide RNAs designed to bind to a corresponding target nucleic acid sequence comprise a mismatch.

37. The system of claim 1, wherein the one or more guide RNAs designed to bind to a corresponding target nucleic acid sequence comprise synthetic mismatches.

38. The system of claim 36, wherein the mismatch is upstream or downstream of a single nucleotide polymorphism or other single nucleotide variation in the target nucleic acid sequence.

39. The system of claim 37, wherein the synthetic mismatch in the guide RNA is located at position 3, 4, 5, or 6 counted from the 5' end of the spacer.

40. The system of claim 37, wherein the synthetic mismatch in the guide RNA is located at position 3 counted from the 5' end of the spacer.

41. The system of claim 36, wherein the mismatch in the guide RNA is at position 1, 2, 3, 4, 5, 6, 7, 8, or 9 counted from the 5' end of the spacer.

42. The system of claim 37, wherein the synthetic mismatch in the guide RNA is located at position 5 counted from the 5' end of the spacer.

43. The system of claim 36, wherein the mismatch is 1, 2, 3, 4, or 5 nucleotides upstream or downstream of the single nucleotide polymorphism or other single nucleotide variation in the guide RNA.

44. The system of claim 36, wherein the mismatch is 2 nucleotides downstream of the single nucleotide polymorphism or other single nucleotide variation in the guide RNA.

45. The system of claim 1, wherein the guide RNA comprises a spacer that is truncated relative to a wild-type spacer.

46. ​​The system of claim 45, wherein the guide RNA comprises a spacer of less than 28 nucleotides.

47. The system of claim 45, wherein the guide RNA comprises a spacer comprised between 20 and 27 nucleotides, inclusive.

48. The system of claim 45, wherein the guide RNA comprises a spacer consisting of 20-25 nucleotides.

49. The system of claim 45, wherein the guide RNA comprises a spacer consisting of 20-23 nucleotides.

50. The system of claim 45, wherein the guide RNA comprises a spacer consisting of 20 or 23 nucleotides.

51. The system of any one of claims 1 to 50, wherein the one or more guide RNAs are designed to detect single nucleotide polymorphisms in target RNA or DNA, or splice variants of RNA transcripts.

52. The system of any one of claims 1 to 50, wherein the system further comprises one or more activation sequences, and wherein each activation sequence comprises a poly A stretch and / or generates hexaadenylate containing 2'3' cyclic phosphate ends when cleaved by the detection CRISPR RNA targeting effector protein.

53. The system of any one of claims 1 to 50, wherein the one or more guide RNAs are designed to bind to one or more disease state diagnostic target nucleic acid sequences.

54. The system of claim 53, wherein the disease state is cancer.

55. The system of claim 53, wherein the disease state is an autoimmune disease.

56. The system of claim 53, wherein the disease state is an infection.

57. The system of claim 56, wherein the infection is caused by a virus, bacteria, fungus, protozoa, or parasite.

58. The system of claim 56, wherein the infection is a viral infection.

59. The system of claim 58, wherein the viral infection is caused by a DNA virus.

60. The system of claim 59, wherein the DNA virus is a Myoviridae, Brachyviridae, Doliviridae, Heteroherpesviridae, Herpesviridae, Malocoherpesviridae, Lipoviridae, Adenoviridae, Ampullaviridae, Vesciviridae, Afriviridae, Baculoviridae, Cicaudaviridae, Clavaviridae, Bacteriophage, Microspinoviridae, Spheroviridae, Guttaviridae, Hytrosaviridae, Iridoviridae, Maseilleviridae, Mimiviridae, Nudiviridae, Nimaviridae, Pandoraviridae, Papillomaviridae, Phycodnaviridae, Plasmaviridae, Polydnaviruses, Polyomaviridae, Poxviridae, Sphaerolipoviridae, Multiviridae, Turriviridae, Dinodnavirus, Haloterminal Protein Virus, or Rhizidovirus.

61. The system of claim 59, wherein the DNA virus is of the family Baculoviridae, human herpes virus, varicella zoster virus, African swine fever virus, simian virus 40, JC virus, BK virus, including vaccinia or smallpox.

62. The system of claim 57, wherein the virus is a double-stranded RNA virus, a positive-sense RNA virus, a negative-sense RNA virus, a retrovirus, or a combination thereof.

63. The system of claim 57, wherein the virus is a Coronaviridae, Picornaviridae, Caliciviridae, Flaviviridae, Togaviridae, Bornaviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, or Deltavirus.

64. The system of claim 63, wherein the virus is a coronavirus, polio virus, rhinovirus, hepatitis A, Norwalk virus, yellow fever virus, West Nile virus, hepatitis C virus, dengue virus, Zika virus, rubella virus, Ross River virus, Sindbis virus, chikungunya virus, Borna disease virus, Ebola virus, Marburg virus, measles virus, mumps virus, Nipah virus, Hendra virus, Newcastle disease virus, human respiratory syncytial virus, rabies virus, Lassa virus, Hanta virus, Crimean-Congo hemorrhagic fever virus, influenza, or hepatitis D virus.

65. The system of claim 63, wherein the virus is SARS.

66. The system of claim 57, wherein the infection is a bacterial infection.

67. The system of claim 66, wherein the bacteria is an Acinetobacter species, an Actinomyces species, an Actinomyces species, an Aeromonas species, an Aeromonas species, an Rhodospora species, an Alcaligenes species, a Bacillus species, a Bacteroides species, a Bartonella species, a Bifidobacterium species, a Bordetella species, a Borrelia species, a Brucella species, a Burkholderia species, a Campylobacter species, a Capnocytophaga species, a Chlamydia species. species, Citrobacter species, Coxiella species, Corynebacterium species, Clostridium species, Eikenella species, Enterobacter species, Escherichia species, Enterococcus species, Ehrlichia species, Epidermophyton species, Erysipelothrix species, Eubacterium species, Francisella species, Fusobacterium species, Gardnerella species, Geminicoccus species, Haemophilus species, Helicobacter species, Kingella species, Klebsiella species, Lactobacillus species, Lactococcus species, Listeria species, Leptospira genus and species, Legionella species, Leptospira species, Leuconostoc species, Mannheimia species, Microsporum species, Micrococcus species, Moraxella species, Morganella species, Mobiluncus species, Mycobacterium species, Mycoplasma species, Nocardia species, Neisseria species, Pasteurelaa species, Pediococcus species, Peptostreptococcus species, Pityrosporum species, Pseudomonas species, Prevotella species, Porphyromonas species, Proteus species, Providencia spp., Pseudomonas species, Propionibacterium species, Rhodococcus species, Rickettsia species, Rhodococcus species, Serratia species, Stenotrophomonas species, Salmonella species, Serratia species, Shigella species, Staphylococcus species, Streptococcus species, Helicobacter species, Streptobacillus species, Treponema species, Tropheryma species, Trichophyton species, Ureaplasma species, Veillonella species, Vibrio species, Yersinia pestis species, Flavobacterium species, or a combination thereof.

68. The system of claim 57, wherein the infection is caused by a fungus.

69. The system of claim 68, wherein the fungus is Aspergillus, Blastomyces, Candidiasis, Coccidioidomycosis, Cryptococcus neoformans, Cryptococcus gati, Histoplasma, Pneumocystis, Stachybotrys, Mucormycosis, Sporothrix, Fungal Eye Infection Tinea, Helminthosporium, Cladosporium, Geotrichum, Saccharomyces, Hansenula species, Candida species, Kluyveromyces species, Debaryomyces species, Pichia species, Penicillium species, Cladosporium species, Mycelium species, or a combination thereof.

70. The system of claim 68, wherein the fungus is Histoplasma capsulatum, Pneumocystis jirovecii, Stachybotrys paper mold, or a combination thereof.

71. The system of claim 57, wherein the infection is caused by a protozoa.

72. The system of claim 71, wherein the protozoa is of the kingdom Euglena, the class Heteropoda, the order Diplomonas, the kingdom Amoeba, the genus Blastocystis, the subphylum Apicomplexa, or a combination thereof.

73. The system of claim 57, wherein the infection is caused by a parasite.

74. The system of claim 73, wherein the parasite is Trypanosoma cruzi, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Leishmania braziliensis, L. infantum, L. mexicana, L. major, L. tropica, L. donovani, Naegleria fowleri, Giardia intestinalis, canthamoeba castellanii, Balamuthia madrillaris, Entamoeba histolytica, Blastocystic hominis, Babesiamicroti, Cryptosporidium parvum, Cyclospora cayetanensis, Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and Toxoplasma gondii, or a combination thereof.

75. The system of claim 73, wherein the parasite is Trypanosoma cruzi, G. lamblia, G. duodenalis, or a combination thereof.

76. The system of claim 53, wherein the target nucleic acid sequence is a drug resistance gene.

77. The system of claim 53, wherein the target nucleic acid sequence is a diagnostic for drug resistance for treatment of Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi.

78. The system of claim 53, wherein the target nucleic acid sequence is an antibiotic resistance or susceptibility gene or transcript.

79. The system of claim 1, further comprising nucleic acid amplification reagents.

80. The system of claim 79, wherein the nucleic acid amplification reagent comprises a reagent for amplifying a target RNA molecule, wherein the reagent for amplifying a target RNA molecule comprises nucleic acid sequence-based amplification (NASBA), recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), helicase-dependent amplification (HDA), nickase amplification reaction (NEAR), PCR, multiple displacement amplification (MDA), rolling circle amplification (RCA), ligase chain reaction (LCR) or branched amplification method (RAM).

81. The system of claim 3, wherein the target nucleic acid sequence comprises a ribonucleic acid sequence of a target RNA molecule or a complementary ribonucleic acid sequence of a target DNA molecule.

82. The system of claim 1, further comprising an enriched CRISPR system comprising a catalytically inactive Type VI CRISPR effector protein.

83. The system of claim 82, wherein the enrichment CRISPR system is designed to bind to the corresponding target nucleic acid sequence prior to detection with the detection CRISPR system.

84. The system of claim 82, wherein the catalytically inactive Type VI CRISPR effector protein is catalytically inactive C2c2.

85. The system of any one of claims 82 to 84, wherein the enriched CRISPR effector system further comprises a tag, wherein the tag is used to pull down the enriched CRISPR effector system, or to bind the enriched CRISPR system to a solid substrate.

86. The system of claim 85, wherein the solid substrate is a flow cell.

87. A diagnostic device for detecting a target nucleic acid sequence in a sample, comprising one or more individual discrete volumes, each individual discrete volume containing a defined amount of the nucleic acid detection system of any one of claims 1 to 86 for mixing with a predetermined volume of sample.

88. The device of claim 87, wherein the individual discrete volumes are droplets.

89. The device of claim 87, wherein the individual discrete volumes are defined on a solid substrate.

90. The device of claim 87, wherein the individual discrete volumes are microwells.

91. The device of claim 87, wherein the individual discrete volumes are spots defined on a substrate.

92. The device of claim 91, wherein the substrate is a flexible material substrate.

93. The device according to claim 92, wherein the flexible material substrate is a paper substrate or a flexible polymer based substrate.

94. A method for detecting a target nucleic acid sequence in a sample, wherein include: Distributing one or more samples into one or more individual discrete volumes, wherein the individual discrete volumes contain the nucleic acid detection system of any one of claims 1 to 86; incubating the one or more samples under conditions that allow binding of the one or more guide RNAs to one or more target nucleic acid sequences; activating the detection CRISPR effector protein by binding of the one or more guide RNAs to the one or more target nucleic acid sequences, wherein activation of said detection CRISPR effector protein results in modification of said one or more RNA-based masking constructs such that a detectable positive signal is generated; and detecting the detectable positive signal, wherein the detection of the detectable positive signal indicates the presence of one or more target nucleic acid sequences in the sample, The method described is not a method for the treatment or diagnosis of a disease.

95. The method of claim 94, wherein the target nucleic acid sequence is a target DNA, and the method further comprises combining the target DNA with a primer comprising an RNA polymerase site.

96. The method of claim 94 or 95, further comprising amplifying the sample RNA.

97. The method of claim 96, wherein amplifying the sample RNA comprises amplifying by NASBA.

98. The method of claim 96, wherein amplifying the sample RNA comprises amplifying by RPA.

99. The method of claim 94 or 95, wherein the sample is a biological sample or an environmental sample.

100. The method of claim 99, wherein the biological sample is blood, plasma, serum, urine, feces, mucus, lymph, synovial fluid, bile, ascites, pleural effusion, seroma, saliva, cerebrospinal fluid, aqueous humor or vitreous humor, or fluid obtained from a joint, or a swab of the skin or mucosal surface.

101. The method of claim 99, wherein the biological sample is fluid obtained from an abscess or any other site of infection or inflammation.

102. The method of claim 100, wherein the fluid obtained from the joint is fluid obtained from a normal joint or a joint affected by disease.

103. The method of claim 102, wherein the disease is rheumatoid arthritis, osteoarthritis, gout, or septic arthritis.

104. The method of claim 99, wherein the environmental sample is obtained from a food sample, a paper surface, a fabric, a metal surface, a wood surface, a plastic surface, a soil sample, a fresh water sample, a waste water sample, a salt water sample, or a combination thereof.

105. The method of claim 94 or 95, wherein the one or more guide RNAs are designed to detect single nucleotide polymorphisms in target RNA or DNA, or splice variants of RNA transcripts.

106. The method of claim 94 or 95, wherein the one or more guide RNAs are designed to bind to cell-free nucleic acid.

107. The method of claim 94 or 95, further comprising comparing the detectable positive signal to a standard signal.

108. A method for detecting a target nucleic acid sequence in a sample, wherein include: contacting the sample with a nucleic acid detection system as described in any one of claims 1 to 86; and applying the contacted sample to a lateral flow immunochromatographic assay, The method described is not a method for the treatment or diagnosis of a disease.

109. The method of claim 108, wherein the nucleic acid detection system comprises an RNA-based masking construct comprising a first and a second molecule, and wherein the lateral flow immunochromatographic assay comprises detecting the first and the second molecules.

110. The method of claim 109, wherein the first and second molecules are detected at discrete detection sites on a lateral flow strip.

111. The method of claim 109, wherein the first molecule and the second molecule are detected by binding the first molecule and the second molecule to an antibody that recognizes the first or second molecule and detecting the bound molecules.

112. The method of claim 111, wherein the antibody is a sandwich antibody.

113. A method according to claim 110, wherein the lateral flow strip comprises an upstream first antibody against the first molecule and a downstream second antibody against the second molecule, and wherein if the target nucleic acid is not present in the sample, the uncut RNA-based masking construct is bound by the first antibody, and wherein if the target nucleic acid is present in the sample, the cut RNA-based masking construct is bound by both the first antibody and the second antibody.

114. The system of claim 1, wherein the detection Type VI CRISPR effector protein is a Cas13a effector protein, a Cas13b effector protein, or a Cas13d effector protein.